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Abstract
Previous studies identified a crosstalk mechanism whereby CRFR1 sensitized 5HT2AR-mediated signaling via interactions with PDZ domain-containing proteins: a
mechanism that may underlie stress-induced anxiety and depression. This prompted an
investigation into uncovering which PDZ domain-containing proteins could regulate the
crosstalk between these two receptors, and how they could be regulated individually. In
the current studies, a subset of PDZ domain-containing proteins were identified that may
interact with CRFR1 and 5-HT2AR. The focus narrowed to two candidates previously
implicated in psychiatric disease: SAP97 and PSD-95. We confirmed SAP97 and PSD-95
as interacting partners of CRFR1 in adult mouse cortex via co-immunoprecipitation. Both
proteins exhibited functional regulation of CRFR1 by antagonizing CRFR1 endocytosis in
HEK293 cells, measured by flow cytometry. Additionally, PSD-95 suppressed β-arrestin2
recruitment, thereby providing a potential mechanism for antagonizing endocytosis.
Although neither SAP97 nor PSD-95 appeared to play a significant role in CRFR1mediated cAMP signaling, endogenous SAP97 was integral for CRF-mediated ERK1/2
phosphorylation in HEK293 and AtT20 cells. Despite extensive sequence homology
between SAP97 and PSD-95, PSD-95 did not appear to play a significant role in CRFmediated ERK1/2 phosphorylation. Thus, we begin to understand subtle signaling biases
between these two proteins. As PSD-95 was already documented to regulate 5-HT2AR, we
investigated if SAP97 could play a role in regulating 5-HT2AR function. The interaction
between SAP97 and 5-HT2AR was confirmed in adult mouse cortex. As was seen with
CRFR1, SAP97 antagonized 5-HT2AR endocytosis. Although SAP97 did not appear to
significantly modulate Gs-coupled signaling via CRFR1, the endogenous expression of
ii

SAP97 was integral for maximal Gq-coupled signaling via 5-HT2AR. Endogenous SAP97
was also required for ERK1/2 phosphorylation, and this regulatory role appears to be
downstream of receptor interactions. Finally, we were unable to prevent the CRFR1mediated sensitization of 5-HT2AR-mediated signaling by knocking down either SAP97 or
PSD-95 using shRNA. Therefore, neither SAP97 nor PSD-95 appear to be exclusively
involved in this heterologous crosstalk mechanism. Nevertheless, we have identified
SAP97 and PSD-95 as novel regulators of CRFR1 function, and SAP97 as a novel regulator
of 5-HT2AR function. These functional interactions may be targeted for the treatment of
CRFR1- and 5-HT2AR-mediated mood disorders.

Keywords: GPCR, PDZ, CRFR1, 5-HT2AR, PSD-95, SAP97, endocytosis, ERK, MAPK,
phosphorylation, IP3 signaling, Gq-coupling, anxiety, depression, schizophrenia
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Chapter 1: Introduction

1.1 G Protein-Coupled Receptors
G protein-coupled receptors (GPCRs) represent an expansive superfamily of
transmembrane receptors that play an important role in regulating every aspect of
mammalian physiology (Heng et al., 2013; Bockaert et al., 2010). Approximately 2% of
the human genome encodes for GPCRs and over 40% of currently prescribed
pharmaceuticals target these receptors for their desired consequence (Urs et al., 2014).
Each of these GPCRs possess common characteristics, including an extracellular amino
terminus, an intracellular carboxyl terminus, and seven transmembrane domains that are
linked by three intracellular- and three extracellular- loops (Baldwin, 1993; Bockaert & Pin,
1999). Another highly conserved feature amongst the GPCR superfamily is the inclus io n
of two cysteine residues within the first- and second-extracellular loops (Bockaert & Pin,
1999). These residues are capable of forming a disulfide bond which is believed to be
integral for stabilizing GPCRs in a finite number of conformations associated with various
activation- and inactivation-states of the receptor (Bockaert & Pin, 1999).
The amino terminal, extracellular loops and portions of the transmembrane domains
are essential for ligand-binding, the most common mechanism for activating GPCRs
(Wess, 1997).

There are a multitude of stimuli responsible for activating GPCRs,

including: hormones, peptides, amino acid-residues, nucleotides, Ca2+, odorants, and
photons of light (Bockaert & Pin, 1999). Each individual GPCR has specific stimuli that
can influence the receptor’s function. Traditional pharmacology can describe these stimuli
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as agonists or antagonists of GPCR signalling. However, recent advances have uncovered
an increasing complexity in GPCR activation and inactivation (Kristiansen, 2004). Ligand
binding can cause a conformational change in the GPCR leading to the exchange of GDP
for GTP on the α-subunit of the heterotrimeric G protein (Kristiansen, 2004). The now
“active” G protein dissociates from the receptor and splits into separate α- and βγ-subunits,
each of which contribute to the regulation of various aspects of GPCR-signalling
(Kristiansen, 2004). The Gα subunit will be of primary focus for the studies to follow.

1.2 G Protein-Coupled Receptor Signalling
The intracellular loops, carboxyl-terminal tail, and the intracellular face of some
transmembrane domains are integral for G protein-coupling, as well as other important
interactions with intracellular proteins such as G protein-coupled receptor kinases (GRKs),
β-arrestins and membrane scaffolding proteins, such as PDZ domain-containing proteins
(Wess, 1997; Lefkowitz, 1998; Kristiansen, 2004; Magalhaes et al., 2012). Each unique
GPCR can initiate an assortment of signalling pathways which are influenced not only by
different extracellular agonists, but also by a diversity of intracellular interacting proteins
(Lefkowitz, 1998; Kristiansen, 2004). Perhaps the most important determinant of GPCR
signalling is the subtype of α-subunit within the heterotrimeric G protein that is coupled to
the receptor. Of these, the stimulative- and inhibitory-regulatory G proteins (Gαs and Gαi)
and Gαq/11 appear most common and have best been described (Lefkowitz, 1998;
Kristiansen, 2004) (Figure 1.1).

3

1.2.1 cAMP Signalling Pathway
The stimulatory- and inhibitory-regulatory G proteins (Gαs and Gαi) act inverse ly
on the same signalling pathway (Lefkowitz, 1998; Kristiansen, 2004). Following receptor
activation, Gαs-coupled receptors activate adenylyl cyclase to increase the conversion of
adenosine triphosphate (ATP) to cyclic-adenosine monophosphate (cAMP) (Lefkowitz,
1998) (Figure 1.1). cAMP acts as a secondary messenger in response to Gαs-coupled
receptor activation and subsequently binds the two regulatory subunits of protein kinase A
(PKA). Once four cAMP molecules have bound, the regulatory subunits of PKA dissociate
from the two catalytic subunits, thereby activating the kinase to phosphorylate a myriad of
intracellular proteins, kinases, and transcription factors that ultimately leads to alterations
in cellular activity (Wess, 1997; Lefkowitz, 1998; Kristiansen, 2004). This signal is
terminated by the cAMP phosphodiesterase- mediated degradation of cAMP into 5’-AMP.
Conversely, Gαi-coupled receptors maintain adenylyl cyclase in the inactive state,
inhibiting the buildup of cAMP and subsequent PKA activation (Lefkowitz, 1998;
Kristiansen, 2004).

1.2.2 IP3 Signalling Pathway
A distinctly different signalling pathway is mediated by Gαq/11 -coupled receptors.
Once GDP is exchanged for GTP, Gαq/11 activates phospholipase C (PLC) which
hydrolyzes phosphatidylinositol 4,5-biphosphate (PIP2 ) from the membrane into inosito l
1,4,5-triphosphate (IP3 ) and diacylglycerol (DAG) (Lefkowitz, 1998; Kristiansen, 2004)
(Figure 1.1). These molecules act as the secondary messengers of Gαq/11 -coupled receptor
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activation. IP3 binds to IP3 receptors located in the endoplasmic reticulum, causing the
release of intracellular Ca2+ stores (Lefkowitz, 1998; Kristiansen, 2004). The concomita nt
increase in intracellular DAG and Ca2+ leads to the activation of protein kinase C (PKC)
and Ca2+-calmodulin kinase (CaMK) (Lefkowitz, 1998; Kristiansen, 2004). These kinases
have many protein targets for phosphorylation including other kinases and transcriptio n
factors that mediate the biological effect at the cellular level (Lefkowitz, 1998; Kristianse n,
2004).

1.2.3 ERK/MAPK Signalling Pathway
Another divergent signalling pathway activated by GPCRs is the mitogen-activated
protein kinase/extracellular signal-related kinase (ERK/MAPK).

Interestingly, this

pathway can be activated following either Gαs or Gαq/11 activation via PKA and PKC
respectively, as well as G protein-independent mechanisms (Luttrell et al., 1997). In the
case of Gαs- or Gαq/11 -mediated ERK1/2 signalling,

PKA or PKC can directly

phosphorylate the small GTPase Ras leading to the exchange of GDP for GTP (Luttrell et
al., 1997). Once Ras is activated, it can subsequently activate Raf, thereby initiating a
cascade of kinase phosphorylation where Raf phosphorylates MAP kinase kinase (MEK),
and MEK phosphorylates ERK1/2 (Luttrell et al., 1997). Phosphorylated ERK1/2 can then
go on to phosphorylate a number of different proteins, including a number

5

Figure 1.1. GPCR signalling pathways from left to right: Gq -coupled signalling, ERK signalling (examp le
shown as G protein-independent, βarrestin-dependent), Gs -coupled signalling, and Gi -coupled signalling.
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of intracellular proteins, kinases, and transcription factors to modulate cellular function
(Luttrell et al., 1997) (Figure 1.1).

1.3 G Protein-Coupled Receptor Trafficking
1.3.1 Endocytosis of G Protein-Coupled Receptors
Following the agonist activation of GPCRs, there exists a series of events that result
in the uncoupling or desensitization of GPCR signalling that are designed to terminate the
GPCR signalling (Ferguson, 2001) (Figure 1.2).

The most rapid of these processes

involves GPCR phosphorylation by second messenger-dependent kinases that are activated
downstream of G protein signalling, and by GRKs that phosphorylate the GPCR’s carboxyl
terminal tail and third intracellular loop to promote the recruitment of β-arrestins (Lohse et
al., 1990; Lohse et al., 1992; Ferguson, 2001; Luttrell and Lefkowitz, 2002). β-Arrestin
binding requires both agonist activation of the receptor and GRK phosphorylatio n
(Ferguson, 2001). β-arrestins not only serve to stericly hinder the reassociation of GPCRs
with the heterotrimeric G protein, but initiate GPCR endocytosis via their association with
both clathrin and the -adaptin subunit of the AP2 adaptor protein complex required for
the formation of clathrin-coated pits (Ferguson, 2001; Luttrell and Lefkowitz, 2002).
Clathrin forms a triskelion protein-structure which, when assembled, provides the
intracellular lattice for endocytotic machinery like β-arrestins (Ferguson, 2001). Clathrinindependent and β-arrestin-independent endocytosis mechanisms have been described
involving lipid rafts or caveolae. However, clathrin- and β-arrestin-dependent mechanis ms
are better described (Gonnord et al., 2012). This dense cluster of endocytotic proteins,
including clathrin, AP-2, and β-arrestins, promotes the invagination of the membrane,
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which ultimately pinches off intracellularly as a membrane-encapsulated endosome, a
process known as receptor endocytosis or receptor internalization (Ferguson, 2001). This
final fission from the rest of the cellular membrane is generally mediated by the large
GTPase dynamin (Ferguson, 2001; Luttrell and Lefkowitz, 2002).
With the displacement of the heterotrimeric G protein and the removal of the
receptor from the membrane, the GPCR-mediated signal prototypically terminates and
becomes desensitized to further ligand activation. Notwithstanding, there have been recent
indications that endosomal signalling may persist or initiate following endocytosis,
whereby β-arrestins may act as scaffolds for ERK1/2 signalling proteins (Sorkin and von
Zastrow, 2009). However, the physiological outcomes of these endosomal signalling
mechanisms are poorly described and receptor endocytosis has prototypically been
correlated with desensitization of traditional signalling pathways. Once the receptor is
contained within the membrane of an early endosome, it can undergo a series of fates.
These include: 1) dephosphorylation of the receptor in the early endosome, 2) sorting of
endosomal contents to recycling pathways, 3) return of the receptor to the plasma
membrane for further activation and/or 4) degradation via lysosomes (Pitcher et al., 1995;
Zerial and McBride, 2001; Sorkin and von Zastrow, 2009; Grant and Donaldson, 2009).

1.3.2 G Protein-Coupled Receptor Recycling
Following receptor endocytosis, the receptor-containing endosome can undergo a
series of fates ranging from receptor degradation to receptor recycling to the membrane.
Interestingly, the intracellular trafficking of the receptor-containing endosome is highly
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regulated by a collection of small Rab GTPases (Zerial and McBride, 2001). These
proteins act as molecular switches that recruit the appropriate trafficking machinery for the
endosomal stage and desired outcome by cycling between GDP- and GTP-bound states
(Zerial and McBride, 2001). The fission of the endosome from the cell membrane aligns
with the recruitment of Rab5, a marker of the early endosome (Zerial and McBride, 2001).
Maturation of the endosome coincides with the dissociation of Rab5 and the initiation of
divergent fates depending on endosomal contents and recruited trafficking machine r y
(Pitcher et al., 1995; Zerial and McBride, 2001; Sorkin and von Zastrow, 2009; Grant and
Donaldson, 2009). For example, recruitment of Rab4 to the endosome initiates the
formation of rapidly recycling endosomes and promotes GPCR dephosphorylation as the
receptor transits from the early to the recycling endosome. GPCRs mobilized to rapidly
recycling endosomes are trafficked back to the cell surface as fully functional resensitized
receptors (Pitcher et al., 1995, Magalhaes et al., 2012). Another method of receptor
recycling involves the Rab11 GTPase. Although the outcome is similar to Rab4-dependent
recycling,

this form of trafficking is mediated through the endosomal recycling

compartment and has a greater latency (Sorkin and von Zastrow, 2009; Grant and
Donaldson, 2009).

1.3.3 Lysosomal Degradation of G Protein-Coupled Receptors
In addition to recycling to the cell surface, GPCRs are also targeted for degradation
in lysosomes (Sorkin and von Zastrow, 2009). This occurs when endosomes mature into
multivesicular bodies and late endosomes (Sorkin and von Zastrow, 2009). The cargo
destined for degradation is often targeted to the intraluminal vesicles via a process called

9

Figure 1.2. Mechanism of GPCR Trafficking and Sorting. PDZ signifies proposed roles for regulatory PDZ
domain-containing proteins. G signifies G protein. E signifies G protein -dependent effector. E3 signifies
ubiquitin ligase. Ub signifies Ubiqitin.
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ubiquitination (Sorkin and von Zastrow, 2009). This post-translational modification is
targeted to lysine residues by ubiquitin ligases and not only promotes receptor
internalization, but delivers the cargo to the lysosomes (Sorkin and von Zastrow, 2009).
After fusion of the intraluminal vesicles with the lysosome, the cargo is released into the
lysosomal compartment where the proteins are met by a myriad of proteolytic enzymes for
degradation (Sorkin and von Zastrow, 2009). This process involves the inclusion of Rab7
GTPase and trafficking machinery is removed and recycled to be used in another lysosoma l
degradation event (Sorkin and von Zastrow, 2009).

1.4 Organization & Structure of the Post-Synaptic Density
Within the central nervous system, GPCRs and ion channels are primarily targeted
at the membrane of dendritic post-synaptic terminals in and around a region termed the
post-synaptic density (PSD) (Zheng and Feng, 2009; Neubig and Siderovski, 2002;
Magalhaes et al., 2012) (Figure 1.3). Each post-synaptic density is specifically organized
such that dozens to hundreds of receptors are targeted to this specialized membrane domain
via the interaction of scaffolding proteins with the receptors. These scaffolding proteins
containing multiple protein-protein interaction domains that allow them to interact with a
multitude of structural and signalling proteins holding them in close proximity with one
another (Zheng and Feng, 2009). Of these scaffolding proteins, it is believed that PDZ
(PSD-95, Disc large, Zona occludens-1) domain-containing proteins are the most abundant,
and often provide direct contact with both GPCRs and ion channels at the post-synaptic
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Figure 1.3. Simplified synapse to demonstrate the structural hierarchy of the postsynaptic density.
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density (Cheng et al., 2006; Zheng and Feng, 2009). Structurally, PDZ domain-containing
proteins make up the second layer of the post-synaptic density after the receptors, and are
arranged perpendicularly such that their amino termini are attached to the membrane
(Cheng et al., 2006; Zheng and Feng, 2009). A large subgroup of these second layer PDZ
domain-containing proteins are known as PSD-95 family membrane-associated guanylyl
kinase (MAGUK) proteins. These MAGUK proteins are characterized not only by the
inclusion of one or multiple PDZ domains, but two additional protein-protein interactio n
domains termed the Src homology 3 (SH3) domain and the guanylyl kinase-like (GK or
GuK) domain (Zheng and Feng, 2009). These domains are important for linking the second
layer of PDZ domain-containing proteins to the third layer within the post-synaptic density
which is abundantly occupied by Shank and guanylate kinase-associated protein family
members (Cheng et al., 2006; Zheng and Feng, 2009). It is this layer that provides the
majority of connections between the post-synaptic density and the actin cytoskeleton and
completes a vast network of protein-protein interactions capable of accommodating a
plethora of signalling molecules and enzymatic proteins (Cheng et al., 2006; Zheng and
Feng, 2009).

1.5 PDZ Domains
Of the network of proteins that make up the post-synaptic density, PDZ domaincontaining proteins appear to be most abundant and influential adaptor proteins involved
in directly regulating GPCR activity (Cheng et al., 2006; Zheng and Feng, 2009; Magalhaes

13

Figure 1.4.

Comparison of conserved domains amongst PDZ domain -containing proteins, focussed

predominantly on PDZ domain-containing proteins demonstrated to functionally regulate GPCRs. See also
Table 1.1.
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et al., 2012) (Figure 1.4). PDZ domains are approximately 80-90 amino acid residues in
length and are the most common protein-protein interaction domain (Doyle et al., 1996;
Zheng & Feng, 2009; Magalhaes et al., 2012). Although there are hundreds of unique PDZ
domain sequences, they all contain a conserved glycine- leucine-glycine-phenylalanine
(GLGF) sequence that provides the domain’s folded, globular, cup-like structure that is
capable of recognizing short, finger- like peptides (Harris and Lim, 2001). Because of this
structure, PDZ domains appear best suited for binding the distal regions of receptor
carboxyl terminal tails, labelled the PDZ-binding motif (Kornau et al., 1995; Niethamme r
et al., 1996; Harris & Lim, 2001; Magalhaes et al., 2012). Interestingly, additional studies
have identified internal PDZ ligands that, like a carboxyl terminal tail, project outwardly
from the protein (Xu et al., 1998; Hillier et al., 1999; Christopherson et al., 1999; Fouassier
et al., 2000; Harris and Lim, 2001; Trejo, 2005). In this case the internal PDZ-binding motif
is manifested as a sharply folded, finger- like projection (Xu et al., 1998; Hillier et al., 1999;
Christopherson et al., 1999; Fouassier et al., 2000; Harris and Lim, 2001; Trejo, 2005).

1.6 PDZ-Binding Motifs
Although seemingly imperfect and biased against internal PDZ ligands, a simple
classification system has evolved to identify potential PDZ-binding motifs on carboxyl
terminal tails and help to predict potential PDZ domain-containing proteins that interact
with them (Songyang et al., 1997; Bezprozvanny and Maximov, 2001; Sheng and Sala,
2001; Vaccaro and Dente, 2002). While there is some debate over how many classes of
PDZ-binding motifs there are, it is most commonly limited to three classes (Sheng and
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Sala, 2001; Magalhaes et al., 2012). Class I PDZ-binding motifs are the most commonly
described class within the literature and are distinguished by their final 3 amino acid
sequence of S/T-X-Φ, where X indicates any amino acid and Φ indicates any hydrophobic
amino acid (Songyang et al., 1997; Bezprozvanny and Maximov, 2001; Sheng and Sala,
2001; Vaccaro and Dente, 2002). However, valine, isoleucine, or leucine appear to be most
common of the hydrophobic amino acids that contribute to the formation of a Class I PDZ
binding motif (Songyang et al., 1997; Bezprozvanny and Maximov, 2001; Sheng and Sala,
2001; Vaccaro and Dente, 2002). Class II and III PDZ-binding motifs are not as well
characterized and show slightly more ambiguous sequences: with class II having its fina l
3 amino acids as Φ-X-Φ, and class III having Ψ-X-Φ, where Ψ represents any acidic amino
acid residue (Sheng and Sala, 2001).

1.7 PSD-95 Family of PDZ Domain-Containing MAGUK
Proteins
PSD-95 is perhaps the best described PDZ domain-containing protein and has been
estimated to be one of the most abundant proteins within the post-synaptic density (Cheng
et al., 2006). PSD-95 immunostaining has been extensively used as a marker to identify
post-synaptic densities by immmunofluoresence imaging.

However, less attention has

been drawn to the specific roles of PSD-95 both within the post-synaptic density and
beyond the central nervous system at other cell junctions (Gardoni et al., 2009).
Interestingly, it now appears that PSD-95 was merely the first identified of a small,
structurally homologous group of PDZ domain-containing proteins that is currently termed
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the PSD-95 family of MAGUK proteins (Gardoni et al., 2009). The members of this group
include PSD-95, synapse-associated protein 97 (SAP97), and the lesser studied PSD-93
and synapse-associated protein 102 (SAP102) (Gardoni et al., 2009).
The hallmark of the PSD95 family of PDZ domain-containing MAGUKs lies
within their protein-protein interaction domains. Although there is some minor variability
at the distal amino termini of these proteins, all members of this family follow with three
PDZ domains followed by an SH3 domain and a GK domain on the carboxyl termini
(Gardoni et al., 2009). The abundance of these proteins within the post-synaptic density,
coupled with these five protein-protein interaction domains, allows for an enormous
potential for scaffolding numerous receptors, ion channels, signalling proteins and
enzymes into a diverse and fluid signalling complex.
In addition to variations in sequence and the distal amino termini, the PSD-95
family of PDZ domain-containing MAGUKs also show differences within their subcellula r
localization in the brain (Gardoni et al., 2009). PSD-95 and PSD-93 exhibit high levels of
palmitylation on their amino termini which promotes their recruitment to the membrane of
the post-synaptic density (El-Husseini et al., 2000; Kim and Sheng, 2004). SAP97 and
SAP102 can also be found within the synapse. However they also show subcellula r
distribution within the axon, dendrites, and the cytosolic compartment (Kim and Sheng,
2004). Another point of difference between these proteins is their expression levels, both
within cell types and during the various stages of development (Kim and Sheng, 2004).
The PSD-95 family of PDZ domain-containing MAGUK proteins play an essentia l
role in human neurophysiology and development. This is demonstrated in mouse knockout
studies, where PSD-95 and PSD-93 double-knockout mice exhibit severe deficiencies in
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AMPA currents, and SAP97 knockout mice show neonatal lethality (Caruana and
Bernstein, 2001; Howard et al., 2010). Of particular interest to the current study, PSD-95
has been shown to be essential for hallucinogenic and atypical antipsychotic action (Abbas
et al., 2009).

SAP102 has also demonstrated importance during early synaptic

development (Kim and Sheng, 2004; Elias et al., 2006). The importance of these proteins
is again highlighted by their diversity of binding partners, including: voltage-gated K +
channels, glutamate-gated AMPA, NMDA, and kainite ion channels, GPCRs and a myriad
of other important neuronal proteins (Kim et al., 1995; Kornau et al., 1995; Muller et al.,
1996; Leonard et al., 1998; Garcia et al., 1998; Magalhaes et al., 2012; Gardoni et al.,
2009). Comprehending both the specific and the redundant roles of the PSD-95 family of
PDZ domain-containing MAGUK proteins promises to be an integral component for
understanding human neurophysiology.

1.8 Regulation of G Protein-Coupled Receptors by PDZ
Domain-Containing Proteins
PDZ domain-containing proteins represent an intriguing group of candidates for the
development of new pharmaceuticals. Their ability to regulate GPCRs is becoming more
apparent throughout the recent literature (Magalhaes et al., 2012), adding another
dimension of GPCR function that only furthers the complexity GPCR signalling.
However, it is this complexity that should aid in developing new pharmaceuticals with
greater efficacy and fewer off-target effects.

Each GPCR-PDZ functional relations hip

appears dependent on the receptor in question, the interacting PDZ domain-containing
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protein, and the cell type in which this interaction takes places (Magalhaes et al., 2012).
For example, the β1 -adrenergic receptor ( 1 AR) contains a class I PDZ-binding motif on
the distal end of its carboxyl terminal tail and has been one of the most documented GPCRs
regulated by PDZ domain-containing proteins (Hu et al., 2000; Xu et al., 2001; Pak et al.,
2002; Hu et al., 2003; He et al., 2004; He et al., 2006; Gardner et al., 2007). While the
PDZ domain-containing proteins PSD-95 and SAP97 both appear to promote membrane
localization of the  1 AR, PSD-95 has been documented to do so by inhibiting receptor
internalization, while SAP97 has been suggested to promote receptor recycling to the
membrane (Hu et al., 2000; Gardner et al., 2007). Conversely, two other PDZ domaincontaining proteins, MAGI-2 and Cal, have been demonstrated to suppress membrane
localization of the  1 AR (Hu et al., 2000; He et al., 2004). However, MAGI-2 prevents
membrane stability by promoting receptor internalization into endocytic vesicles, while
Cal traps receptor in the Golgi apparatus (Hu et al., 2000; He et al., 2004). The ability of
PSD-95 to suppress  1 AR internalization is also observed for the serotonin 2A receptor (5HT2AR). However, it appears to play the opposite role in promoting

5-HT2CR

internalization (Xia et al., 2003; Gavarini et al., 2006).
Albeit confusing, understanding each of these specified GPCR-PDZ functio na l
relationships may lead to fine-tuned development of new pharmaceuticals that specifica lly
target GPCR-PDZ interactions.

A table of these documented GPCR-PDZ functio na l

relationships is outlined in Table 1.1 and some trends are developing.

For example,

NHERF1 has demonstrated a clear importance for receptor trafficking and membrane
localization by both inhibiting receptor endocytosis and, to a lesser extent, promoting
receptor recycling (Rochdi and Parent, 2003; Wang et al., 2007; Wang et al., 2009; Li et
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PDZ Protein
CAL
(PIST, GOPC, FIG)

GPCR

 1 AR
mGluR1a
mGluR5a
SSTR5

Reported Effect on GPCR

Reference

↓ membrane expression
Agonist-induced intracellular co-localization with receptor, ↓ ERK activation
↑ mGluR5a protein expression, ↓ receptor ubiquitination
Targets receptor to Golgi apparatus (agonist-independent), ↓ membranetargeting/recycling

He et al, 2004
Zhang et al, 2008
Cheng et al, 2010


 1 AR
D2
D3
hLHR

↓ ERK activation, no effect on cAMP signalling
Targets receptor to Golgi region
↓ signal transduction through Gi, targets receptor to Golgi region, ↓ D3 degradation
Maintains receptor cell surface expression during hormone internalization

Hu et al, 2003
Jeanneteau et al, 2004
Jeanneteau et al, 2004
Hirakawa et al, 2003


 1 AR
VPAC1

↑ agonist-induced internalization, no effect on cAMP signalling
↓ cAMP signalling, ↓ agonist-induced internalization

Xu et al, 2001
Gee et al, 2009

MAGI-3


 1 AR
  AR
LPA2

↓ ERK activation
↓ ERK activation
↑ ERK activation, ↑ RhoA activation

He et al, 2005
Yang et al, 2010
Zhang et al, 2007

MPP3

5-HT2c

↑ membrane stability, ↓desensitization

Gavarini et al, 2006

MUPP-1

5-HT2a
GABAB
MT1
OR2AG1

↑ localization to cell surface
↑ Ca2+ signalling
↑ coupling with Gi protein, ↑ inhibition of adenylyl cyclase activity
Modulates Ca2+ signalling

Jones et al, 2009
Balasubramanian et al, 2006
Guillaume et al, 2008
Dooley et al, 2009

5-HT4a

Targets receptor to microvilli to interact with ezrin (potential role in cytoskeletal
remodelling)
Agonist-induced co-localization with receptor
Regulates receptor sorting through ERM-binding domain interactions
↓ receptor down-regulation, ↑ recycling
↓ agonist-induced internalization, negligible effect on recycling and cAMP signalling
↑ coupling to, and activation of, Gq
↓ interaction with -arrestin-2, ↓ desensitization
Targets receptor to membrane regions in close proximity to cytoskeleton, ↑ cAMP signalling
↓ internalization

Joubert et al, 2004
Hall et al, 1998
Cao et al, 1999
Li et al, 2002
Wang et al, 2007
Wang et al, 2010
Wang et al, 2009
Wheeler et al, 2008
Rochdi et al, 2003

↑ interaction with PLC3
↑ IP 3 signalling , ↑ ERK activation
↑ agonist-induced Ca2+ signalling
↑ interaction with PLC, ↑ agonist-induced Ca2+ signalling
↑ interaction with, and activates, PLC
↓ adenylyl cyclase activity through stimulation of inhibitory G proteins (Gi/o proteins).
↑ coupling to, and activation of, Gq and Gi; ↓ coupling to, and activation of, Gs

Choi et al, 2010
Oh et al, 2004
Paquet et al, 2006
Fam et al, 2005
Mahon et al, 2002
Mahon et al, 2002
Wang et al, 2010

↑ interaction with PLC1

Choi et al, 2010

Required for agonist-induced Ras activation via Gs-mediated cAMP signalling

Pak et al, 2002

↓ PKC-mediated receptor phosphorylation
↑ intracellular clustering of receptor

Dev et al, 2000
Lin et al, 2001

GIPC
(TIP-2, Synectin)

MAGI-2
(S-SCAM, ARIP-1)

NHERF1
(EBP50)

  AR
  AR
hKOR
PTH1R
PTH1R
PTH1R
PTH1R
TP

NHERF2
(E3KARP, SIP-1, TKA-1)

LPA2
LPA2
mGluR5a
P2Y 1 R
PTH1R
PTH1R
PTH1R

PAR-3

BK

PDZ-GEF
(CNrasGEF, RA-GEF, Rap GEP)


 1 AR


Wente et al, 2005

PICK1

mGluR7a
PrRP (GPR10)

PSD-95
(DLG4, SAP90)

5-HT2a
5-HT2c
 1 AR
D1
D1

↓ agonist-induced internalization, ↑ IP 3 signalling
↑ constitutive and agonist-induced internalization, ↑ desensitization
↓ agonist-induced internalization, no effect on cAMP signalling
↑ constitutive internalization, ↓ cAMP signalling
↑ recycling, ↑ resensitization, no effect on Gs activation or cAMP signalling

Xia et al, 2003
Gavarini et al, 2006
Hu et al, 2000
Zhang et al, 2007
Sun et al, 2009


 1 AR


↑ PKA-mediated receptor phosphorylation, ↑ recycling

Gardner et al, 2007

↑ membrane expression, ↑ complex formation with cytohesin-2 (GEF)

Kitano et al, 2002

SAP97
(DLG1)
Tamalin
(GRASP)

mGluR1a

Table 1. Functional interactions of PDZ domain-containing proteins and GPCRs. A version of this table is
published in the British Journal of Pharmacology: Magalhaes AC, Dunn H and Ferguson SS (2012)
Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol
165:1717-1736.
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al., 2002). Conversely, NHERF2 does not yet have a well-documented role in GPCR
trafficking, but appears to have a significant role in Gαq-coupling, and subsequent PLC
activation, IP3 accumulation and Ca2+ release (Wang et al., 2010; Mahon et al., 2002; Choi
et al., 2010; Fam et al., 2005; Oh et al., 2004; Paquet et al., 2006). MAGI2 has also
demonstrated a role in the regulation of GPCR trafficking, whereas the role of MAGI3 has
been described primarily in the context of ERK signalling (Xu et al., 2001; Gee et al., 2009;
He et al., 2006; Zhang et al., 2007; Yang et al., 2010). Interestingly, PDZ domaincontaining proteins Cal and GIPC both appear to be Golgi-associated proteins that have a
role in post-translational modifications of GPCRs and regulating the forward trafficking of
the receptor from the Golgi to the cell surface (Wente et al., 2005; Cheng et al., 2010;
Jeanneteau et al., 2004). A schematic of proposed roles of PDZ domain-containing proteins
in regulating GPCR activity is shown in Figure 1.2 and is based on the currently availab le
evidence. For the studies to follow in Chapter 2, 3, and 4, PSD-95 and SAP97 will be the
focus.

1.8.1 PSD-95 and SAP97 in Regulating G Protein-Coupled Receptor
Function
Although the definitive roles for PSD-95 and SAP97 in GPCR regulation have yet
to be clearly elucidated, there is a small body of work to make inferences upon the
subcellular physiological processes they may contribute to (Magalhaes et al., 2012). PSD95 has been demonstrated to decrease the agonist-induced endocytosis of both the 5HT2AR
and the  1 AR (Xia et al., 2003; Hu et al., 2000). While this interaction is capable of
enhancing 5HT2AR-mediated IP3 signalling via Gq, it had no effect on  1 AR -stimula ted
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cAMP signalling via Gs (Xia et al., 2003; Hu et al., 2000). As mentioned previously, the
role for PSD-95 in regulating 5HT2CR appears to be in opposition to what is observed for
 1 AR, as PSD-95 increases both constitutive and agonist-mediated endocytosis of 5-HT2CR
leading to increased desensitization of 5-HT2CR signalling (Gavarini et al., 2006).
Interestingly, PSD-95 has been demonstrated to also increase both the constitutive
endocytosis, recycling and resensitization of the dopamine D1 receptor (Zhang et al., 2007;
Sun et al., 2009). However, there have been conflicting results regarding whether PSD-95
inhibits D1 receptor-mediated cAMP signalling (Zhang et al., 2007; Sun et al., 2009).
Nevertheless, the potential role of PSD-95 in enhancing receptor recycling is mirrored by
the ability of SAP97 to regulate the recycling of the  1 AR (Gardner et al., 2007). Although
there are some discrepancies in the functional characterization of PDZ domain-containing
proteins, these studies suggest PSD-95 and SAP97 play a major role in regulating GPCR
trafficking with a predisposition for promoting increased plasma membrane localization of
GPCRs, and that this mechanism involves a reduction in GPCR internalization and an
enhancement in GPCR recycling.

1.9 Mood Disorders and Psychiatric Disease
One of the least effective and minimally developed group of pharmaceuticals over
the past half-century has been those used to treat mood disorders and psychiatric disease
(Urs et al., 2014). This is undoubtedly due to our insufficient knowledge of the cellula r
and subcellular pathologies that are associated with these disorders (Urs et al., 2014). It is
estimated that 25% of the population will be affected by some form of mental illness :
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ranging from drug abuse, anxiety disorders, depression, bipolarism, schizophrenia and
other psychiatric illnesses (WHO, 2001; Urs et al., 2014). A common misconception about
mental illnesses, like depression, is the suggestion that patients could conquer the illnes s
without medical intervention (Catapano and Manji, 2007; Fribourg et al., 2011). In fact,
many studies have demonstrated that those suffering from mental illness frequently have
pathological differences in their brain that could benefit from pharmacological interventio n
(Catapano and Manji, 2007; Fribourg et al., 2011). Although many of these disorders have
similarities and co-morbidities, properly identifying the illness can heavily influence the
treatment strategy.

1.9.1 Anxiety Disorders
Anxiety is a common emotional state exemplified by intensified emotional arousal
and autonomic nervous system activity (Lowry et al., 2005). This complex emotion is
believed to be prevalent in scenarios where the outcome of a particularly emotionallysalient event is undefined, and both positive and negative outcomes are possible (Lowry et
al., 2005). It is the uncertainty and uncontrollability of the outcome associated with one’s
actions that leads to this heightened state of emotional arousal, often promoting the
avoidance of the emotionally-salient scenario and the associated behaviours (Lowry et al.,
2005). Although anxiety can be positive in heightening arousal levels when faced with
difficult decisions of high emotional salience, anxiety disorders can prolong or sensitize
the anxiety in seemingly mild scenarios. These disorders include phobias, panic disorders,
separation anxiety, obsessive-compulsive disorder, situational anxiety, post-traumatic
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stress disorder and general anxiety disorder. Although there are subtle differences amongst
these disorders, they are united by the intense emotional and autonomic arousal under
innocuous circumstances with perceivably undefined, uncontrolled, and/or unpredictab le
outcomes (Lowry et al., 2005).

1.9.2 Depressive Disorders
Anxiety disorders and major depressive disorders are often mentioned in the same
sentence, often because of the comorbidity of these two forms of mental illness (Nesler et
al., 2002; Lowry et al., 2005). Nonetheless, there are tangible differences between the two.
In anxiety disorders, there exists a heightened state of arousal caused by the uncertainty of
an outcome, where both positive and negative outcomes are possible (Lowry et al., 2005).
Depression is instead characterized by a state of low energy, fatigue, and lowered
concentration, with feelings of hopelessness, low self-esteem and general depressed mood
(Nestler et al., 2002). Depressed individuals exhibit higher levels of irritability and have
dysfunctions in their sleeping patterns, appetite, and metabolism (Nestler et al., 2002;
Shelton, 2007). Futhermore, the hallmarks of the disease include negative rumination, a
lack of motivation, the inability to experience pleasure (termed anhedonia) and often
reoccurring thoughts of death and/or suicide (Nestler et al., 2002; Shelton, 2007). Of these
characteristics, anhedonia may be the most distinguishing factor from general anxiety
disorders. The inability to experience pleasure eliminates a potential positive or reinforc ing
outcome for the depressed individual’s behaviours: which can lead to the observed
avoidance behaviours and feelings of early defeat and hopelessness (Nestler et al., 2002;
Shelton, 2007).

Nevertheless, there is a high-degree of similarity between anxiety

disorders and major depressive disorders, as well as comorbidity of the disorders.

24

Depressive disorders affect an astounding 15-20% of North Americans within their
lifetime with a high rate of reoccurrence and therefore represents a serious threat to the
health of the population (Nestler et al., 2002; Krishnan and Nestler, 2008). Not only do
depressed individuals have a heightened risk of suicide, but prolonged depression can
increase the probability of many other serious and chronic diseases, including coronary
heart disease and type II diabetes (Evans et al., 2005; Krishnan and Nestler, 2008). Despite
the prevalence and severity of major depressive disorders, the underlying pathology and
treatment/prevention strategies remain poorly understood. The hypothesized molecula r
neurobiology of anxiety disorders, depressive disorders, and schizophrenia will be
discussed in the “G Protein-Coupled Receptors Implicated in Mood Regulation and
Psychiatric Disorders” section.

1.9.3 Schizophrenia
Schizophrenia is a serious psychiatric disorder that occurs in approximately 1% of
the general population (Bromet and Fennig, 1999). The severity of schizophrenia can vary
from one individual to another, with symptoms ranging from dulled emotion, lack of
motivation, poor attention, debilitated memory, and dysfunction in cognitive control, to the
inclusion of delusional beliefs, hallucinogenic experiences, and disorganized think ing
(Lewis and Lieberman, 2000). Many of these symptoms could be mistaken for anxiety or
depressive disorders in earlier life, however the severe symptoms of delusions and
hallucinations often don’t present until early adulthood (Lewis and Lieberman, 2000).
Sadly, over 10% of individuals suffering from schizophrenia will commit suicide within
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their lifetime, and there is a strong genetic component in the etiology of the disease (Lewis
and Lieberman, 2000).

Despite the genetic predisposition for schizophrenia, the

comorbidity of schizophrenia and anxiety and depressive disorders suggests early
experience with these disorders may increase the risk of the manifestation of the psychosisbased disease (Marcelis et al., 1998; Hartley et al., 2013). Although second generatio n
atypical antipsychotics have become the preferred treatment for this disorder, efficacy of
these drugs remains suboptimal and serious side-effects remain prevalent, such as
extrapyramidal symptoms and tardive dyskinesia (Pierre, 2005; Lewis and Lieberma n,
2000).

1.9.4 G Protein-Coupled Receptors Implicated in Mood Regulation
and Psychiatric Disorders

GPCRs are targeted by over 30% of currently available pharmaceuticals because of
their widespread regulation of human physiological processes (Urs et al., 2014). This
regulatory role of GPCRs has additionally been implicated in the modulation of mood and
the manifestation of psychiatric disease (Catapano and Manji, 2007). This notion is
supported by the fact that 90% of GPCRs are located within the brain (Vassilatis et al.,
2003). Interestingly, this regulation of mood is not limited to a single family of GPCRs
(Catapano and Manji, 2007). For example, agonists of dopamine receptors (D1-4 ) have
demonstrated some value as antidepressants, whereas antagonizing these receptors could
be utilized for the treatment of acute periods of mania (Sporn et al., 2000). Antidepressa nts
have been shown to generally downreguate both α- and β-AR activity, with exception of
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the α1 AR, which appears to be up-regulated by antidepressants (Catapano and Manji,
2007).

Additionally, antidepressants have been associated with down-regulation of

cholinergic GPCRs, and cholinergic muscarinic receptor 2 polymorphisms have been
implicated in depression (Ellis and Lenox, 1990; Comings et al., 2002). Although the
majority of research on the glutamatergic system’s role in mood regulation has focussed
on the ionotropic AMPA and NMDA receptors, metabotropic glutamate receptor 2
(mGluR2) has been demonstrated to be up-regulated

with treatment of atypical

antipsychotics (Fribourg et al., 2011). Furthermore, GABAB receptor agonists have been
shown to induce acute depression and antagonism of neurokinin1 (NK1) receptors offer
effects similar to antidepressants (Post et al., 1991; Gobbi and Blier, 2005).
Despite an obvious complexity and diversity of GPCRs involved in mood
regulation, the serotonergic and corticotrophic systems are of primary focus to our studies.
5HT2AR, 5-HT2CR, and corticotropin-releasing factor receptor 1 (CRFR1) are thought to
contribute to the manifestation of mood disorders, whereas 5HT1AR and CRFR2 may play
more of a preventative role (Fernandes et al., 1997; Mansbach et al., 1997; Meltzer et al.,
2003; Bale and Vale, 2004; Catapano and Manji, 2007). The studies to follow in Chapters
2, 3, and 4 will focus primarily on 5HT2AR and CRFR1.

1.9.4.1 Serotonin 2A Receptor (5-HT2AR)
Serotonin, or 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter that
has a large role in regulating mood and behaviour (Hale et al., 2012). Serotonin also
contributes to the modulation of sleep cycles, circadian rhythms, and appetite. These
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important physiological systems that are commonly dysregulated in mood disorders and
psychiatric disease (Krishnan and Nestler, 2008; Hale et al., 2012). The vast majority of
serotonergic neurons in the brain are densely clustered within the raphe nuclei of the
reticular formation, within the brain stem (Bobillier, 1976; Hornung, 2003). These neurons
project towards many cortical and subcortical regions of the brain, including important
regions of the limbic system like the nucleus accumbens, amygdaloid structures, basal
ganglia, hippocampus, and prefrontal cortex (Hornung, 2003; Lowry et al., 2005). These
limbic regions have been heavily implicated in regulating many aspects of mood and
behaviour, such as emotional salience, reward, punishment, memory, and decision-mak ing
(Hornung, 2003; Lowry et al., 2005).
Serotonin can act on a seven different receptor subtypes and, with the exception of
the 5-HT3 R ion-channel, all of these receptors are GPCRs (Barnes, 2011). Interestingly, a
number of these receptors have been implicated in contributing to the antipsychotic action
of second generation atypical antipsychotics, however the 5-HT2 R subtype, primarily 5HT2AR and 5-HT2CR appear to be of greatest significance (Meltzer et al., 2003; Catapano
and Manji, 2007).
In a study of the post-mortem brains of suicide victims who had been known to be
afflicted with a major depressive disorder, a significant enhancement in 5-HT2AR and 5HT2CR expression levels was observed when compared to control brains (Catapano and
Manji, 2007).

Interestingly,

a similar increase in 5-HT2AR expression has been

documented in a population of schizophrenics who had not been treated with second
generation atypical antipsychotics, whereas those who had received this treatment saw a
decrease in 5-HT2AR expression (Fribourg et al., 2011). Furthermore, the efficacy of
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atypical antipsychotics, such as clozapine, ariprizaole, and rispiridone appears to be reliant
on the compounds ability to suppress 5-HT2AR-biased signalling of a 5-HT2AR-mGluR2
heterodimer (Fribourg et al., 2011).

Additionally, 5-HT2AR knockout mice exhibit

significantly lower anxiety-related behaviours when compared to control mice (Weisstaub
et al., 2006). For these reasons, 5-HT2AR and 5-HT2CR have become primary targets for
the treatment of a range of mental illnesses including anxiety disorders, major depressive
disorders, eating disorders, obsessive-compulsive disorder, and schizophrenia (Gray and
Roth, 2001; Roth and Xia., 2004; Catapano and Manji, 2007).
Although 5-HT2 Rs appear to be relevant for a continuum of mental illnesse s,
relatively little is known about the subcellular regulation of 5-HT2 Rs in the brain (Schmid
et al., 2008; Abbas et al., 2009).

Both the increased 5-HT2AR expression levels in

depressed patients, and the strong antagonism of 5-HT2AR exhibited by the most
efficacious atypical antipsychotics, drive the hypothesis that suppressing 5-HT2AR
expression and activity may be a pertinent strategy in mood regulation across a multitude
of mental illness (Catapano and Manji, 2007; Fribourg et al., 2011). An emerging topic of
the past decade has been the demonstration that 5-HT2 Rs are subject to the regulation of
PDZ domain-containing proteins (Table 1). These proteins regulate specific receptor
activities

including

membrane

localization,

receptor signalling,

endocytosis,

and

desensitization (Table 1). In regards to the 5-HT2AR and 5-HT2CR, these signalling
pathways primarily include IP 3 signalling and ERK/MAPK signalling (Raymond et al.,
2009).
Perhaps the most important study exemplifying the importance of PDZ-regulatio n
of 5-HT2AR in mental illness demonstrated that atypical antipsychotic action via 5-HT2AR
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was dependent on the endogenous expression of PDZ domain-containing protein PSD-95
(Abbas et al., 2009). Although atypical antipsychotics represent the latest and most
effective development in the treatment of psychoses-based psychiatric disease, the efficac y
of these drugs remains suboptimal. Manipulating 5-HT2AR interactions with specific PDZ
domain-containing proteins may represent a viable strategy for the advancement of more
effective psychiatric medications and mood regulation strategies. Although PSD-95 has
previously been recognized as a regulator of 5-HT2AR-mediated IP3 signalling and receptor
trafficking, an additional subset of PDZ domain-containing proteins have been identified
that biochemically interact with 5-HT2AR and may participate in regulating its functio n
(Xia et al., 2003; Becamel et al., 2004; Abbas et al., 2009). Understanding how each of
these PDZ domain-containing proteins may specifically influence 5-HT2AR function may
provide the opportunity to design new pharmacological intervention strategies to fine-tune
5-HT2AR function and minimize the side-effects seen in current medications of mental
illness.

1.9.4.2 Corticotropin-Releasing Factor Receptor 1 (CRFR1)
Corticotropin-releasing factor (CRF), also referred to as corticotropin-releas ing
hormone (CRH), is a neuropeptide commonly associated with its ability to initiate the
hypothalamic-pituitary-adrenal (HPA) axis “stress response” (Tsigos and Choursos, 2002).
This pathway is activated in response to stressors and leads to the release of CRF from the
paraventricular nucleus of the hypothalamus (Tsigos and Choursos, 2002). CRF travels
through the blood via the hypothalamic- hypophyseal portal system towards the anterior
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pituitary.

Following CRF stimulation, the anterior pituitary subsequently releases

adrenocorticotropic hormone (ACTH) into the bloodstream, which ultimately reaches the
adrenal cortex of the adrenal glands located atop the kidneys (Tsigos and Choursos, 2002).
This ACTH stimulation promotes the synthesis and release of cortisol and other
glucocorticoids from the adrenal glands into the blood stream. Cortisol consequently
circulates throughout the bloodstream and is capable of activating glucocorticoid receptors
in the brain to regulate behaviour and liberate glucose from intracellular stores to provide
energy for coping with the stressor (Tsigos and Choursos, 2002).
CRF’s role in initiating the HPA axis stress response clearly demonstrates the
neuropeptides importance in the body’s physiological response to stress. However,
emerging research suggests that an elevation of CRF in extra-hypothalamic brain regions
can correlate with both anxiety disorders and depression (Austin et al., 2003). Apart from
the paraventricular nucleus of the hypothalamus, CRF can also be synthesized and released
from additional limbic regions such as the central amygdala and the bed nucleus of the stria
terminalis (Swanson et al., 1983). Notably, increased levels of CRF in extra-hypothala mic
brain regions have been observed in the post-mortem brains of depressed individuals who
fell victim to suicide (Austin et al., 2003). Apart from the well-established role in stress,
the CRF system has now become a major pharmacological target for the treatment of both
anxiety disorders and depressive disorders.
CRF mediates its response via two different receptors, CRFR1 and CRFR2 both of
which are GPCRs. Although these receptors have both been implicated in regulating mood
and behaviour, CRFR1 has a ten-fold greater affinity for CRF neuropeptide and is
expressed at higher levels throughout the brain (Bale and Vale, 2004). Additionally,
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CRFR1 antagonists have demonstrated anxiolytic-

and antidepressant- like

effects:

suggesting this receptor may be the most viable target for mood regulation and psychiatr ic
treatment (Mansbach et al., 1997; Catapano and Manji, 2007). Analyzing all of the studies
on knockout mice further reinforces CRFR1’s role in anxiogenesis (Bale and Vale, 2004;
Janssen and Kozicz, 2013).

Although some inconsistencies have been documented

depending on the type of knockout mouse, the majority of work demonstrates that CRFR1
knockout mice exhibit lowered-levels of anxiety-like behaviour, whereas CRFR2 knockout
mice have heightened levels of anxiety- and depressive-like behaviour (Bale and Vale,
2004; Janssen and Kozicz, 2013). Although CRF-regulation of anxiety and depression is
likely far more complicated than this model for receptor dualism, it is clear that CRFR1,
and likely CRFR2, are viable targets for the treatment of mental illness.
Despite the promise of CRFR1 as a pharmacological target, very little is known
about the regulation of CRFR1 function at the subcellular- level. CRFR1 is prototypically
coupled to Gαs and thereby signals primarily through the cAMP signalling pathway.
However, it has additionally been demonstrated to activate the MAPK/ERK signalling
pathway (Hauger et al., 2009).

In terms of receptor trafficking, CRFR1 has been

demonstrated to be phosphorylated by GRKs leading to the recruitment of β-arrestins and
the initiation of receptor endocytosis (Holmes et al., 2006). CRFR1 colocalizes with the
early endosomal small GTPase Rab5 during receptor internalization, and subsequently with
Rab4 which initiates recycling of the receptor (Holmes et al., 2006).
Interestingly, a recent study in mouse cortical slices has demonstrated that CRFR1
is capable of enhancing the signalling of the 5-HT2AR, another GPCR heavily involved in
mood regulation and psychiatric pharmacology (see section 1.9.4.1) (Magalhaes et al.,
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2010). Cotreatment of both CRF and DOI, a potent 5-HT2AR agonist, was demonstrated
to elicit a significant enhancement in anxiety- like behaviour in mice that was not observed
with DOI alone (Magalhaes et al., 2010). Additionally, suicide victims with documented
major depressive disorder have been observed with significantly enhanced CRF levels
within serotonergic neurons of the raphe nuclei (Austin et al., 2003). Furthermore, CRF is
capable of activating serotonergic efferents of the raphe nuclei that terminate in the medial
prefrontal cortex (mPFC) and initiate anxiety- like behaviour (Meloni et al., 2008). Taken
together, it is clear that the interaction of the CRF and serotonergic systems could play an
integral role in mood regulation and the manifestation of psychiatric disease.
Some insight into potential CRFR1 regulation mechanisms was recently provided
by the observation that the CRFR1 pre-activation enhances 5-HT2AR -mediated IP3
signalling and that this effect of CRFR1 on 5-HT2AR signaling is dependent upon intact
receptor PDZ-binding motifs (Magalhaes et al., 2010). Specifically, when deleted, the lack
of a PDZ-binding motif in the distal carboxyl terminus of either the CRFR1 or 5-HT2AR
prevented the heterologous sensitization of 5-HT2AR signaling by CRFR1 (Magalhaes et
al., 2010). Interestingly, this phenomenon was also dependent upon effective receptor
endocytosis and rapid recycling to the membrane, as blocking these processes abolished
receptor crosstalk (Magalhaes et al., 2010). As PDZ domain-containing proteins appear
integral in the regulation of GPCR trafficking, this finding provides further evidence for
involvement of PDZ domain-containing proteins in the heterologous sensitization of 5HT2AR by CRFR1 (Magalhaes et al., 2010; Magalhaes et al., 2012) This suggests that not
only could PDZ domain-containing proteins be important in regulating the crosstalk
between CRFR1 and 5-HT2AR, but PDZ interactions could foreseeably regulate CRFR1
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function independently of 5-HT2AR. The interaction of PDZ domain-containing protein
PSD-95 with 5-HT2AR has proved to be essential for the action of second generatio n
atypical antipsychotics (Abbas et al., 2009). Therefore, it is plausible that PDZ proteindependent regulation of CRFR1 may prove important in the manifestation of mental illnes s
and the development of new pharmacological treatment strategies (Abbas et al., 2009).

1.9.5 Implications for PSD-95 and SAP97 in the Manifestation of
Psychiatric Disease
PDZ domain-containing proteins have been implicated in regulating two important
receptors involved in mood regulation: 5-HT2AR and CRFR1 (Magalhaes et al., 2010).
However, the specific PDZ domain-containing proteins that are involved in regulating 5HT2AR and CRFR1 remains relatively unknown.

The first and only PDZ domain-

containing protein documented to regulate 5-HT2AR is PSD-95, and regulation of CRFR1
by PDZ domain-containing proteins has yet to be documented (Xia et al., 2003). Although
the mechanisms for regulating mood-related receptors are yet to be understood,
abnormalities in both PSD-95 and SAP97 have previously been implicated in psychiatr ic
disease (Toyooka et al., 2002; Clinton et al., 2003; Clinton & Meador-Woodruff, 2004;
Toro and Deakin, 2005; Clinton et al., 2006; Kristiansen, 2006; Tsai et al., 2007; Sato et
al., 2008; Funk et al., 2009). In examining post-mortem brains of schizophrenic patients,
a reduction of PSD-95 has been observed in the thalamus, hippocampus, and anterior
cingulate cortex (Clinton & Meador-Woodruff, 2004; Toro and Deakin, 2005; Kristianse n,
2006; Funk et al., 2009). Conversely, other studies demonstrate that PSD-95 appears to be
increased in the thalamus in elderly populations of schizophrenic patients (Clinton et al.,
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2003; Clinton et al., 2006). This discrepancy is complicated by the method of determining
changes in PSD-95 expression, mRNA transcript levels versus protein expression, as one
study documented

higher

transcript

levels

associated with lower protein levels

(Kristiansen, 2006). This suggests that despite potential increases in PSD-95 translatio n,
increased PSD-95 protein degradation may prevail as the mechanism regulating functio na l
PSD-95 protein available to regulate receptor activity at the synapse. Although the changes
in SAP97 expression have not been examined in anxiety and depression, one study has
reported that SAP97 expression is significantly lower in the prefrontal cortex of
schizophrenic patients (Toyooka et al., 2002). Additionally, a variety of single nucleotide
polymorphisms (SNPs) of the genes encoding PSD-95 and SAP97 have been associated
with schizophrenia (Tsai et al., 2007; Sato et al., 2008).

Most convincingly, the

antipsychotic action of second generation atypical antipsychotics appears dependent on the
endogenous expression of PSD-95 (Abbas et al., 2009). Taken together, it is clear that
PSD-95 and SAP97 play an important role in the progression of psychiatric disease, and
this role may be linked to their potential ability to regulate CRFR1 and 5-HT2AR fu-nctio n.

1.10 Current Study Hypothesis, Objectives and Scientific
Design

From the aforementioned evidence, CRFR1 and 5-HT2AR appear to play a role in
the manifestation of mental illness, and there is indication that these receptors may be
regulated by PDZ domain-containing proteins. One of these studies indicated that the PDZ
domain-containing protein PSD-95 was capable of regulating 5-HT2AR trafficking and IP3

35

signalling (Xia et al., 2003). Interestingly, PSD-95, and the similar structural homologue
SAP97, have both been implicated in psychiatric disease. For this reason, it is possible that
PSD-95 and SAP97 may regulate these receptors and this relationship may be of relevance
for understanding,

treating,

and preventing

mental illness.

In addition,

CRFR1

heterologously sensitizes 5-HT2AR signalling in a PDZ protein interaction-depende nt
manner and synergistically increases 5-HT2AR-mediated anxiety behaviour in mice
(Magalhaes et al., 2010). Therefore, this thesis will test the hypothesis that the MAGUK
family PDZ proteins, PSD-95 and SAP97, not only contribute to the regulation of CRFR1
and 5-HT2AR activity, but that these interactions are involved in the sensitization of 5HT2AR signalling by CRFR1.
Because PSD-95 was already demonstrated to regulate 5-HT2AR function (Xia et
al., 2003), our objectives were as follows:
1. Evaluate whether SAP97 regulates CRFR1 signalling and trafficking
2. Evaluate whether SAP97 regulates 5-HT2AR signalling and trafficking
 Determine whether SAP97 is responsible for CRFR1-mediated
sensitization of 5-HT2AR signalling
3. Evaluate whether PSD-95 regulates CRFR1 signalling and trafficking


Determine whether PSD-95 is responsible for CRFR1-mediated
sensitization of 5-HT2AR signalling

To achieve these objectives, a number of experimental techniques were
utilized. The interaction between PDZ domain-containing protein and receptor was
determined

via

co-immunoprecipitation

and

immunofluorescent

confocal

microscopy utilizing HEK293 cells, rat neurons, or homogenized adult mouse
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brain.

To investigate the roles of PSD-95 or SAP97 in receptor trafficking,

immunofluorescent confocal microscopy and flow cytometry were also employed.
To determine PDZ protein effect on receptor signalling, a combination of cAMP
assays, radiolabelled IP accumulation experiments, and western blot analysis of
ERK1/2 phosphorylation were performed.
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Chapter 2: SAP97 Regulation of CRFR1
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2.1 Introduction
Corticotropin-releasing

factor (CRF) is a neuropeptide

that regulates

the

physiological response of the body to stress and initiates the hypothalamic-pituitar yadrenal axis stress response (Vale et al., 1981; Leonard, 2005). CRF mediates these
responses by activating two distinct G protein-coupled receptors (GPCRs): CRF receptor
1 (CRFR1) and CRF receptor 2 (CRFR2) (Chalmers et al., 1996; Dautzenberg et al., 2002).
In comparison to CRFR2, CRFR1 exhibits a significantly higher affinity for CRF and
shows far greater expression within the brain and in the pituitary (Chalmers et al., 1995;
Palchaudhuri et al., 1998). The dysregulation of the hypothalamic-pituitary-adrenal axis is
thought to be involved in the onset of psychiatric diseases, such as depression, and CRFR1
antagonists have recently been shown to demonstrate anxiolytic- and antidepressant- like
effects (Overstreet et al., 2004; Chaki et al., 2004). GPCRs, like CRFR1, and their
associated GPCR-interacting Proteins (GIPs) have vast potential as pharmacologica l
targets in the treatment of disease. Over 40% of modern pharmaceuticals target G proteincoupled receptors because of their widespread contributions to physiology (Marshall et al.,
2001). For these reasons, CRFR1 represents an excellent candidate as a pharmacologica l
target for the treatment of mood disorders, such as depression, and thus better
understanding of the trafficking and signaling properties of CRFR1 may lead to the
discovery of new pharmacological targets for mood regulation.
The physiological effects of GPCRs, like the CRFR1, are determined by the
activation of receptor-mediated intracellular signaling pathways, and the intracellula r
trafficking of the receptor is responsible for determining the availability of receptor for
agonist activation (Ferguson et al., 1998; von Zastrow et al., 2001; Brady et al., 2002).
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CRFR1 has recently been shown to couple to, and activate, multiple different G proteins,
including Gαs, Gαi, Gαq/11 , Gαo , and Gαz (Grammatopoulous et al., 2001; Gutknecht et al.,
2009). However, CRFR1 is thought to preferentially couple to Gαs leading to adenylyl
cyclase activation and cAMP production, which functions to stimulate protein kinase A
(Chen et al., 1986; Dautzenberg et al., 2002; Grammatopoulos et al., 2002; Hauger et al.,
2006; Arzt et al., 2006). In addition, agonist stimulation of the CRFR1 results in the
desensitization of CRFR1 signaling, as a consequence of both second-messengerdependent protein kinase and G protein-coupled receptor kinase phosphorylation (Holmes
et al., 2006; Oakley et al., 2007). In particular, GRK6 promotes β-arrestin recruitment to
CRFR1 to facilitate CRFR1 endocytosis (Holmes et al., 2006). However, unlike what is
observed for many GPCRs, CRFR1 stimulates the redistribution of β-arrestin2 to
intracellular vesicles, but does not colocalize with β-arrestin2 in the intracellula r
compartment (Holmes et al., 2006).
Previous work from our laboratory has demonstrated a functional significance for
the CRFR1 carboxyl terminal Class I (S/T-X-Φ-COOH, where Φ represents any aliphatic
amino acid residue) PSD-95/Discs Large/Zona Occludens-1 (PDZ)-binding motif in the
heterologous sensitization of serotonin 2A receptor (5-HT2AR) signaling, suggesting a
novel role for PDZ domain-containing proteins in the regulation of CRFR1 functio n
(Magalhaes et al., 2010). Specifically, CRFR1 pre-activation selectively leads to increased
5-HT2AR signaling in response to subsequent 5-HT treatment, which is dependent upon
both intact CRFR1 and 5-HT2AR carboxyl-terminal tail PDZ domain binding motifs. This
CRFR1-dependent sensitization of 5-HT2AR-signaling is also correlated with increased
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anxiety responses in mice (Magalhaes et al., 2010). However, the identity of the specific
PDZ protein(s) involved remains unknown.
We have investigated the capacity of the CRFR1 carboxyl-terminal tail to bind to a
proteomic array of 96 Class I PDZ domains (Fam et al., 2005; He et al., 2006). We found
that the CRFR1 carboxyl-terminal tail binds to a selective subset of Class I PDZ domains
on the array. In the present study, we investigated the role of one of the positive CRFR1interacting PDZ proteins identified in the screen that has been linked to the regulation of
GPCR trafficking and signaling: synapse-associated protein 97 (SAP97; also known as
DLG1). SAP97 has previously been identified as a GIP that binds to the 5-HT2AR, 5HT2CR, β1 -adrenergic receptor (β1 AR), and somatostatin receptor subtype 1 and is reported
to regulate β1 AR recycling, as well as to couple somatostatin receptor subtype 1 activatio n
to neurite outgrowth in development (Cai et al., 2008; Becamel et al., 2004; Gardner et al.,
2007). We found that CRFR1 expression results in the PDZ binding motif-depende nt
redistribution of SAP97 from the cytoplasm to the plasma membrane and that SAP97
functions to negatively regulate CRFR1 endocytosis and is required for CRFR1-mediated
activation of extracellular signal-regulated kinase (ERK1/2) phosphorylation, without
affecting CRFR1-stimulated cAMP formation.

2.2 Experimental Procedures

Materials:
Goat anti-glutathione-S-transferase (GST) antibodies as well as ECL Western blotting
detection reagents were purchased from GE Healthcare (Oakville, ON, Canada). Rabbit
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anti-phospho-p44/42 MAP kinase (Thr202/Tyr402), and rabbit anti-p44/42 MAP kinase
antibodies were obtained from Cell Signalling Technology (Pickering, ON, Canada).
Rabbit anti-GFP antibody was obtained from Invitrogen/Life Technologies (Burlingto n,
ON, Canada). Mouse anti-SAP97 antibody was obtained from Assay Designs/Enzo Life
Sciences (Farmingdale, NY, USA). Alexa Fluor 647 anti-mouse IgG and Alexa Fluor 633
goat anti-mouse IgG Zenon antibodies were purchased from Invitrogen/Molecular Probes
(Burlington, ON, Canada). cAMP GLO Assay was obtained from Promega (Madison, WI,
USA). Mouse anti-HA antibody and all other biochemical reagents were purchased from
Sigma-Aldrich (Oakville, ON, Canada).

Plasmid Constructs:

HA-tagged CRFR1 contructs (HA-CRFR1 and HA-CRFR1ΔTAV) were described
previously (Holmes et al., 2006; Magalhaes et al., 2010). The YFP-SAP97 and SAP97
single hairpin RNA (shRNA) constructs were graciously provided by Dr. Suleiman W.
Bahouth (Neuroscience Institute, University of Tennessee Health Sciences Center)
(Gardner et al., 2007). The YFP-SAP97 (rat isoform 2) was subcloned into the pEGFP1
vector. For the human siRNA studies (HEK293 cells), we used Silencer Validated siRNA
(SAP97/DLG1) ID#146328 human NM_004087 GGAGAUCGUAUUAUAUCGGTT
from Invitrogen (Burlington, ON, Canada). For the mouse siRNA studies (AtT20), we used
Silencer

Select

siRNA

(SAP97/DLG1)

ID#

s232370

mouse

NM_007862

AUGACAAGCGUAAAAAGAATT from Invitrogen (Burlington, ON, Canada). For the
negative

controls,

we

used

Silencer

Negative

Control

#1

AM4635
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AGUACUGCUUACGAUACGGTT from Invitrogen (Burlington, ON, Canada). The
EPAC cAMP biosensor was the gift of Drs. Ali Salahpour (University of Toronto) and
Marc Caron (Duke University) (Barak et al., 2008). The CRFR1 carboxyl-terminal tail
was cloned into pGEX-4 with ECOR1/NotI.

Cell Culture and Transfection:
Human embryonic kidney (HEK 293) cells were maintained in Eagle’s minimal essentia l
medium supplemented with 10% fetal bovine serum. Cells were seeded on 10 cm dishes
at 70-80% density 24 h prior to transfection. Transfection was performed using a modified
calcium phosphate method, as described previously (Ferguson et al., 2004). Transfectio ns
were performed with 1 μg of each construct, with exception that 3 μg of plasmid cDNA
was used for all shRNA constructs. Empty pcDNA3.1 vector was used to equalize the total
amount of plasmid cDNA used to transfect cells. 18 h post-transfection, cells were washed
with phosphate buffered saline (PBS) and re-suspended with Trypsin 0.25% EDTA.
For AtT20 cells, 3 mL aliquots of suspended AtT20 cells were transferred to T25
Nunc flasks 30 μL of Lipofectamine was incubated with 250 μL of Opti-MEM for 5
minutes at room temperature and then added to 250 μL of Opti-MEM and 80 pmol of either
control or SAP97 siRNA. After 6 hours, cells were centrifuged at 13,000 g and transfectio n
reagents were aspirated and replaced with 3 mL media. Cells were then reseeded for
experimentation.

72 hours post-transfection, cells were spun down and media was

aspirated and replaced with 3 mL HBSS for 1 hour at 37ºC. Control and SAP97 siRNA
samples were aliquoted into 1 mL samples and stimulated with 500 nM CRF for 0, 5, or
10 minutes. Cells were put on ice, spun down at 13,000 g at 4ºC, HEPES-buffered saline
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solution (HBSS) was aspirated and cells were lysed with 200 μL of lysis buffer(50 mM
Tris, pH 8.0, 150 mM NaCl, and 0.1% Triton X-100) containing protease inhibitors (1 mM
AEBSF, 10 μg/ml leupeptin, and 5 μg/ml aprotinin).
All experiments were conducted approximately 48 h after the initial transfection,
with exception of transfections involving SAP97 shRNA, which were conducted 72 h
after initial transfection to optimize the knockdown of endogenous SAP97, as confirmed
by Western blotting.

PDZ blot overlay assay:
GST and GST-CRFR1 fusion proteins were generated by growing recombinant BL21
bacteria at 21o C to an A600 of 0.6-1.0. Cultures were induced for 3 hrs with 1mM IPTG,
pelleted, resuspended in PBS containing protease inhibitors (1 mM AEBSF, 10 μg/ml
leupeptin, and 5 μg/ml aprotinin) and lysed by mild sonication. The bacterial lysates were
cleared of cellular debris by centrifugation and then applied to Glutathione Sepharose 4B
overnight at 4o C. GST and GST-CRFR1 fusion proteins bound to the matrix were washed
extensively in PBS-containing 0.3% Triton X-100. 100 nM of GST and GST-CRFR1 in
blot buffer (2% nonfat dry milk, 0.1% Tween 20, 50 mM NaCl, 10 mM Hepes, pH 7.4)
were incubated with gridded nylon membranes that were spotted with His/S-tagged PDZ
domain fusion proteins (1 μg/bin) for 1 h at room temperature (Fam et al., 2005; He et al.,
2006). The arrays were then washed three times with blot buffer, and incubated with a
horseradish peroxidase-conjugated anti-GST antibody (1:3000). Interactions of the GST
fusion proteins with the various PDZ domains were then visualized via chemiluminesce nce
using the enhanced chemiluminescence kit from GE Healthcare.
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Co-immunoprecipitation:
Transfected HEK 293 cells were seeded on 10 cm dishes the day before the experiment.
Cells were serum-starved for 1 hour in HBSS, and dishes were treated with either HBSS
alone or with 100 nM CRF agonist in HBSS for 30 min at 37ºC. Cells were subsequently
lysed in lysis buffer for 20 min on a rocking platform at 4ºC. Samples were collected into
1.5 mL Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4 ºC to pellet insolub le
material.

A Bronsted-Lowry protein assay was performed and 400 μg of protein was

incubated for 1-2 h at 4ºC with Protein G Sepharose and mouse anti-HA antibody (1:50).
After incubation, beads were washed 3 times with cold lysis buffer and incubated overnight
at room temperature in 3X SDS Loading Buffer containing 2-mercaptoethanol. Samples
were separated by SDS-PAGE, transferred

to a nitrocellulose

membrane,

and

immunoblotted to identify co-immunoprecipitated GFP-SAP97 (rabbit anti-GFP, 1:1000).
An additional Western blot was performed to examine HA-CRFR1, HA-CRFR1ΔTAV
(mouse anti-HA, 1:1000) and GFP-SAP97 (rabbit anti-GFP, 1:1000) protein expression.
For the co-immunoprecipitation of endogenous proteins from cortical extracts,
adult mouse brains were employed. Tissue was dissected and homogenized on ice in lysis
buffer containing protease inhibitors.

The particulate fraction was removed by

centrifugation and 2 mg of supernatant protein was incubated with 5 μL/sample of either
goat polyclonal anti-CRFR1 (CRF-RI (V14) sc-12381) or CRFR2 (CRF-RII (C-15) sc20550) antibody from Santa Cruz (Santa Cruz, CA, USA) and protein G-sepharose beads
by 2 hr rotation at 4C. Afterwards, the beads were washed 2 times with lysis buffer and 1
time with PBS, and proteins were eluted in SDS-PAGE loading buffer by warming the
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samples at 55ºC for 5 min. Eluted samples were subjected to SDS-PAGE, followed by
electroblotting onto nitrocellulose membranes for immunoblotting with antibodies
described in the Figure Legends.

Live HEK293 Cell Immunofluorescent Confocal Microscopy:
Following transfection, HEK 293 cells were re-seeded on 35-mm glass-bottom confocal
dishes. Cells were serum-starved for 1 hour at 37ºC in HBSS, then labeled with mouse
anti-HA antibody (1:200) and Zenon Alexa Fluor 647 mouse IgG1 Labeling Kit
(Invitrogen, Burlington, ON, Canada) at 4ºC for 30 minutes. The cells were washed wit h
HBSS and warmed to 37ºC for live imaging using a heated stage. Confocal microscopy
was performed on a Zeiss LSM-510 META laser scanning confocal microscope using a
Zeiss 63X, 1.3 NA, oil immersion lens. Co-localization studies were performed using dual
excitation (488nm, 633nm) and emission (band pass 505-550nm and long pass 650nm for
YFP/GFP and Alexa Fluor 647, respectively) filter sets. The specificity of labeling and
absence of signal crossover were established by examination of single- labeled samples. In
receptor endocytosis experiments, the cells were additionally stimulated with 500 nM CRF
agonist (Tocris) and specified cells were re-imaged at regular intervals for up to 60 minute s.
Colocalization analysis was performed using Imaris 7.0 Colocalization module (bit-plane)
to determine the colocalization of the brightest 2% of pixels in each channel, as described
previously (Lorenzen et al., 2010).
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Receptor Endocytosis:
Following transfection, HEK 293 cells were re-seeded into 12-well plates. Cells were
serum-starved for 1 h at 37ºC in HBSS and then stimulated for 30 minutes with or without
500 nM CRF in HBSS at 37ºC or for the times indicated in the Figure Legends. Cells were
washed with cold HBSS and treated with mouse anti-HA antibody (1:500) for 45 min on
ice. Cells were washed with cold HBSS and additionally treated with Alexa Fluor 633 goat
anti-mouse IgG (Invitrogen, Burlington, ON, Canada) (1:500) for 45 min on ice. Cells
were washed with cold PBS and treated with 5 mM EDTA in PBS for 5 min on ice. Newly
suspended HEK 293 cells were then transferred to flow cytometry tubes containing 4%
formaldehyde in PBS. Samples were run on a FACSCalibur cytometer using BD CellQuest
Pro software until 10,000 cells were counted. The geometric mean of fluorescence was
determined using FlowJo analysis software, with less fluorescence corresponding to less
CRFR1 on the membrane.

cAMP Assay:
The cAMP GLO Assay protocol was carried out as suggested by the manufacture r
(Promega). Transfected HEK 293 cells were seeded into 96-well plate (~10,000 cells per
well).

Cells were incubated in induction buffer (HBSS with 500 μM isobutyl- 1-

methylxanthine (IBMX) and increasing concentrations of CRF agonist for 30 min at 37 °C.
Following stimulation, cells were solubilized with cAMP-GLO Lysis Buffer for 15 min
with gentle shaking at 20–23 °C. cAMP-GLO detection solution containing protein kinase
A was added for 20 min at 20–23 °C, followed by the addition of Kinase-Glo Reagent for
10 min. Each solution was carefully transferred to a white, opaque, 96-well plate and
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Luminescence was measured using a Victor Plate Reader (Perkin-Elmer).

SAP97

knockdown experiments were additionally performed using a BRET-based biosensor
(EPAC) for cAMP and the protocol was adapted from Barak et al. (2008).

ERK Phosphorylation:
Following transfection, HEK 293 cells were re-seeded into 6-well plates. Cells were
serum-starved for 1 hour at 37ºC in HBSS and then stimulated with 500 nM CRF agonist
for the duration of the described time-points. Cells were lysed with lysis buffer (50 mM
Tris, pH 8.0, 150 mM NaCl, and 0.1% Triton X-100) containing protease inhibitors (1 mM
AEBSF, 10 g/ml leupeptin, and 5 μg/ml aprotinin) for 20 min on a rocking platform at
4ºC. Samples were collected into 1.5 mL Eppendorf tubes and centrifuged at 15,000 g for
15 min at 4 ºC to pellet insoluble material. A Bronsted-Lowry protein assay was performed
and 50 μg of protein was incubated overnight at room temperature in 3X SDS Loading
Buffer containing 2-mercaptoethanol. Samples were separated by SDS-PAGE, transferred
to a nitrocellulose membrane, and immunoblotted for ERK1/2 (rabbit anti-p44/42 mitogenactivated protein kinase (MAPK), 1:1000), phospho-ERK1/2 (rabbit anti-phospho-p44/42
MAPK, 1:1000), SAP97 (mouse anti-SAP97, 1:1000), and HA-CRFR1 expression (mouse
anti-HA, 1:1000), followed by a horseradish peroxidase-conjugated secondary anti-rabbit
antibody (1:10,000) or anti-mouse antibody (1:10,000) where appropriate. Proteins were
detected using chemiluminescence with the enhanced chemiluminescence kit from GE
Healthcare.
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Statistical Analysis:
Densitometric data were normalized first for protein expression and the maximum value
was set to 100, with all other values displayed as percentage thereof. One-way analysis of
variance test (ANOVA) was performed to determine significance, followed by a post-hoc
Tukey multiple comparison test or Bonferroni’s multiple comparisons test to determine
which means were significantly different (p < 0.05) from one another.

2.3 Results

Proteomic Analysis of CRFR1-interacting PDZ proteins. Previously, we demonstrated
that the carboxyl-terminal tail class I CRFR1 PDZ binding motif was essential for CRFR1mediated sensitization of 5-HT2AR signaling (Magalhaes et al., 2010). Therefore, we
utilized an array of 96 class I PDZ domains spotted on a gridded nylon membrane, as
described previously (Fam et al., 2005; He et al., 2006), to identify potential CRFR1
interacting PDZ domain-containing proteins. The PDZ array was overlaid with 100 nM of
either purified glutathione-S-transferase GST-CRFR1-carboxyl-terminal tail or GST (as a
control). As can be observed in Fig. 1.1, a subset of PDZ proteins on the array exhibited
binding to the GST-CRFR1-carboxyl-terminal tail. Specifically, we found that the CRFR1
carboxyl-terminal tail selectively bound to a discrete group of PDZ domain-containing
proteins: MAGI-1 PDZ1, MAGI-2 PDZ1, MAGI-3 PDZ1, PSD95 PDZ 1&2, PSD95
PDZ3, CAL PDZ, SAP97 PDZ 1&2, PTPN13 PDZ 4&5, PDZK2 PDZ1 and MUPP1 PDZ
12.
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Figure 2.1: The CRFR1-CT binds to a specific subset of PDZ proteins. Equal amounts of purified His tagged fusion proteins corresponding to a subset of PDZ domains were spotted on nylon membranes and
overlaid with GST (A) versus GST-CRFR1-CT (B) to reveal specific CRFR1-CT binding to the spotted PDZ
domains. (C) Identity of 96 distinct PDZ domains that were spotted on the nylon membranes. Data are
representative of four independent experiments.
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SAP97 is co-immunoprecipitated with CRFR1 in a PDZ-binding motif-depende nt
manner.

SAP97 was one of the candidate CRFR1 binding proteins identified in the

proteomic PDZ domain screen (Fig. 1.1). Since our previous data revealed that PDZ
interactions were critical for cross-talk between CRFR1 and 5-HT2AR (Magalhaes et al.,
2010), and SAP97 was previously identified as an interacting partner of 5-HT2AR functio n
(Becamel et al., 2004), we focused on SAP97 in further experiments. First, we sought to
confirm that SAP97 interacted with CRFR1 by co-immunoprecipitation. We found that
GFP-SAP97 was co-immunoprecipitated with HA-CRFR1 from HEK 293 cells, but that
this interaction was not increased by agonist activation of HA-CRFR1 with 100 nM CRF
(Fig. 2.2A and B). The interaction was dependent upon an intact CRFR1 carboxyl-termina l
PDZ binding motif, as the deletion of the last three critical amino acids (TAV) of the
CRFR1 carboxyl-terminal tail prevented the co-immunoprecipitation of SAP97 with the
subsequent HA-CRFR1-ΔTAV mutant (Fig. 2.2A and B). Furthermore, we found that
endogenous SAP97 could be co-immunoprecipitated with CRFR1 from cortical mouse
brain lysates (Fig. 2.C). Thus, an intact CRFR1 carboxyl-terminal PDZ binding motif was
required for SAP97 interactions with the receptor.

SAP97 recruitment to the plasma membrane is dependent on the CRFR1 PDZ
binding motif.

When expressed alone in HEK 293 cells, GFP-SAP97 was diffuse ly

localized throughout the cytoplasm and did not exhibit localization to the plasma
membrane (data not shown). However, when GFP-SAP97 (green) was co-expressed with
HA-CRFR1 (red), the GFP-SAP97 was predominantly localized with the receptor at the
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Figure 2.2: GFP-SAP97 co-immunopreci pitates with HA-CRFR1 in a PDZ-binding motif-depende nt ,
CRF agonist-independent manner. (A) Representative immunoblot of SAP97 co-immunoprecipitated
with HA-CRFR1 but not HA-CRFR1ΔTA V.

Transient transfections were performed in HEK 293 cells as

labelled. Samples were run using SDS-PAGE and immunoblotted with rabbit anti-GFP. GFP-SAP97 coimmunoprecipitated with HA-CRFR1, but not HA-CRFR1ΔTA V which lacks the PDZ-binding motif. (B)
Effect of CRF treatment was quantified using densitometry and had no significant effect on the amount of
GFP-SAP97

co-immunoprecipitated with HA-CRFR1.

Data are representative of six independent

experiments. (C) Representative immunoblot for endogenous SAP97 co -immunoprecipitated

with

endogenous CRFR1 but not CRFR2 from 2 mg of mouse cortical lysate. SAP97, CRFR1 and CRFR2
expression in 100 μg of cortical lysate are shown below. Data are representative of three independent
experiments.
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Figure 2.3: GFP-SAP97 co-localizes at the membrane with HA-CRFR1 in a PDZ-bindi ng motifdependent manner. (A) Representative confocal microscopy image demonstrating the colocalizat ion of
GFP-SAP97 (green) and cell surface HA-CRFR1 (red) labelled with Zenon Alexa Fluor 633-conjguated
mouse HA antibody in live HEK 293 cells. (B) Representative confocal microscopy image demonstrating
the colocalization of GFP-SAP97 (green) and cell surface HA-CRFR1-ΔTA V (red) labelled with Zenon
Alexa Fluor 633-conjguated mouse HA antibody in live HEK 293 cells. Data are representative of 37 (HA CRFR1) and 17 (HA-CRFR1-ΔTA V) cells.
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plasma membrane (Fig. 2.3A). When the CRFR1 PDZ motif was deleted from the
carboxyl-terminus of the receptor (TAV), the resulting HA-CRFR1-ΔTAV mutant did not
promote the plasma membrane localization of GFP-SAP97 (Fig. 2.3B). We found that 62
± 2 % of SAP97 was colocalized with HA-CRFR1 at the cell surface, whereas only 8 ± 3
% of SAP97 was colocalized with the HA-CRFR1-ΔTAV mutant (Fig. 2.3C). Thus, these
data in combination with the co-immunoprecipitation data indicated that SAP97 interacts
with CRFR1 in a cellular context and that this interaction is dependent upon the CRFR1
PDZ binding motif.

SAP97 antagonizes CRFR1 endocytosis in a PDZ motif-dependent manner.

PDZ

interactions have been reported to regulate the endocytosis and trafficking of a number of
GPCRs (Ritter et al., 2009; Magalhaes et al., 2012). Therefore, we initially examined the
effect of overexpressing GFP-SAP97 on the endocytosis of wild-type CRFR1 and the
CRFR1 mutant lacking a PDZ binding motif (TAV). In cells expressing only wild-type
CRFR1, agonist treatment for 30 min with 500 nM CRF at 37ºC resulted in a 24 ± 4 % loss
of cell surface HA-CRFR1 as measured by flow cytometry (Fig. 2.4A). However, coexpression of GFP-SAP97 led to a significant attenuation of HA-CRFR1 endocytosis (Fig.
2.4A). Unexpectedly, deletion of the CRFR1 PDZ binding motif resulted in a HA-CRFR1ΔTAV mutant that was impaired in its endocytosis when compared with the internalizatio n
of the wild-type receptor (Fig. 4A). GFP-SAP97 overexpression did not further antagonize
the internalization of the HA-CRFR1-ΔTAV mutant (Fig. 2.4A). To examine the role of
endogenous SAP97 in the regulation of agonist-stimulated CRFR1 endocytosis in HEK
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Figure 2.4: SAP97 antagonizes HA-CRFR1 endocytosis. (A) Agonist-stimulated internalization of either
HA-CRFR1 or HA-CRFR1-ΔTA V in cells co-transfected with either GFP or GFP-SAP97.

The

internalization of HA tagged receptors labelled with Alexa Fluor-conjugated mouse anti-NA antibody was
measured in cells treated with 500 nM CRF for 30 min and compared with vehicle treated control cells. The
data represent the mean ± SEM of nine independent experiments. * P < 0.05 versus control CRFR1
internalization. (B) Representative immunoblot of endogenous SAP97 protein expression in HEK 293 cells
transfected with 3 μg plasmid cDNA encoding either scrambled (SCR) or SAP97 shRNA at 48 and 72 h
initial transfection. (C) Agonist stimulated (500 nM CRF) internalization of HA -CRFR1 in cells cotransfected with scrambled (SCR) and SAP shRNA at 5, 15, 30 and 60 min. The data represent the mean ±
SEM of five independent experiments. * P < 0.05 versus SCR shRNA treated cells. (D) Agonist stimulated
(500 nM CRF) internalization of HA-CRFR1-ΔTA V in cells co-transfected with scrambled (SCR) and SAP
shRNA at 30 and 60 min. The data represent the mean ± SEM of four independent experiments.
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293 cells, we transfected the cells with either scrambled shRNA or a shRNA SAP97
construct that was previously shown to knockdown SAP97 expression and tested CRFR1
internalization (Gardner et al., 2007). As shown in Fig. 2.4B, the SAP97 shRNA construct
effectively knocked down the expression of endogenous SAP97 protein expression in HEK
293 cells 72 h post-transfection. Consequently, all subsequent shRNA experiments were
performed 72 h after HEK 293 cell transfection. We found that shRNA knockdown of
SAP97 significantly increased the maximal extent of HA-CRFR1 endocytosis following
30 and 60 minutes of agonist treatment with 500 nM CRF (Fig. 2.4C). In contrast
knockdown of endogenous SAP97 expression did not influence the extent of HA-CRFR1ΔTAV mutant internalization (Fig. 2.4D). Thus, taken together these data indicated that
SAP97 antagonizes agonist-stimulated internalization of CRFR1, but that the CRFR1 PDZ
binding motif is required for effective internalization of the receptor.

SAP97 co-localizes with CRFR1 during receptor endocytosis. The overexpression of
GFP-SAP97 antagonized HA-CRFR1 endocytosis, but did not completely block the
internalization of the receptor. Therefore, we examined whether internalized HA-CRFR1
was either internalized as a complex with GFP-SAP97 or whether a population of HACRFR1 was internalized independently of GFP-SAP97. To do this, HEK 293 cells were
transfected with both HA-CRFR1 and GFP-SAP97 and the HA-CRFR1 was labeled with
Alexa Fluor 633-conjugated monoclonal HA mouse antibody (1:1000 dilution) for 45 min
on ice. Live labeled cells were then imaged by laser scanning confocal microscopy. Each
cell was allowed to warm to 37ºC and imaged prior to the addition of 500 nM CRF, then
consecutively imaged every 30 s for 30 min. We found that, prior to agonist treatment,
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Figure 2.5: GFP-SAP97 exhibits limited endocytosis with HA-CRFR1. Live cell microscopic imaging
of GFP-SAP97 (green) and HA-CRFR1 (red) labelled with Alexa Fluor 633-conjugated mouse anti-HA
antibody (A) prior to and following (B) 500 nM activation for 30 min in a live HEK293 cell. Image is
representative of 20 cells.
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Alexa Fluor 633-conjugated mouse monoclonal HA antibody-labeled

CRFR1 was

colocalized with GFP-SAP97 at the cell surface (Fig. 2.5A). Upon CRF treatment, we
observed limited internalization of HA-CRFR1 at 30 min stimulation with agonist, but the
HA-CRFR1 that was internalized was co-localized with GFP-SAP97 in endocytic vesicles
(Fig. 2.5B). This indicated that endocytosed CRFR1 redistributed GFP-SAP97 into the
endosomal compartment, despite the role for SAP97 in antagonizing CRFR1 endocytosis.

SAP97 does not regulate CRFR1-mediated cAMP signaling:

Because SAP97

overexpression antagonized CRFR1 internalization and SAP97 down-regulation enhanced
CRFR1 endocytosis, we sought to determine whether SAP97 and/or the CRFR1 PDZ
binding motif contributed to the regulation of CRFR1-mediated cAMP formation. In cells
transfected with HA-CRFR1 with and without GFP-SAP97 and treated with increasing
concentrations of CRF, there was no significant change in the maximum efficacy for CRFstimulated cAMP formation (Fig. 2.6A). Similarly, deletion of the CRFR1 PDZ binding
motif had no effect on the maximum efficacy for CRF-stimulated cAMP formation in
response to the activation of either the wild-type CRFR1 or the CRFR1-ΔTAV mutant (Fig.
2.6B). Consistent with what was observed following GFP-SAP97 overexpression, SAP97
shRNA knockdown did not result in an increase in the maximum efficacy for CRFstimulated cAMP formation by the CRFR1 (Fig. 2.6C). Thus, SAP97 did not appear to
contribute to the regulation of CRFR1-stimulated cAMP production.
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Figure 2.6: SAP97 does not regulate CRFR1-mediated cAMP formation. (A) CRFR1-mediated cAMP
formation, as assessed by a cAMP GLO assay, following co-transfection with either GFP (control) or GFP SAP97. The data represent the mean ± SEM of seven independent experiments. (B) CRFR1- and CRFR1ΔTAV-mediated cAMP formation, as assessed by a cAMP GLO assay. The data represent the mean ± SEM
of four independent experiments. (C) CRFR1-med iated cAMP formation as assessed by a cAMP GLO assay
following co-transfection with either scrambled (SCR) or SAP97 shRNA. The data represent the mea n ±
SEM of five independent experiments.

72

CRFR1-mediated ERK1/2 phosphorylation is dependent on endogenous SAP97
expression. Previous work has demonstrated CRFR1 can activate the MAPK signaling
pathway, as evidenced by CRFR1-mediated ERK1/2 phosphorylation (Kageyama et al.,
2007). Therefore, we examined whether endogenous SAP97 expression was required for
CRFR1-mediated ERK1/2 phosphorylation. HEK 293 cells were transiently transfected
with and without HA-CRFR1 along with either scrambled shRNA or SAP97 shRNA to
knockdown SAP97 expression and ERK1/2 phosphorylation in response to 500 nM CRF
for 0, 2, 5, 15 and 30 min was determined by densitometric analysis of immunoblots (2.7B).
We found that the treatment of non-transfected HEK 293 cells with 500 nM CRF led to an
increase in detectable ERK1/2 phosphorylation at 5 min, which was likely due to
endogenous CRFR2 that is expressed in these cells (Fig. 2.7A and B) (Magalhaes et al.,
2010). However, in cells transfected with HA-CRFR1 and scrambled shRNA, 500 nM
CRF treatment

resulted in a more robust and sustained

activation

of ERK1/2

phosphorylation (Fig. 2.7A and B). Knockdown of SAP97 protein expression led to an
attenuation of CRFR1-mediated ERK1/2 phosphorylation following 500 nM CRF
treatment, to levels that were comparable to those observed in non-transfected cells (Fig.
2.7A and B). The over-expression of GFP-SAP97 had no significant effect on ERK1/2
phosphorylation (data not shown).

To examine whether SAP97 regulates ERK1/2

phosphorylation in response to the activation of endogenous CRFR1 activation, identica l
experiments were performed in AtT20 cells that express endogenous CRFR1 (Westendorf
and Schonbrunn, 1985). AtT20 cells grow in suspension, thereby complicating transfectio n
efficiency and determinations of ERK1/2 phosphorylation in this cell type. Nevertheless,
following siRNA knockdown of endogenous SAP97, we observed a small but
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Figure 2.7:

Knockdown

of endogenous

SAP97 suppresses HA-CRFR1-medi ated

ERK1/ 2

phosphorylation. (A) Representative immunoblot showing ERK1/2 phosphorylation in response 500 nM
CRF treatment for 0, 5, 15 and 30 min in non-transfected (NT) HEK 293 cell, and HEK 293 cells transfected
with HA-CRFR1 and either scrambled (SCR) or SAP97 shRNA. Shown in the panels belo w are
corresponding immunoblots for total ERK1/2, SAP97 and HA -CRFR1 protein expression. (B) Densitometric
analysis of ERK1/2 phosphorylation in response to 500 nM CRF treatment for 0, 5, 15 and 30 min in non transfected (NT) HEK 293 cell, and HEK 293 cells transfected with HA -CRFR1 and either scrambled (SCR)
or SAP97 shRNA. The data represent the mean ± SEM of four independent experiments. * P < 0.05 versus
SCR shRNA treated cells. (C) Representative immunoblot showing ERK1/2 phosphorylation in response
500 nM CRF treatment for 0, 5, and 10 min in AtT20 cells transfected with either scrambled (SCR) or SAP97
siRNA. Shown in the panels below are corresponding immunoblots for total ERK1/2, and SAP97 protein
expression. (D) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF treatment
for 0, 5, and 10 min in AtT20 cells trans fected with either scrambled (SCR) or SAP97 siRNA. The data
represent the mean ± SEM of four independent experiments. * P < 0.05 versus SCR shRNA treated cells.
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significant attenuation of ERK1/2 phosphorylation following 5 min CRF stimulation (Fig.
2.7C and 7D).
To further examine the specificity of SAP97 with the CRFR1 PDZ binding motif
we

assessed

whether

deleting

the

motif

altered

CRFR1-stimulated

ERK1/2

phosphorylation in the presence and absence of SAP97 expression. Surprisingly, we found
that the deletion of the CRFR1 PDZ binding motif did not prevent ERK1/2 phosphorylatio n
following agonist activation of CRFR1-ΔTAV mutant (Fig. 2.8A and B). Moreover, we
found that shRNA knockdown of SAP97 reduced CRFR1-ΔTAV mutant ERK1/2
phosphorylation to the same extent to that was observed for the wild-type CRFR1 (Fig.
2.8A and B). To determine whether this effect of SAP97 was specific to CRFR1-mediated
ERK1/2 activation

we assessed whether SAP97 knockdown attenuated

ERK1/2

phosphorylation following the stimulation of CRFR2, a GPCR that does not encode a PDZ
binding motif. Again, we found that SAP97 knockdown resulted in a significant reduction
of CRFR2-mediated ERK1/2 phosphorylation (Fig. 2.8C and 8D). Taken together, these
data suggested that SAP97 is required for the activation of ERK1/2 signaling by the
CRFR1, without modulating cAMP production, but does so via a mechanism that is
independent of interactions with a PDZ binding motif.

2.4 Discussion
In a previous study, we found that PDZ protein interactions with CRFR1 play an
important role in regulating CRFR1-dependent sensitization of 5-HT2AR signaling
(Magalhaes et al., 2010), prompting us to search for candidate PDZ proteins that interact
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Figure 2.8: Knockdown of endogenous SAP97 suppresses HA-CRFR1-ΔTAV- and HA-CRFR2 mediated ERK1/2 phosphorylation. (A) Representative immunoblot showing ERK1/2 phosphorylation in
response 500 nM CRF treatment for 0, 2, and 5 min in HEK 293 cells transfected with HA -CRFR1-ΔTA V
and either scrambled (SCR) or SAP97 shRNA. Shown in the panels below are corresponding immunoblots
for total ERK1/2, SAP97 and HA-CRFR1-ΔTA V protein expression. (B) Densitometric analysis of ERK1/ 2
phosphorylation in response to 500 nM CRF treatment for 0, 2 and 5 min in HEK 293 cells t ransfected with
HA-CRFR1-ΔTA V and either scrambled (SCR) or SAP97 shRNA. The data represent the mean ± SEM of
four independent experiments. * P < 0.05 versus SCR shRNA treated cells. (C) Representative immunoblo t
showing ERK1/2 phosphorylation in respons e 500 nM CRF treatment for 0, 5, 15 and 30 min in nontransfected (NT) HEK 293 cell, and HEK 293 cells transfected with HA -CRFR2 and either scrambled (SCR)
or SAP97 shRNA. Shown in the panels below are corresponding immunoblots for total ERK1/2, SAP97 and
HA-CRFR2 protein expression. (D) Densitometric analysis of ERK1/2 phosphorylation in response to 500
nM CRF treatment for 0, 5, 15 and 30 min in non-transfected (NT) HEK 293 cell, and HEK 293 cells
transfected with HA-CRFR2 and either scrambled (SCR) or SAP97 shRNA. The data represent the mean ±
SEM of three independent experiments. * P < 0.05 versus SCR shRNA treated cells.
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with CRFR1. We found that a subset of Class I PDZ proteins, including SAP97, interact
with the CRFR1 C-tail on a proteomic PDZ domain array. We further demonstrated that
SAP97 interacts with the carboxyl-terminal CRFR1 PDZ binding motif resulting in
recruitment of SAP97 to the cell surface as well as antagonism of CRFR1 endocytosis and
promotion of CRFR1-stimulated ERK1/2 signaling but not cAMP production.

CRFR1

represents the fifth GPCR to which SAP97 has been demonstrated to interact (Gardner et
al., 2007; Cai et al., 2008; Becamel et al., 2004). SAP97 was previously shown to regulate
the recycling of the β1 AR and neurite outgrowth in response to somatostatin receptor
activation (Gardner et al., 2007; Cai et al., 2008). In contrast to the positive effects of
SAP97 on CRFR1-stimulated signaling to ERK1/2 observed in the present study, the
interaction of the PDZ domain-containing protein MAGI-3 with the β1 AR was shown to
antagonize β1 AR-dependent activation of ERK1/2 (He et al., 2006). Our studies indicate
that SAP97 may be required for the activation of ERK1/2 phosphorylation by many GPCRs
independent of PDZ domain interactions as a loss of SAP97 expression resulted in
significantly reduced ERK1/2 phosphorylation following the activation of CRFR1-ΔTAV
mutant and CRFR2 that does not encode a PDZ binding motif.
Previous to our current studies with CRFR1, SAP97 had been demonstrated to bind
to the β1 AR to regulate the recycling of the receptor (Gardner et al., 2007; Magalhaes et al;
2010). Interestingly, both receptors share a similar Class I carboxyl terminal PDZ motif,
defined by S/T-X-Ф, where Ф represents any hydrophobic residue (Songyang et al., 1997;
Beuming et al., 2005). Gardner et al. (2007) provided evidence that SAP97 may link the
β1 AR to A-Kinase Anchoring Protein 79/150 (AKAP79/150).

This interaction was

hypothesized to facilitate protein kinase A-mediated phosphorylation of Ser 312 of the
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β1 AR third intracellular loop, thereby promoting receptor recycling and resensitizatio n
(Gardner et al., 2004; Gardner et al., 2007). In support of this hypothesis, knock-down of
endogenous SAP97 suppresses β1 AR phosphorylation and recycling.

Based on these

previous data with the β1 AR (Gardner et al., 2007), it might seem tempting to speculate
that SAP97 may play a generalized role in regulating the activity of GPCRs that encode a
Class I PDZ binding motifs. However, PDZ protein interactions with a variety of GPCRs
have demonstrated PDZ protein-specific functions with respect to the regulation of GPCR
activity. There are several examples to support this assertion. First, PSD-95 was reported
to suppress 5HT2AR receptor internalization (Xia et al., 2003) but yet promotes the
internalization of the 5HT2CR (Gavarini et al., 2006). Second, MAGI-2 overexpressio n
was found to have no effect on β1 AR-mediated cAMP signaling and promotes agonistinduced β1 AR internalization (Xu et al., 2001), but was found to reduce vasoactive
intestinal polypeptide type-1 receptor-mediated cAMP signaling and suppress agonistinduced receptor internalization (Gee et al., 2009). Finally, while MUPP1 enhances
GABAB receptor signaling, it functions to uncouple the melatonin-1 receptor from Gαi
(Balasubramanian et al., 2007; Guillaume et al., 2008). Similarly, our current study
demonstrates that SAP97 regulates CRFR1 trafficking, since over-expression of GFPSAP97 prevents CRFR1 endocytosis and knockdown of endogenous SAP97 promotes
CRFR1 endocytosis.

However, due to the antagonism of CRFR1 endocytosis in the

presence of SAP97, it is unlikely that SAP97 subserves the same recycling function for
CRFR1 as it does for the β1 AR. For this reason, discussions of PDZ protein functions in
the regulation of GPCR activity should likely be prefaced by the GPCR with which a given
PDZ protein is interacting.
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Previous research has identified a number of proteins that appear to form complexes
with CRFR1 at various stages of receptor activation and trafficking.

It has been

demonstrated that CRFR1 activation leads to β-arrestin1 and β-arrestin2 recruitment to the
membrane where they co-localize and directly interact with CRFR1 (Rasmussen et al.,
2004; Perry et al., 2005; Holmes et al., 2006). Additionally, CRFR1 has been shown to
internalize to both Rab5-positive early endosomes and Rab4-positive recycling endosomes
(Holmes et al., 2006). Previous work on the parathyroid hormone 1 receptor (PTH1R) and
another PDZ domain-containing protein, NHERF1, demonstrated that the β-arrestin2
interaction with the PTH1R was prevented by the receptor’s interaction with NHERF1
(Wang et al., 2009). Additionally, NHERF1 inhibited the uncoupling of PTH1R from Gαs
(Wang et al., 2009). It is plausible that SAP97 and/or one of the other CRFR1-interacting
PDZ scaffolds identified in our screens could similarly dictate which proteins are
associating with CRFR1 during different states of receptor activation and trafficking,
thereby regulating the trafficking and signaling of CRFR1. Future studies will look to
examine what role SAP97 and other CFRF1-interacting PDZ scaffolds might play in
preventing CRFR1 recruitment of β-arrestin1/2. However, quantitative studies of potential
SAP97-mediated antagonism of β-arrestin translocation to CRFR1 are technica lly
challenging due to the fact that any carboxyl-terminal fusion of bioluminescent reporter
proteins may disrupt PDZ protein interactions with the receptor.
Neither the overexpression of GFP-SAP97 nor the shRNA knockdown of
endogenous SAP97 in our studies had a significant effect on the EC 50 or maximal CRFR1mediated cAMP accumulation. Additionally, deletion of the CRFR1 receptor PDZ-binding
motif had no significant effect on CRFR1-mediated cAMP accumulation. These results
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are consistent with previous research on the β1 AR, where mutation of the PDZ-binding
motif had no effect on β1 AR-mediated cAMP accumulation (Gardner et al., 2007).
Interestingly, PSD-95 has similar structural domains to SAP97 and has similarly been
shown to suppress β1 AR endocytosis and have no effect on β1 AR-mediated cAMP
accumulation (Hu et al., 2000).
Previous work has demonstrated CRFR1 can signal through the MAPK pathway,
as evidenced by CRFR1-mediated ERK1/2 phosphorylation (Kageyama et al., 2007).
Interestingly, shRNA knockdown of endogenous SAP97 significantly reduced ERK1/2
phosphorylation to levels comparable with cells lacking the overexpressed HA-CRFR1.
Work from our lab has demonstrated that HEK 293 cells express endogenous functio na l
CRFR2, as evidenced by stimulation of cAMP production at the high CRF concentratio ns
necessary to activate CRFR2 (Holmes et al., 2006). Thus, the observed CRF-induced
increases in ERK1/2 phosphorylation in non-transfected control cells in the present studies
were expected. Knockdown of SAP97 would not be expected to alter CRFR2-mediated
ERK1/2 phosphorylation, as the receptor does not possess a PDZ binding motif at its
carboxyl-terminal tail. However, we found that SAP97 knockdown significantly impaired
ERK1/2 phosphorylation in cells either overexpressing CRFR2 or a CRFR1-ΔTAV mutant
suggesting that SAP97 may not only play a role in scaffolding ERK1/2 protein complexes,
but may function to regulate GPCR-mediated ERK1/2 signaling independently of receptor
interactions. Thus, our studies suggest a novel role for SAP97 in GPCR-mediated
signaling, but further studies will be required to understand the precise role SAP97 plays
in the regulation of ERK1/2 phosphorylation by GPCRs.
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Although this is the first evidence of a role for SAP97 in the GPCR-mediated
activation of ERK1/2 phosphorylation, previous research has demonstrated an ability of
members of the MAPK family to phosphorylate SAP97, including ERK2 specifica lly
(Sabio et al., 2005). This phosphorylation of SAP97 by MAPK family members was
shown to lead to its dissociation

from guanylate-kinase-associated

protein and,

consequently, the cytoskeleton (Sabio et al., 2005). Additionally, PSD-95 has been shown
to be phosphorylated by MAPKs, including ERK2, in response to mitogens (Sabio et al.,
2004). It is plausible that SAP97-dependent CRFR1-mediated ERK1/2 phosphorylatio n
may participate in a negative feedback loop whereby “activated” pERK1/2 could slowly
phosphorylate SAP97, leading to dissociation of a signaling complex that would lead to
attenuated receptor-mediated ERK1/2 phosphorylation. The dissociation of this signaling
complex could also disrupt cytoskeletal interactions and allow for relocalization of proteins
through trafficking mechanisms.

The mechanism by which SAP97 facilitates CRFR1-

mediated activation of ERK1/2 remains to be determined. However, the demonstratio n
that

SAP97

knockdown

significantly

attenuates

CRFR1-mediated

ERK1/2

phosphorylation indicates that other GIPs scaffolded by GPCR protein interaction motifs,
in addition to β-arrestins, play a role in dictating the intracellular signaling pathways
activated by GPCRs. Thus, it may be that in addition to ligand-dependent stabilization of
distinct “biased” GPCR activation states (Luttrell et al., 2010; Galandrin et al., 2007;
Kenakin et al., 2007), the association of intracellular GIPs with GPCRs bias GPCR signa l
transduction.

It is likely that these two events are not mutually exclusive but functio n

interdependently, thereby complicating the outcome of ligand biased screening approaches
for “biased” GPCR ligands.
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In conclusion, we have presented the first evidence for SAP97 as a regulator of
CRFR1 trafficking and signaling. Specifically, we have found that SAP97 interacts with
the CRFR1 PDZ binding motif to antagonize CRFR1 endocytosis without affecting cAMP
production, whereas the regulation of ERK1/2 phosphorylation by the receptor does not
require PDZ motif interactions. This suggests that SAP97 may function to bias CRFR1
signaling toward the ERK1/2 pathway. This provides the potential for GIPs other than βarrestins to mediate biased signaling of GPCRs. This interaction may be a pharmaceutica l
target for the regulation of CRFR1 function, and therefore has implications in the potential
treatment of mood disorders, such as depression.
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3.1 Introduction

Serotonin (5-HT) is a monoamine neurotransmitter that regulates a wide range of
higher neurological functions including the regulation of mood, behaviour, sleep, and
appetite (Hale et al., 2012). The majority of serotonergic neurons in the brain project
outwards from the raphe nuclei towards a multitude of brain regions, including many
structures within the limbic system (Bobillier et al., 1976). Once released, serotonin
activates a large subset of 5-HT recepters (5-HT1-7 R), all of which, with exception to 5HT3 R, are G protein-coupled receptors (GPCRs) (Barnes, 2011). The 5-HT2AR and 5HT2CR GPCRs are currently primary molecular targets for drugs used in the treatment of
mood and behavioral disorders, such as: anxiety disorders, depression, schizophrenia,
obsessive-compulsive disorder, and eating disorders (Gray and Roth, 2001; Roth and Xia.,
2004; Catapano and Manji, 2007).

The involvement of these specific 5-HT2 Rs in

depression is highlighted by the examination of post-mortem human brain tissue from
depressed individuals and victims of suicide (Catapano and Manji, 2007). These brains of
these subjects are found to have significantly greater expression of both 5-HT2AR and 5HT2CR when compared to their control counterparts. Untreated schizophrenics show a
similar increase in 5-HT2AR expression in the brain (Fribourg et al., 2011). Additionally,
current

antidepressants

and

atypical

(second

generation)

anti-psychotics

have

demonstrated the ability to down-regulate 5-HT2AR expression in the cortical brain
(Catapano and Manji, 2007; Fribourg et al., 2011), suggesting an importance for 5-HT2AR
in the symptoms of depression and psychoses. In particular, pharmacological studies and
knockout mice have demonstrated that 5-HT2AR and 5-HT2CR contribute to anxiety and
are pharmacological targets for the treatment of anxiety (Weisstaub et al., 2006).
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Although many studies have investigated the pharmacological regulation of 5HT2AR and 5-HT2CR in psychiatric disorders, there is a limited number of studies that have
focused on the contribution of C-terminal 5-HT2AR and 5-HT2CR PSD-95/Disc Large/Zona
Occludens (PDZ) binding motif interactions with PDZ domain-containing proteins to 5HT2 R-related disorders (Abbas et al., 2009; Jones et al., 2009; Magalhaes et al. 2010;
Pichon et al., 2010; Wattiez et al., 2013). For example, PSD-95 regulates the actions of
atypical antipsychotics on 5-HT2 Rs, and kalirin-7 mediates 5-HT2 R-medaited modulatio n
of spine morphology (Abbas et al., 2009; Jones et al., 2009). In addition, disruption of 5HT2AR PDZ protein interactions enhances SSRI efficacy in neuropathic pain and alleviate s
mechanical sensitivity to inflammation (Pichon et al., 2010; Wattiez et al., 2013). Thus,
the emerging understanding of the importance of PDZ domain-containing proteins in the
regulation of 5-HT2AR activity will be essential for our understanding of how the
intracellular trafficking of 5-HT2AR may contribute to the regulation of agonist-stimula ted
5-HT2AR cellular responses (Backstrom et al., 2000; Xia et al., 2003a; Xia et al., 2003b;
Gavarini et al., 2006; Jones et al., 2009; Magalhaes et al. 2010; Pichon et al., 2010; Wattiez
et al., 2013).
The 5-HT2AR primarily signals via the activation of Gαq/11 -mediated signa ling
pathways, leading to PLC activation and the accumulation of inositol phosphate (IP) and
diacylglycerol resulting in the release of intracellular Ca 2+ stores and the activation of
protein kinase C. However, alternate signaling pathways have been identified, includ ing
the extracellular regulated protein kinase 1/2 (ERK1/2) signalling pathway that can be
activated by both G protein-dependent and - independent mechanisms (Raymond et al.,
2001; Magalhaes et al., 2012). Recently, studies from our laboratory have demonstrated
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that the activation of the corticotropin releasing factor receptor 1 (CRFR1) enhances
subsequent 5HT2A/CR-mediated IP3 signaling via a mechanism that is dependent upon PDZ
protein-interactions with both receptors (Magalhaes et al., 2010). This suggests that one
or more PPDZ domain-containing receptors interact with both CRFR1 and 5HT2AR to
positively modulate 5HT2AR signaling.
Previously, SAP97 has been demonstrated to interact with both 5-HT2AR and 5HT2CR (Becamel et al., 2002; Becamel et al., 2002), and we have shown that SAP97
interacts with and negatively regulates CRFR1 endocytosis, without affecting CRFR1stimulated cAMP accumulation (Dunn et al., 2013). Therefore, in the present study, we
have tested the hypothesis that 5-HT2AR signaling and trafficking may also be modulated
as a consequence of the interaction with SAP97 with the receptor. We find that similar to
what we reported for CRFR1, SAP97 is involved in the regulation of 5-HT2AR endocytosis
and ERK1/2 activation.

However, unlike what was previously observed for CRFR1

signaling, SAP97 expression is required for 5-HT2AR G protein coupling, but is not
involved in the observed CRFR1 pretreatment-dependent enhancement of 5-HT2AR
signaling.

3.2 Experimental Procedures

Materials:
ECL Western blotting detection reagents were purchased from GE Healthcare and BioRad.
The Dowex 1-X8 (formate form) resin with 200-400 mesh was purchased from Bio-Rad
(Mississauga, ON). Bovine serum albumin (BSA) was obtained from BioShop Canada Inc.
(Mississauga,

ON).

Horseradish peroxidase-conjugated

anti-rabbit IgG secondary
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antibody was from BioRad (Mississauga, ON). Rabbit anti-phospho-p44/42 MAPK (Thr202/Tyr-402) and rabbit anti-p44/42 MAPK antibodies were obtained from Cell Signaling
Technology (Pickering, Ontario, Canada). Rabbit anti-GFP antibody was obtained from
Invitrogen. Mouse anti-SAP97 antibody was obtained from Assay Designs/Enzo Life
Sciences (Farmingdale, NY). Alexa Fluor 647 anti-rabbit IgG and Zenon antibody were
purchased from Invitrogen (Burlington, ON, Canada). Rabbit anti-FLAG antibody and all
other biochemical reagents were purchased from Sigma.

Plasmid Constructs:
FLAG-tagged 5-HT2AR and 5-HT2AR-ΔSCV constructs were described previous ly
(Magalhaes et al., 2010). The GFP-SAP97 (rat isoform 2) construct and SAP97 shRNA
were described previously and graciously provided by Dr. Suleiman W. Bahouth
(Neuroscience Institute, University of Tennessee Health Sciences Center) (Gardner et al.,
2006; Dunn et al., 2013). The GFP-SAP97 (rat isoform 2) construct was subcloned into
peYFP-N1. A FLAG-tagged 5-HT2AR renilla luciferase (rLuc) fusion protein (5-HT2ARx22-SCV) was custom synthesized by GenScript (Piscataway, NJ) to insert rLuc into the
5-HT2AR C-terminal tail 22 amino acids upstream of the PDZ binding motif. The construct
was digested HindIII/EcoR1 from a pU57 plasmid and subcloned into a pcDNA3.1 plasmid
expression vector digested with the same restriction enzymes.

Cell Culture and Transfection:
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Human embryonic kidney (HEK 293) cells were maintained in Eagle’s minimal essentia l
medium supplemented with 10% fetal bovine serum. Cells were seeded on 10-cm dishes
at 70–80% density 24 h prior to transfection. Transfection was performed using a modified
calcium phosphate method, as described previously (Caron and Ferguson, 2004).
Transfections were performed with 1μg of each construct, with exception that 3μg of
plasmid cDNA was used for all shRNA constructs. Empty pcDNA3.1 vector was used to
equalize the total amount of plasmid cDNA used to transfect cells. 18 h post-transfectio n,
cells were washed with phosphate-buffered saline (PBS) and suspended with trypsin,
0.25% EDTA. All experiments were conducted 48 hours after the initial transfection, with
the exception of transfections involving SAP97 shRNA, which were conducted 72 hours
after initial transfection to optimize the knockdown of endogenous SAP97, as confir med
by Western blotting.

Co-immunoprecipitation:
Transfected HEK293 cells were seeded onto 10-cm dishes the day before the experiment.
Cells were serum-starved for 1 hour in HBSS, and dishes were treated with either HBSS
alone or with 10 μM 5HT agonist in HBSS for 30 min at 37 °C. Cells were subsequently
lysed in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 1% Triton X-100) containing
protease inhibitors (1mM AEBSF, 10 μg/ml leupeptin, and 5μg/ml aprotinin) for 20
minutes on a rocking platform at 4°C. Samples were collected into 1.5 ml Eppendorf tubes
and centrifuged at 15,000 x g for 15 min at 4°C to pellet insoluble material. A Bronsted Lowry protein assay was performed, and 400 μg of protein was incubated for overnight at
4 °C with FLAG-immunoprecipitation beads from Sigma. After incubation, beads were
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washed three times with cold lysis buffer and incubated overnight at room temperature in
3x SDS Loading Buffer containing 2-mercaptoethanol. Samples were separated by SDSPAGE, transferred to a nitrocellulose membrane, and immunoblotted to identify coimmunoprecipitated GFP-SAP97 (rabbit anti-GFP, 1:1000). An additional Western blot
was performed to examine FLAG-5-HT2AR/FLAG-5-HT2AR-ΔSCR (rabbit anti-FLAG,
1:1000), and GFP-SAP97 (rabbit anti-GFP, 1:1000) protein expression. For the coimmunoprecipitation of endogenous proteins from cortical extracts, adult mouse brains
were employed. Tissue was dissected and homogenized on ice in lysis buffer containing
protease inhibitors. The particulate fraction was removed by centrifugation, and 2 mg of
supernatant protein was incubated with 5 μl/sample of either goat polyclonal 5-HT2AR or
FLAG antibody from Santa Cruz Biotechnology (Santa Cruz, CA) and protein G Sepharose
beads overnight at 4°C. Afterwards, the beads were washed three times with lysis buffer
and proteins were eluted in 3x SDS-PAGE loading buffer by warming the samples at 55°C
for 5 min. Eluted samples were subjected to SDS-PAGE, followed by transfer onto
nitrocellulose membranes for immunoblotting with antibodies described in the Figure
Legends.

Live Cell Confocal Microscopy:
Following transfection, HEK 293 cells were re-seeded onto 35 mm glass bottom confocal
dishes. Cells were serum-starved for 1h at 37°C in HBSS and then labeled with rabbit antiFLAG antibody (1:200) and Zenon Alexa Fluor 647 rabbit IgG1 labeling kit (Invitroge n)
at 4°C for 30 min. The cells were washed with HBSS and warmed to 37°C for live imaging
using a heated stage. Confocal microscopy was performed on a Zeiss LSM-510 META
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laser scanning confocal microscope using a Zeiss 63x, 1.3 NA, oil immersion lens. Colocalization studies were performed using dual excitation (488 and 633 nm) and emissio n
(band pass 505–550 nm and long pass 650 nm for YFP/GFP and Alexa Fluor 647,
respectively) filter sets. The specificity of labeling and absence of signal crossover were
established by examination of single- labeled samples.

Receptor Endocytosis:
Following transfection, HEK 293 cells were re-seeded into 12-well plates. Cells were
serum-starved for 1h at 37°C in HBSS and then stimulated with or without 10 μM 5HT in
HBSS at 37°C for the times indicated in the figure legends. Cells were washed with cold
HBSS and treated with mouse anti-FLAG antibody (1:1000) for 45 min on ice. Cells were
washed with cold HBSS and additionally treated with Alexa Fluor 647 donkey anti-mouse
IgG (Invitrogen) (1:1000) for 45 min on ice. Cells were washed with cold PBS and treated
with 5mM EDTA in PBS for 5 min on ice. Newly suspended HEK 293 cells were then
transferred to flow cytometry tubes containing 4% formaldehyde in PBS. Samples were
run on a FACSCalibur cytometer using BD CellQuest Pro software until 10,000 cells were
counted. The geometric mean of fluorescence was determined using FlowJo analysis
software, with less fluorescence corresponding to less 5-HT2AR on the membrane.

Measurement of inositol phosphate formation:
HEK 293 cells were transiently transfected with the cDNAs as described in the Figure
Legends. 48 h post-transfection cells were incubated overnight in inositol- and glutaminefree DMEM with 100 μCi/ml myo-[3 H]-Inositol. For all experiments cells were incubated
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for 1 h in warm HBSS (116 mM NaCl, 20 mM HEPES, 11 mM glucose, 5 mM NaHCO3,
4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, pH 7.4) and were then
incubated with 10 mM LiCl alone for 10 min followed by 30 μM quisqualate in LiCl for
30 min. Cells were placed on ice and the reaction was stopped with 500 µl of perchloric
acid and was neutralized with 400 μl of 0.72 M KOH, 0.6 M KHCO 3 . Total cellular [3 H]inositol incorporation was determined in 50 μl of cell lysate. Total inositol phosphate was
purified by anion exchange chromatography using Dowex 1-X8 (formate form) 200-400
mesh anion exchange resin and [3 H]-inositol phosphate formation was determined by liquid
scintillation using a Beckman LS 6500 scintillation system.

ERK Phosphorylation:
Following transfection, HEK 293 cells were re-seeded into 6-well plates. Cells were serum
starved for 1h at 37°C in HBSS and then stimulated with 10 μM 5HT agonist for the
duration of the described time points. Cells were lysed with lysis buffer (50 mM Tris, pH
8.0, 150 mM NaCl, and 1% Triton X-100) containing protease inhibitors (1mM AEBSF,
10 μg/ml leupeptin, and 5 μg/ml aprotinin) for 20 min on a rocking platform at 4°C.
Samples were collected into 1.5 mL Eppendorf tubes and centrifuged at 15,000 x g for 15
minutes at 4 °C to pellet insoluble material. A Bronsted-Lowry protein assay was
performed, and 50 μg of protein was incubated overnight at room temperature in 3x SDS
Loading Buffer containing 2-mercaptoethanol. Samples were separated by SDS-PAGE,
transferred to a nitrocellulose membrane, and immunoblotted for ERK1/2 (rabbit antip44/42 MAPK, 1:1000), phospho-ERK1/2 (rabbit anti-phospho-p44/42 MAPK, 1:1000),
SAP97 (mouse anti-SAP97, 1:1000), and FLAG-5-HT2AR expression (rabbit anti-FLAG,
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1:1000), followed by a horseradish peroxidase-conjugated secondary anti-rabbit antibody
(1:10,000) or anti-mouse antibody (1:10,000) where appropriate. Proteins were detected
using chemiluminescence with the enhanced chemiluminescence kit from GE Healthcare.

Statistical Analysis:
Densitometric data were normalized first for protein expression, and the maximum value
was set to 100, with all other values displayed as the percentage thereof. One-way analysis
of variance test was performed to determine significance, followed by a post hoc Tukey
multiple comparison test test to determine which means were significantly different (p <
0.05) from one another.

3.3 Results
SAP97 is co-immunoprecipitated with 5-HT2AR in a PDZ-binding motif-depende nt
manner. Previously, we demonstrated that the class I carboxyl-terminal tail CRFR1 PDZ
binding motif was essential for CRFR1-mediated sensitization of 5-HT2AR signaling and
that the PDZ domain-containing protein SAP97 interacted with CRFR1 to regulate its
endocytosis and signaling (Magalhaes et al., 2010; Dunn et al., 2013). Therefore, we tested
whether SAP97 might also be co-immunoprecipitated with 5-HT2AR in a PDZ motifdependent manner. We found that green fluorescent protein (GFP-SAP97) fusion protein
was co-immunoprecipitated with a FLAG (FL) epitope-tagged 5-HT2AR (FL-5-HT2AR)
from HEK 293 cells, but that agonist stimulation with 10 μM 5-HT did not increase the
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Figure 3.1: SAP97 co-immunoprecipi tates with 5-HT2A R in a PDZ-binding motif-dependent and
agonist-independent manner: (A) Representative immunoblot of SAP97 co-immunoprecipitated with FL5-HT2A R but not FL-5-HT2A R-ΔSCV, which lacks the PDZ-binding motif. Transient transfections with 1μg
of plasmid cDNA for each construct were performed in HEK 293 cells as labelled. Samples were run using
SDS-PAGE and immunoblotted with rabbit anti-GFP. (B) Effect of 5HT treatment was quantified using
densitometry and had no significant effect on the amount of YFP-SAP97 co-immunoprecipitated with FL-5HT2A R. Data are representative of the mean ± SEM of six independent experiments. (C) Representative
immunoblot of endogenous SAP97 co-immunoprecipitated with 5-HT2A R antibody from adult mouse cortex.
Data are representative of three independent experiments.
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association of GFP-SAP97 with FL-5-HT2AR (Fig. 3.1A and B). This interaction was
dependent on an intact PDZ binding motif at the end of the carboxyl-terminal tail, as the
deletion of the last three critical amino acid residues (SCV) of the 5-HT2AR carboxylterminal tail prevent GFP-SAP97 co-immunoprecipitation with the resulting FL-5-HT2ARΔSCV mutant (Fig. 3.1A and B). We found that endogenous SAP97 could also be coimmunoprecipitated with endogenous 5-HT2AR from cortical brain lysates (Fig. 3.1C).
Thus, SAP97 interacts with 5-HT2AR via the 5-HT2AR carboxyl-terminal PDZ binding
motif.

SAP97 colocalization with 5HT2AR at the plasma membrane is dependent on an intact
5HT2AR PDZ-binding motif. GFP-SAP97 when expressed alone in HEK 293 cells was
diffusely localized throughout the cytoplasm and was not localized to the plasma
membrane (Fig. 3.2A). However, when GFP-SAP97 was co-expressed with FL-5-HT2AR
in HEK293 cells, GFP-SAP97 immunofluorescence redistributed to the plasma membrane,
where it colocalized with Alexa Fluor 647 labeled FL-5-HT2AR (Fig. 3.2B). In contrast,
deletion of the 5-HT2AR carboxyl-terminal PDZ binding motif (SCV) resulted in a FL-5HT2AR-ΔSCV mutant that was unable to promote the redistribution of GFP-SAP97 from
the cytosol to the plasma membrane (Fig. 3.2C). To further establish whether SAP-97
interacts with 5-HT2AR, we prepared a FL-5-HT2AR renilla luciferase (rLuc) fusion protein,
where rLuc was inserted in frame into the 5-HT2AR carboxyl-terminal tail 22 amino acid
residues upstream of the SCV PDZ binding motif (FL-5-HT2AR-rLuc-x22-SCV). We
found that this construct was expressed at the cell surface of HEK 293 cells (Fig. 3.3A) and
was coupled to the stimulation of inositol phosphate formation (Fig. 3.3B). The EC 50 for
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Figure 3.2: GFP-SAP97 co-localizes at the membrane with FL-5-HT2A R in a PDZ-binding motifdependent

manner: (A) Representative confocal microscopy image demonstrating the subcellular

localization of GFP-SAP97 (green) when expressed alone HEK 293 cells. (B) Representative confocal
image demonstrating the colocalization of FLAG-tagged 5-HT2A R (red) labelled with Zenon Alexa Fluor
633-conjugated mouse anti-FLAG antibody GFP-SAP97 (green). (C) Representative confocal image
demonstrating the colocalization of FLAG-tagged 5-HT2A R-ΔSCV (red) labelled with Zenon Alexa Fluor
633-conjugated mouse anti-FLAG antibody GFP-SAP97 (green). HEK 293 cells were transfected with 3 μg
of receptor and 1 μg of GFP-SAP97 plasmid cDNA, respectively. Data are representative of over 30 cells.
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Figure 3.3: YFP-SAP97 directly interacts with 5-HT2A R-rLuc and FL-5-HT2A R -rLuc-x22-SCV. (A)
Representative confocal microscopy image demonstrating surface expression of FL-5-HT2A R (green) and (B)
FL-5-HT2A R-rLuc-x22-SCV (green) with mouse anti-FLAG followed by secondary mouse Alexa Fluor 488.
(C) Dose response curves for 5-HT-mediated IP formation in response to treatment with increasing
concentrations of 5-HT for 30 minutes in HEK 293 cells transfected with 1 μg of plasmid cDNA expressing
FL-5-HT2A R or 5-HT2A R -rLuc-x22-SCV. The EC50 for FL-5-HT2A R –mediated IP formation was 8.6 nM
and the EC50 for FL-5-HT2A R -Luc-x22-SCV– mediated IP formation was 9.3 nM. The data are
representative of the mean ± S.E.M. of three independent experiments. (D) HEK 293 cells were transfected
with 20 ng of plasmid cDNA expressing FL-5-HT2A R -rLuc-x22-SCV cDNA with increasing ratios of
plasmid cDNA expressing either YFP-SAP97 or YFP-Htt. Total cDNA was normalized with pcDNA3.1 and
the BRET ratio determined. The data represent the mean ± S.E.M. of six independent experiments .
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FL-5-HT2AR mediated IP formation was 8.6 nM and the EC50 for FL-5-HT2AR-rLuc-x22SCV mediated IP formation was 9.3 nM. Although the maximum efficacy for FL-5HT2AR-rLuc-x22-SCV stimulated IP formation was attenuated when compared with FL-5HT2AR, this was the consequence of reduced cell surface FL-5-HT2AR-rLuc-x22-SCV
expression (data not shown).

When HEK 293 cells were transfected with a constant

amount of FL-5-HT2AR-rLuc-x22-SCV plasmid cDNA (1 μg) along with increasing ratios
of plasmid cDNA expressing SAP97-YFP we observed an increasing, but saturable level
of bioluminescence resonance energy transfer (BRET) (Fig. 3.3D).

In contrast, co-

expression of FL-5-HT2AR-rLuc-x22-SCV with increasing rations of wild-type huntingtinYFP did not result in an increased BRET ratio (Fig. 3.3D). Thus, the immunofluorsce nce
subcellular localization data, co-immunoprecipitation data, and BRET data all indicated
that SAP97 interactions 5-HT2AR were PDZ binding motif dependent.

SAP97 antagonizes the internalization of 5-HT2AR. We previously demonstrated that
SAP97 contributed to the regulation of agonist-stimulated CRFR1 internalization by
attenuating the endocytosis of the receptor (Dunn et al., 2013). Therefore, we tested
whether the overexpression of GFP-SAP97 or knockdown of endogenous SAP97
expression in HEK 293 cells would alter the agonist-stimulated internalization of FL-5HT2AR. In HEK 293 cells expressing FL-5-HT2AR the overexpression of SAP97 reduced
agonist-stimulated (30 min, 10 μM 5-HT) internalization of the receptor and SAP97
shRNA expression resulted in an increase in FL-5-HT2AR endocytosis, as measured by a
loss of cell surface FL-5-HT2AR immunofluorescence (Fig.3.4). In contrast, deletion of the
FL-5-HT2AR PDZ binding motif resulted in a FL-5-HT2AR-ΔSCV mutant that was
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Figure 3.4: Role of SAP97 in the internalization of 5HT2A R: (A) HEK 293 cells were transfected with 1
μg of plasmid cDNA expressing either FL-5-HT2A R or FL-5-HT2A R -ΔSCV along with either 3 μg of plasmid
cDNA expressing scrambled shRNA (SCR), 1 μg of plasmid cDNA exp ressing GFP-SAP97 or 3 μg of
plasmid cDNA expressing SAP97 shRNA. Shown is the loss of cell surface receptor following the treatment
of cells with 10 μM 5-HT for 30 min, as assessed by flow cytometry. The data represents the mean ± SEM.
(B) Basal levels of cell surface expression across various conditions examined in panel A, as measured by
flow cytometry. The data represents the mean ± SEM.
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impaired in its internalization when compared to the wild-type type receptor and neither
GFP-SAP97 overexpression nor SAP97 shRNA expression altered the extent of FL-5HT2AR-ΔSCV endocytosis (Fig. 3.4A). Basal cell surface receptor was unchanged (Fig.
3.4B). Taken together, similar to what was observed for the CRFR1 (Dunn et al., 2013),
FL-5-HT2AR internalization

was modulated

by SAP97 expression,

but normal

internalization of the receptor was dependent upon an intact PDZ binding motif.

This

observation suggests that another PDZ protein may be integral for receptor endocytosis.

SAP97 regulates 5HT2AR-mediated IP formation. We previously found that SAP97 did
not contribute to the regulation of CRFR1-mediated cAMP signaling (Dunn et al., 2013).
However, a structurally similar PDZ containing protein, PSD95, was previous ly
demonstrated to enhance 5-HT2AR-mediated inositol phosphate (IP) signaling (Xia et al.,
2003b). Therefore, we tested whether either the overexpression of GFP-SAP97 or SAP97
shRNA treatment altered 5-HT-stimulated IP formation in FL-5-HT2AR expressing HEK
293 cells. In HEK 293 cells transfected with FL-5-HT2AR overexpression of GFP-SAP97
did not alter IP formation in response to increasing concentrations of 5-HT (Fig. 3.5A).
However, shRNA knockdown of endogenous SAP97 significantly attenuated the
maximum efficacy for 5-HT-stimulated IP formation in cells transfected FL-5-HT2AR,
when compared to cells treated with scrambled shRNA (Fig. 3.5A). In contrast, neither
GFP-SAP97 overexpression nor SAP97 shRNA treatment altered the dose response for 5HT-stimulated

IP formation

in cells

expressing

FL-5-HT2AR-ΔSCV (Fig.

5B).

Interestingly, when the dose response curves for 5-HT-stimulated IP formation in FL-5HT2AR and FL-5-HT2AR-ΔSCV were compared, the maximum efficacy for FL-5-HT2AR-
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Figure 3.5: SAP97 plays an integral role in 5-HT2A R-mediated IP3 -signaling. (A) Dose response curves
for 5-HT2A R-mediated IP formation in response to treatment with increasing concentrations of 5-HT for 30
min in cells transfected with 1 μg of plasmid cDNA expressing FL-5-HT2A R along with either 3 μg of plasmid
cDNA expressing scrambled shRNA (SCR), 1 μg of plasmid cDNA expressing GFP-SAP97 or 3 μg of
plasmid cDNA expressing SAP97 shRNA. (B) Dose response curves for 5-HT2A R-ΔSCV-mediated IP
formation in response to treatment with increasing concentrations of 5-HT for 30 min in cells transfected
with 1 μg of plasmid cDNA expressing FL-5-HT2A R -ΔSCV along with either 3 μg of plasmid cDNA
expressing scrambled shRNA (SCR), 1 μg of plasmid cDNA expressing or 3 μg of plasmid cDNA expressing
SAP97 shRNA. (C) Comparison of the dose response curves for 5-HT2A R- and 5-HT2A R-ΔSCV-mediat ed
IP formation in response to treatment with increasing concentrations of 5-HT for 30 min.

Cells were

transfected with 1 μg of plasmid cDNA expressing either FL-5-HT2A R or FL-5-HT2A R-ΔSCV. The data
represent the mean ± SEM of six independent experiments .
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ΔSCV-stimulated IP formation was found to be significantly attenuated when compared to
wild-type FL-5-HT2AR (Fig. 3.5C). These results indicated that endogenous SAP97
interactions with the 5-HT2AR PDZ binding motif contribute to the regulation of 5-HT2ARmediated Gαq/11 signaling.

SAP97 regulation 5HT2AR-mediated ERK1/2 phosphorylation is PDZ binding motifindependent. We recently demonstrated that SAP97 regulated CRFR1-mediated ERK1/2
phosphorylation in a manner that was independent of SAP97 interactions with CRFR1 PDZ
binding motif (Dunn et al., 2013).

Therefore, we tested the effect of GFP-SAP97

overexpression and shRNA knockdown on ERK1/2 phosphorylation in response to 10 μM
5-HT stimulation of the 5-HT2AR for 0, 5 and 10 min. We found the overexpression of
GFP-SAP97 did not significantly alter 5-HT-stimulated ERK1/2 phosphorylation in
response to the activation of the 5-HT2AR, but SAP97 shRNA treatment significantly
attenuated 5-HT2AR-mediated ERK1/2 phosphorylation (Fig. 3.6A). Similar to what we
observed for a CRFR1 mutant receptor that lacked its carboxyl-terminal PDZ binding
motif, ERK1/2 phosphorylation in response to the activation of the 5-HT2AR-ΔSCV mutant
was also unaffected by GFP-SAP97 overexpression, but was still significantly attenuated
following the knockdown of SAP97 following SAP97 shRNA treatment (Fig. 3.6B).
Taken together these results support a generalized role for SAP97 in the regulation of
GPCR-mediated ERK1/2 phosphorylation that does not require PDZ domain interactio ns
with GPCRs.
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Figure 3.6:

Endogenous

SAP97 is required for 5HT2A R-mediated ERK1/2 phosphorylati o n

independent of PDZ-binding motif interactions:

(A) Representative immunoblot showing ERK1/ 2

phosphorylation in response 10 μM 5-HT treatment for 0, 5, 10 min in HEK 293 cells transfected with 1 μg
of plasmid cDNA encoding FL-5-HT2A R 1 μg of plasmid cDNA expressing FL-5HT2A R along with either 3
μg of plasmid cDNA expressing scrambled shRNA (SCR), 1 μg of plasmid cDNA expressing GFP-SA P97
or 3 μg of plasmid cDNA expressing SAP97 shRNA.. Shown in the panels below are corresponding
immunoblots for total ERK1/2, FL-5-HT2A R, GFP-SAP97, and endogenous SAP97 protein expression.
Immunoblot of GFP-SAP97 overexpression is shown at a different exposure (as indicated by box) than the
exposure for endogenous SAP97 treated with scrambled and SAP97 shRNA. (B) Densitometric analysis of
ERK1/2 phosphorylation in response to 10 μM 5HT treatment for 0, 5, and 10 min in HEK 293 cells
transfected with FLAG-5HT2A R and either scrambled shRNA, GFP-SAP97, or SAP97 shRNA. The data
represent the mean ± SEM of four independent experiments.

(C) Representative immunoblot showing

ERK1/2 phosphorylation in response 10 μM 5-HT treatment for 0, 5, 10 min in HEK 293 cells transfected
with 1 μg of plasmid cDNA encoding FL-5-HT2A R-ΔSCV 1 μg of plasmid cDNA expressing FL-5HT2A R
along with either 3 μg of plasmid cDNA expressing scrambled shRNA (SCR), 1 μg of plasmid cDNA
expressing GFP-SAP97 or 3 μg of plasmid cDNA expressing SAP97 shRNA.. Shown in the panels below
are corresponding immunoblots for total ERK1/2, FL-5-HT2A R-ΔSCV, GFP-SAP97, and endogenous SAP97
protein expression. Immunoblot of GFP-SAP97 overexpression is shown at a different exposure (as indicated
by box) than the exposure for endogenous SAP97 treated with scrambled and SAP97 shRNA.

(D)

Densitometric analysis of ERK1/2 phosphorylation in response to 10 μM 5HT treatment for 0, 5, and 10 min
in HEK 293 cells transfected with FLAG-5HT2A R-ΔSCV and either scrambled shRNA, GFP-SAP97, or
SAP97 shRNA. The data represent the mean ± SEM of four independent experiments.
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SAP97 is not exclusively involved in CRFR1-mediated enhancement of 5-HT2ARmediated IP formation. Our primary rationale for assessing the role of SAP97 in the
regulation of CRFR1 and 5-HT2AR signaling and endocytosis was to determine whether
SAP97 was the PDZ protein underlying CRFR1-mediated sensitization of 5-HT2AR
signaling (Magalhaes et al., 2010). Therefore, we tested the effect of SAP97 shRNAmediated knockdown on CRFR1-stimulated enhancement of 5-HT2AR signaling. In HEK
293 cells transfected with CRFR1, 5-HT2AR and scrambled shRNA, pretreatment with 500
nM CRF for 30 min resulted in an increase in the maximum efficacy for 5-HT-stimula ted
IP formation, when compared to cells that were not CRF pretreated (Fig. 3.7). As
demonstrated in Fig. 5.5A, SAP97 shRNA treatment reduced the maximum efficacy for 5HT-stimulated IP formation, when compared to 5-HT-stimulated IP responses in cells
transfected with CRFR1, 5-HT2AR and scrambled shRNA (Fig. 3.7). However, SAP97
shRNA down-regulation of SAP97 expression did not block the CRF pretreatment-induced
increase in the maximum efficacy for 5-HT-stimulated IP formation CRFR1 and 5-HT2AR
expressing cells (Fig. 3.7). Taken together, these results indicated that, although SAP97
contributed to the regulation of 5-HT2AR-mediated IP formation, it did not contribute to
the CRFR1-mediated

sensitization

Magalhaes and colleagues (2010).

of 5-HT2AR-signaling

previously

reported by
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Figure 3.7: SAP97 shRNA knockdown does not prevent CRFR1-medi ated enhancement of 5-HT2A Rmediated signaling: 5-HT stimulated dose response curves for inositol phosphate (IP) formation in HEK
293 cells that are transfected with 1μg of plasmid cDNA encoding HA -CRFR1 and 1 μg of plasmid cDNA
encoding either FL-5-HT2A R or FL-5-HT2A R-ΔSCV along with 3 μg of plasmid cDNA encoding either
scrambled shRNA (SCR) or SAP97 shRNA. Transfected HEK 293 cells were treated either with or without
500 nM CRF for 30 min prior to being treated with increasing concentrations of 5-HT for 30 min. The data
represent the mean ± SEM of 5 independent experiments.

110

3.4 Discussion

We previously demonstrated that two GPCRs linked to the manifestation of mood
disorders and psychiatric disease, CRFR1 and 5-HT2AR, exhibit crosstalk that is dependent
upon PDZ-binding motif interactions with an unknown PDZ protein that results in the
heterologous sensitization of 5HT2AR signaling (Magalhaes et al., 2010). This prompted
us to screen for PDZ-containing proteins that may interact with both CRFR1 and 5-HT2AR
(Dunn et al., 2013) and which may also function as novel regulators of both CRFR1 and 5HT2AR trafficking and signaling.

We show here, that similar to what we previous ly

reported for CRFR1 (Dunn et al., 2013), SAP97 functions to antagonize 5-HT2AR
endocytosis. Thus, SAP97 appears to play a generalized and functionally consistent role
in regulating the endocytosis of both the CRFR1 and 5-HT2AR.

Although SAP97

expression is essential for both CRFR1- and 5-HT2AR -mediated activation of ERK1/2
phosphorylation, the role of SAP97 in regulating GPCR-dependent ERK1/2 signaling is
independent of PDZ domain interactions with the receptors. Moreover, we find that the
loss of SAP97 expression impairs 5-HT2AR -stimulated IP signaling, but that PDZ domain
containing protein SAP97 is not exclusively required for CRFR1-dependent heterologous
sensitization of 5HT2AR signaling (Magalhaes et al., 2010).
SAP97 has previously been reported to interact with several neurotransmitte r
receptors including: the β1 -adrenergic receptor (β1 AR), CRFR1, somatostatin receptor
subtype 1, kainite

receptor, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic

acid

receptor (AMPAR), N-methyl-D-aspartate receptor (NMDAR) and was identified as a 5HT2AR interacting protein in a proteomic screen (Leonard et al., 1998; Bassand et al., 1999;
Metha et al., 2001; Sans et al., 2001; Rumbaugh et al., 2003; Bécamel et al., 2004; He et
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al., 2006; Gardner et al., 2007; Cai et al., 2008; Dunn et al., 2013). Interestingly, each of
these receptors have a class I PDZ-binding motif on the distal region of the carboxyl
terminal tail.

SAP97 plays a role in regulating either the cell surface localizatio n,

endocytosis, signaling, compartmentalization or recycling of each of these receptors
proteins. For example, SAP97 regulates the cell surface expression of the AMPAR via its
association with the AMPAR GluR1 subunit in the secretory pathway, but SAP97 is not
involved in the NMDAR-mediated internalization of the receptor (Sans et al., 2001;
Rumbaugh et al., 2003). SAP97 is also involved in the subcellular localization of kanaite
receptors (Metha et al., 2001) and in the case of the NMDAR, SAP97 modulates NMDARmediated CaMKII phosphorylation and NMDAR synaptic localization (Gardoni et al.,
2003). It is also reported that SAP97 may mediate somatostatin receptor type 1-dependent
regulation of synaptic growth cone dynamics (Cai et al., 2008). We have shown previous ly
(Dunn et al., 2013) and in the present study that SAP97 interactions also contribute to the
antagonism of agonist-induced endocytosis of both CRFR1 and 5-HT2AR. Taken together,
it appears that SAP97 may have a general role in promoting the membrane localization of
transmembrane receptors that specifically encode class I PDZ-binding motifs.

Future

studies will be required to understand how PDZ proteins regulate the functional activity of
GPCRs in vivo and contribute to the physiological regulation of GPCR-modulated anima l
behaviours and pathophysiological GPCR signaling.
Our previous studies have shown that SAP97 does not contribute to the regulatio n
of Gαs-mediated cAMP signaling in response to CRFR1 activation (Dunn et al., 2013). In
contrast, our current study now suggests that SAP97 expression facilitates the ability of the
5-HT2AR to stimulate IP formation via the activation of Gαq/11 . Previous studies have
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demonstrated that PSD95 and NHERF1 contribute to the regulation of IP signaling via the
thromboxane A2 receptor (TP receptor) and 5-HT2AR, respectively (Rochdi et al., 2002;
Xia et al., 2003b). The association of PSD95 with 5-HT2AR enhances 5-HT2AR signa l
transduction similar to what we have observed for the structurally related PDZ protein
SAP97 (Xia et al., 2003b). In contrast, activation of the TP receptor increases NHERF1
interactions with Gαq/11 , which in turn functions to impair Gαq/11 /TP receptor interactio ns
that are required for the activation of phospholipase C-mediated IP formation (Rochdi et
al., 2002). This suggests that PDZ domain containing proteins may function to both
positively and negatively regulate the interface between GPCRs and heterotrimeric G
proteins such as Gαq/11 . Future studies will be required to determine the mechanism by
which PSD95 and SAP97 function to enhance 5-HT2AR signaling and whether this
mechanism is either complimentary to or antagonistic to the means by which NHERF1
antagonizes TP receptor signaling.
We previously demonstrated that CRF-mediated ERK1/2 phosphorylation is
dependent upon the endogenous expression of SAP97 in both HEK293 and AtT20 cells
(Dunn et al., 2013). This role for SAP97 in the regulation of ERK1/2 signaling is
independent of the class I CRFR1 PDZ-binding motif, and SAP97 expression is required
for CRFR2-mediated ERK1/2 phosphorylation, a receptor which, despite ~60% sequence
homology with CRFR1, does not contain a class I PDZ-binding motif (Dunn et al., 2013).
Our studies with 5-HT2AR indicate that SAP97 plays a generalized role in regulating
GPCR-dependent ERK1/2 signaling. Previous studies have demonstrated the ability of
p38 MAPK family proteins to interact with and subsequently phosphorylate SAP97
following cellular stress responses resulting in disrupted SAP97 interactions with the actin
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cytoskeleton (Sabio et al., 2005). The fact that SAP97 is a substrate for p38 MAPK
suggests that it may also serve as a scaffold for for the assembly of ERK signaling
complexes.

This provides a potential molecular mechanism whereby SAP97 might

regulate ERK1/2 signaling downstream of SAP97/GPCR.
Of central importance to this study was to assess whether SAP97 represents the
PDZ protein that is required for CRFR1-mediated sensitization of 5-HT2AR signaling.
Although SAP97 shRNA-dependent knockdown of SAP97 protein expression significantly
attenuates 5-HT2AR -mediated IP signaling, CRF pretreatment in the absence of SAP97
expression still evokes heterologous sensitization of 5-HT2AR-mediated IP signaling. This
suggests that SAP97 is either not involved in the crosstalk between CRFR1 and 5-HT2AR,
or that other PDZ proteins are also required and/or compensate for the loss of SAP97
expression.
In summary, in the current study we have characterized the role of the PDZ domaincontaining protein SAP97 as a novel regulator of 5-HT2AR trafficking and signaling and
confirm a receptor-independent role for SAP97 in regulating ERK1/2 signaling.

PDZ

domain containing proteins of the PSD95/SAP97 family have an established link to the
regulation and treatment of mood disorders and psychiatric disease that may implicate 5HT2AR signaling (Gray and Roth, 2001; Roth et al., 2004; Catapano and Manji, 2007).
Further understanding of how PDZ proteins regulate CRFR1 and 5-HT2AR function will
be essential for understanding their contribution to the pathological cell signaling
associated with psychiatric diseases and the development of new strategies to treat these
diseases.
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Chapter 4: PSD-95 Regulation of CRFR1
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4.1 Introduction

Corticotropin-releasing factor (CRF) is a neuropeptide that is released from the
hypothalamus during periods of stress and ultimately serves to increase blood-cortisol
levels, subsequently leading to the production of energy to cope with the stressor (Emeric Sauval, 1986). Once released, CRF can activate two receptor subtypes, CRF receptor 1
(CRFR1) and CRF receptor 2 (CRFR2), both of which are G protein-coupled receptors
(GPCRs) (Chalmers et al., 1996; Dautzenberg & Hauger, 2002). Although both receptors
appear to contribute to stress responses and mood-regulation (Laryea et al., 2012), CRFR1
has an order of magnitude higher affinity for CRF than CRFR2, and CRFR1 is also
expressed at higher levels throughout the brain (Chalmers et al., 1995; Palchaudhuri et al.,
1998). CRFR1 antagonists have demonstrated anxiolytic and antidepressant- like effects
suggesting that CRFR1 is a viable target for mood-regulation (Overstreet & Griebel, 2004;
Chaki et al., 2004). The link between stress, mood disorders, and psychiatric disease has
long been hypothesized. Recent studies suggest a potential molecular mechanism whereby
CRFR1 activation leads to enhanced 5-HT2AR expression and signaling that leads to
increased stress-induced anxiety and depression (Leonard, 2005; Magalhaes et al., 2010).
5HT2AR has consistently been implicated in psychiatric disease and 5HT2AR antagonists
have shown limited success in alleviating the negative effects of depression and psychoses
(Eison et al., 1991; Marek et al, 2005; Fribourg et al., 2011).
Although CRFR1 represents an intriguing target for regulating mood, the
characterization of CRFR1-interacting proteins that influence its signal transduction and
trafficking have not been extensively characterized.

Recently, we have shown that the
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PSD-95/Disc Large/Zona Occludens (PDZ) protein, SAP97, is a novel CRFR1-interacting
protein that functions to reduce CRFR1 endocytosis, but also promotes CRFR1-mediated
ERK1/2 signaling independently of receptor interactions (Dunn et al., 2013). Interestingly,
PDZ interactions are also integral for CRFR1-mediated enhancement of 5-HT2AR signaling
(Magalhaes et al., 2010). However, SAP97 is not the PDZ domain-containing protein that
is independently responsible for the heterologous sensitization of 5-HT2AR signaling (Dunn
et al., 2014).
PSD-95 is another PDZ domain-containing protein with structural similarities to
SAP97 that we identified as a CRFR1-interacting protein in a screen for PDZ domains that
bind to the CRFR1 C-tail (Dunn et al., 2013). SAP97 and PSD-95 have both been linked
to psychiatric disease, specifically schizophrenia (Toyooka et al., 2002; Clinton et al.,
2003; Sato et al., 2008; Clinton & Meador-Woodruff, 2004; Toro & Deakin, 2005;
Kristiansen et al., 2006; Clinton et al., 2006; Funk et al., 2009; Chen et al., 2010; Balan et
al., 2013). Additionally, hallucinogen and atypical antipsychotic actions of 5-HT2AR are
dependent upon the expression of PSD-95 (Abbas et al., 2009). Thus, PSD-95 represents
a viable target in the regulation of CRFR1 function, as it has been previously demonstrated
to regulate the function of other GPCRs, in addition to 5HT2AR (Hu et al., 2000; Xu et al.,
2001; Hu et al., 2002; Xia et al., 2003; Gavarini et al., 2006; Zhang et al., 2007; Sun et al.,
2009, Abbas et al., 2009). With respect to 5-HT2AR, which like CRFR1, encodes a class I
PDZ-binding motif at the distal end of its carboxyl terminal tail, PSD-95 overexpression is
shown to inhibit 5-HT2AR endocytosis and to facilitate 5-HT2AR-stimulated inosito l
phosphate (IP) formation (Xia et al., 2003; Abbas et al., 2009).

Consequently,

understanding the contribution of PSD-95 to the regulation of CRFR1 activity, as well as
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the crosstalk between CRFR1 and 5-HT2AR signaling, may provide significant insight into
the development of new therapeutic strategies for mood disorders and psychiatric disease.
In this study, we identified PSD-95 as a CRFR1 interacting protein that colocalize s
with CRFR1 at the cell surface of HEK 293 cells and in the dendrites of cortical neurons
in a PDZ motif-dependent manner. Unlike SAP97, PSD-95 overexpression or knockdown
does not affect either CRFR1-stimulated IP formation or ERK1/2 phosphorylatio n.
However, similar to what is observed for SAP97, the overexpression of PSD-95 attenuates
CRFR1 internalization

and a reduction of PSD-95 expression increases CRFR1

internalization. PSD-95 modulates CRFR1 endocytosis by competing with β-arrestin for
receptor binding, but PSD-95 is not required for CRFR1-dependent sensitization of 5HT2AR signaling. We conclude that although PSD-95 and SAP97 are structurally simila r
they play distinct roles in the regulation of CRFR1 and 5-HT2AR signaling.

4.2 Experimental Procedures

Materials:
Goat anti-glutathione-S-transferase (GST) antibodies, as well as ECL Western blotting
detection reagents were purchased from GE Healthcare (Oakville, ON, Canada). Rabbit
anti-phospho-p44/42 MAP kinase (Thr202/Tyr402), and rabbit anti-p42/44 MAP kinase
and rabbit PSD-95 antibodies were obtained from Cell Signalling Technology (Pickering,
ON, Canada). Rabbit anti-GFP antibody was obtained from Invitrogen/Life Technologie s
(Burlington, ON, Canada). Alexa Fluor 647 anti-mouse IgG and Alexa Fluor 633 goat
anti-mouse IgG Zenon antibodies were purchased from Invitrogen/Molecular Probes
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(Burlington, ON, Canada). cAMP GLO Assay was obtained from Promega (Madison, WI,
USA). Mouse anti-HA antibody and all other biochemical reagents were purchased from
Sigma-Aldrich (Oakville, ON, Canada). All other biochemical reagents were purchased
from Sigma-Aldrich (Oakville, ON, Canada).
.
Plasmid Constructs:
HA-CRFR1 AND HA-CRFR1-ΔTAV were described previously (Dunn et al., 2013).
GFP-PSD-95 was provided by Dr. Gregory Dekaban (Robarts Research Institute).

The

myc-PSD-95 construct was a gift from Dr. Richard Huganir (John’s Hopkins). The PSD95 shRNA construct was kindly provided by Dr. Roger Nicoll (UCSF). The EPAC BRETbased cAMP biosensor was the gift of Drs. Ali Salahpour (University of Toronto) and Marc
Caron (Duke University) (Barak et al., 2008).

Cell Culture and Transfection:
Human embryonic kidney (HEK 293) cells were maintained in Eagle’s minimal essentia l
medium supplemented with 10% fetal bovine serum. Cells were seeded in 10 cm dishes at
70-80% density 24 h prior to transfection.

All transfections (except for the β-arrestin2

recruitment experiments) were performed using a modified calcium phosphate method, as
described previously (Ferguson and Caron, 2003). 18 hours post-transfection, cells were
washed with phosphate-buffered saline (PBS) and resuspended with trypsin, 0.25% EDTA.
These transfections were performed with 1 μg of each construct, with exception that 3 μg
of plasmid cDNA was used for all shRNA constructs. Transfections for BRET-based βarrestin2-recruitment assays utilized Lipofectamine 2000 reagent with each cDNA
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transfected in units of 150 ng total cDNA. Empty pcDNA3.1 vector was used to equalize
the total amount of plasmid cDNA used to transfect cells. All experiments were conducted
48 hours after the initial transfection, with the exception of transfections involving PSD95 shRNA which were conducted 72 hours after initial transfection.

Primary mouse

cortical cultures were prepared from E18 embryos as described previously (Ribiero et al.,
2009) and were maintained in Neurobasal medium containing B27 and N2 supplements as
well as pen/strep and L-glutamine. Cells were plated on poly- L-lysine coated 50 mm glass
coverslips in Neurobasal media for 5 h at 37 o C and 5% CO 2 in a humidified incubator to
permit cell attachment. Neurobasal media was subsequently replaced with culture media
that was replenished every 3 days.

Culture media consisted of neurobasal media

supplemented with B-27, 0.5 U/ penicillin, 0.5 μg/ streptomycin, 10 μM MK-801, 25 mM
KCl and 5 pg/glial-derived neurotrophic factor. Primary neuronal cultures were astrocyte
free and transfected using Lipofectamine 2000 following the manufacturer’s instructio ns.
The University of Western Ontario Animal Care Committee approved all anima l
procedures.

Co-immunoprecipitation:
Transfected HEK 293 cells were seeded into 10 cm dishes the day before the experiments.
Cells were serum-starved for 1 h in HBSS, and dishes were treated with either HBSS alone
or with 500 nM CRF agonist in HBSS for 30 min at 37°C. Cells were subsequently lysed
in lysis buffer for 20 min on a rocking platform at 4°C. Samples were collected into 1.5
mL Eppendorf tubes and centrifuged at 15,000 x g for 15 min at 4°C to pellet insolub le
material.

A Bronsted-Lowry protein assay was performed, and 400 μg of protein was
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incubated overnight at 4 °C with protein G-sepharose and mouse anti-HA antibody (1:50).
After incubation, beads were washed three times with cold lysis buffer and incubated
overnight at room temperature in 3x SDS loading buffer containing 2-mercaptoethano l.
Samples were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and
immunoblotted to identify co-immunoprecipitated GFP-PSD95 (rabbit anti-GFP, 1:1000).
An additional Western blot was performed to examine HA-CRFR1, HA-CRFR1-ΔTAV
(mouse anti-HA, 1:1000), and GFP-PSD95 (rabbit anti-GFP, 1:1000) protein expression.
For the co-immunoprecipitation of endogenous proteins from cortical extracts, adult mouse
brains were employed.

Tissue was dissected and homogenized on ice in lysis buffer

containing protease inhibitors. The particulate fraction was removed by centrifugation, and
2 mg of supernatant protein was incubated with 5 μL/sample of either goat polyclona l
CRFR1 or CRFR2 antibody from Santa Cruz Biotechnology (Santa Cruz, CA) and protein
G-Sepharose beads overnight at 4°C. The beads were then washed three times with 1%
triton-X lysis buffer and proteins were eluted in 3x SDS loading buffer by warming the
samples at 55 °C for 5 min. Eluted samples were subjected to SDS-PAGE, followed by
electroblotting onto nitrocellulose membranes for immunoblotting with antibodies
described in the figure legends.

Immunofluorescent confocal microscopy:
HEK293 cells grown on 35 mm confocal dishes or primary mouse cortical cultures grown
on round 15 mm glass cover slips were fixed for 30 min in 4% formaldehyde in PBS at 48
h post transfection with 1 μg of either HA-CRFR1 or HA-CRFR1-ΔTAV along with GFPPSD-95. Cells were washed twice with PBS and then incubated for 20 min at room
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temperature in PBS-TB (PBS containing 0.05% Triton X-100 and 3% BSA) to permeablize
cells and block non-specific sites. Cells were then incubated in PBS-TB containing antiHA antibody (1:1000) labelled with Zenon Alexa Fluor 647 rabbit IgG1. Cells were then
washed twice with PBS and stored at 4 o C until imaged.

Confocal microscopy was

performed on a Zeiss LSM-510 META laser scanning confocal microscope using a Zeiss
63X, 1.3 NA, oil immersion lens. HEK 293 cells in 35 mm glass bottomed dishes and
neuronal cultures maintained on cover slips were imaged using dual excitation (488, 543
nm) and emission (BP 505-530 nm and LP 585 nm for GFP and AlexaFluor 546,
respectively) filter sets. Specificity of labeling and absence of signal crossover were
established by examination of single- labeled samples.

cAMP Signaling:
Quantification of cAMP accumulation utilized a BRET-based cAMP biosensor that has
previously been described (Barak et al., 2008; Dunn et al., 2013).

ERK Phosphorylation:
Following transfection, HEK 293 cells were reseeded into 6 well plates. Cells were serum
starved for 1 hour at 37°C in HBSS and then stimulated with 500 nM CRF agonist for the
duration of the described time points. Cells were lysed with lysis buffer (50 mM Tris, pH
8.0, 150 mM NaCl, and 1% Triton X-100) containing protease inhibitors (1mM AEBSF,
10 μg/ml leupeptin, and 5 μg/ml aprotinin) for 20 min on a rocking platform at 4°C.
Samples were collected into 1.5 mL Eppendorf tubes and centrifuged at 15,000 x g for 15
minutes at 4°C to pellet insoluble material. A Bronsted-Lowry protein assay was
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performed, and 50 μg of protein was incubated overnight at room temperature in 3x SDS
Loading Buffer containing 2-mercaptoethanol. Samples were separated by SDS-PAGE,
transferred to a nitrocellulose membrane, and immunoblotted for ERK1/2 (rabbit antip44/42 MAPK, 1:1000), phospho-ERK1/2 (rabbit anti-phospho-p42/44 MAPK, 1:1000),
PSD-95 (rabbit anti-PSD-95, 1:500), GFP-PSD-95 (rabbit anti-GFP, 1:1000) and HACRFR1 expression (mouse anti-HA, 1:1000), followed by a horseradish peroxidaseconjugated secondary anti-rabbit antibody (1:5000-1:10,000) or anti-mouse antibody
(1:10,000) where appropriate. GFP-PSD95 blots were separated from endogenous PSD-95
blots because of the vast overexpression of GFP-PSD95 when compared with endogenous
PSD-95 levels in HEK293 cells. Proteins were detected using chemiluminescence with the
enhanced chemiluminescence kit from GE Healthcare (Mississauga, ON).

Receptor Endocytosis:
Following transfection, HEK 293 cells were reseeded into 12 well plates. Cells were serumstarved for 1 h at 37°C in HBSS and then stimulated for 30 min with or without 500 nM
CRF in HBSS at 37°C. Cells were washed with cold HBSS and treated with mouse antiHA antibody (1:1000) for 45 min on ice. Cells were washed with cold HBSS and
additionally treated with Alexa Fluor 647 donkey anti-mouse IgG (Invitrogen) (1:1000) for
45 min on ice. Cells were washed again with cold PBS and treated with 5mM EDTA in
PBS for 5 min on ice. Newly suspended HEK 293 cells were then transferred to flow
cytometry tubes containing 4% formaldehyde in PBS. Samples were run on a FACSCalibur
cytometer using BD CellQuest Pro software until 10,000 cells were counted (BD
Biosciences, Mississauga, ON). The geometric mean of fluorescence was determined
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using

FlowJo analysis

software (BD Biosciences,

Mississauga,

ON), with less

fluorescence corresponding to less CRFR1 on the membrane.

β-Arrestin2 BRET:
HEK 293 cells were transfected using Lipofectamine 2000 with 20 ng of plasmid cDNA
encoding HA-CRFR1-rLuc and β-arrestin2 (βarr2)-YFP and 60 ng of either pcDNA3.1,
myc-PSD-95, SCR shRNA, or PSD-95 shRNA in 96 well plates along with empty vector
for a total of 150 ng of transfected cDNA. Coelenterazine, was added to each well and
light emission was measured from the luciferase donor and YFP acceptor at 460 nm and
535 nm wavelengths, respectively. The BRET ratio was defined as [(emission at 535 nm) (emission at 460 nm) X Cf]/(emission at 460 nm) where Cf corresponded to (emission at
535 nm/emission at 460 nm) for the control, Rluc expressed alone. Cells were then treated
with 500nM CRF and the BRET ratio was determined over time.

Statistical Analysis:
Densitometric data were normalized first for protein expression, and the maximum value
was set to 100, with all other values displayed as the percentage thereof for ERK1/2
phosphorylation analysis. One-way analysis of variance test was performed to determine
significance, followed by either a post hoc Tukey multiple comparison test or Bonferroni’ s
multiple comparisons test to determine which means were significantly different (p < 0.05)
from one another.
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4.3 Results
PSD-95 interacts with CRFR1 via the class I PDZ-binding motif.

We previous ly

identified SAP97, which is structurally similar to PSD-95 as a novel regulator of CRFR1
(Dunn et al., 2013). We found here, that GFP-PSD-95 was co-immunoprecipitated with
HA-CRFR1, but not with the truncated HA-CRFR1-ΔTAV mutant which lacked a class I
PDZ-binding motif on the distal region of the carboxyl terminal tail (Fig. 4.1A). Moreover,
stimulation with 500 nM CRF for 30 minutes did not lead to a significant increase in GFPPSD-95 co-immunoprecipitated with HA-CRFR1 (Fig. 4.1B). To determine whether
endogenous CRFR1 and PSD-95 interact, lysates from adult mouse cortex were incubated
with either a CRFR1- or CRFR2-specific antibody for receptor immunoprecipitation on
protein G sepharose beads (Fig. 4.1C). We found that endogenous PSD-95 was coimmunoprecipitated with endogenous CRFR1, but not CRFR2, which has a disrupted PDZbinding motif (TAAV) (Fig. 4.1C). Therefore, we concluded that endogenous PSD-95
interacts with CRFR1 in PDZ-binding motif-dependent manner.

Colocalization of PSD-95 with CRFR1. To confirm the biochemical interaction between
CRFR1 and PSD-95, we investigated whether the two proteins colocalized with one
another when transfected into either HEK 293 cells or mouse cortical neurons.

As

predicted by the co-immunoprecipitation data (Fig. 4.1), GFP-PSD-95 colocalized with
HA-CRFR1 at the plasma membrane in HEK 293 cells (Fig. 4.2A). In contrast, GFP-PSD95 was not colocalized at the plasma membrane with HA-CRFR1-ΔTAV (Fig. 4.2B).
Because PSD-95 is a major component and marker of the post-synaptic density (Iasevoli
et al., 2013), we hypothesized that HA-CRFR1 transfected into primary mouse cortical
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Figure 4.1: PSD-95 co-immunopreci pitates with CRFR1 in a PDZ-binding motif-dependent and
agonist-independent manner.

(A) Representative immunoblot of PSD-95 co-immunoprecipitated with

CRFR1, but not CRFR1-ΔTAV, which lacks the PDZ-binding motif. Transient transfections were performed
in HEK 293 cells as labelled. Samples were run using SDS-PAGE and immunoblotted with rabbit anti-GFP.
(B) Effect of CRF treatment was quantified using densitometry and had no significant effect on the amount
of GFP-PSD-95 co-immunoprecipitated with HA-CRFR1. Data represents the mean ± SD of four
independent experiments. (C) Representative immunoblot of endogenous PSD-95 co-immunoprecipitated
with CRFR1 antibody, but not CRFR2 antibody, and appropriate cell lysates from adult mouse cortex. Data
is representative of two independent experiments.
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neurons may be targeted to the post-synaptic density via its interaction with PSD-95.
Consistent with this hypothesis, HA-CRFR1 was colocalized with GFP-PSD-95 in cortical
dendrites (Fig. 4.2C). However, transfected HA-CRFR1-ΔTAV was not colocalized with
GFP-PSD-95, despite exhibiting punctate distribution in dendrites (Fig. 4.2D). Taken
together these results suggested that the CRFR1 class I PDZ-binding motif was integral for
its interaction with PSD-95 and the synaptic targeting of CRFR1.

PSD-95 does not regulate CRFR1-mediated cAMP signaling. Although PSD-95 was
previously demonstrated to play a role in regulating Gαq-mediated IP formation (Xia et al.,
2003), there are conflicting reports regarding the role of PSD-95 in the regulation of Gαsmediated cAMP signaling (Hu et al., 2000; Zhang et al., 2007; Sun et al., 2009). We found
that neither the overexpression of PSD-95, shRNA knockdown of endogenous PSD-95
expression nor the truncation of the CRFR1 C-tail (HA-CRFR1-ΔTAV) had a significa nt
effect on CRFR1-mediated cAMP formation in response to increasing concentrations of
CRF (Fig. 4.3A and B). Thus, our results were consistent with the idea that PSD-95 does
not contribute to the regulation of Gαs-mediated cAMP signaling (Hu et al., 2000; Sun et
al., 2009).

PSD-95 does not contribute to the regulation of CRFR1-mediated ERK1/2 signaling.
Previously, we demonstrated that SAP97, a PDZ protein that is structurally similar to PSD95, was required for CRFR1- and 5-HT2AR-stimulated ERK1/2 phosphorylation in a PDZ
interaction- independent manner (Dunn et al., 2013; Dunn et al., 2014). Given the extensive
sequence homology between SAP97 and PSD95, we hypothesized that PSD95 might also
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Figure 4.2: GFP-PSD-95 co-localizes at the membrane with HA-CRFR1 in a PDZ-binding motifdependent manner. A: Representative confocal microscopy image demonstrating the colocalization of GFP PSD-95 (green) and HA-CRFR1 (red) labelled with Alexa Fluor 633-conjugated secondary antibody in fixed
and permeabilized HEK293 cells. B: Representative confocal microscopy image demonstrating the lack of
colocalization of GFP-PSD-95 (green) and HA-CRFR1-ΔTA V (red) labelled with Alexa Fluor 633conjugated secondary antibody in fixed and permeabilized HEK293 cells C: Representative confocal
microscopy image demonstrating the colocalization of GFP-PSD-95 (green) and HA-CRFR1 (red) labelled
with Alexa Fluor 633-conjugated secondary antibody in fixed and permeabilized cultured embryonic mouse
dendrites (E18). D: Representative confocal microscopy image demonstrating the lack of colocalization of
GFP-PSD-95 (green) and HA- CRFR1-ΔTA V (red) labelled with Alexa Fluor 633-conjugated secondary
antibody in fixed and permeabilized cultured embryonic mouse dendrites (E18). Images are representative of
4 independent experiments.
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Figure 4.3: PSD-95 does not regulate CRFR1-medi ated cAMP formation. (A) HA-CRFR1-mediat ed
and HA-CRFR1-ΔTA V-med iated cAMP formation, as assessed by BRET-based cAMP biosensor (protocol
adapted from Barak et al., 2008.), following co-transfection with either pcDNA3.1 (control) or myc-PSD-95.
The data represent the mean ± SEM of four independent experiments. (B) HA-CRFR1-mediated and HACRFR1-ΔTA V-mediated cAMP formation following co-transfection with either scrambled shRNA (control)
or PSD95 shRNA. The data represent the mean ± SEM of four independent experiments.
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be essential for CRFR1-mediated activation of ERK1/2 phosphorylation. However, we did
not find that GFP-PSD-95 overexpression or shRNA knockdown of endogenous PSD-95
expression

altered

either

HA-CRFR1- or HA-CRFR1-ΔTAV-stimulated

ERK1/2

phosphorylation (Fig. 4.4A and B).

PSD-95 regulates CRFR1 endocytosis. PSD-95 was previously shown to inhibit β1adrenergic receptor (β1 AR) and 5-HT2AR endocytosis (Hu et al, 2000; Xia et al., 2003; He
et al, 2004), and it’s structurally related homologue SAP97 functioned to attenuate both
CRFR1 and 5-HT2AR internalization (Dunn et al., 2013; Dunn et al., 2014). Therefore, we
assessed whether PSD-95 was involved in the regulation of CRFR1 endocytosis. We found
that overexpression of GFP-PSD-95 reduced CRF-stimulated HA-CRFR1 internalizatio n
and shRNA knockdown of endogenous PSD-95 expression increased HA-CRFR1
endocytosis (Fig. 4.5). The truncation of the CRFR1 C-tail attenuated HA-CRFR1
internalization and prevented PSD-95-dependent regulation of HA-CRFR1 internalizatio n
(Fig. 4.5). Taken together, these data provided further evidence for the importance of PDZ
protein interactions in the endocytosis and trafficking of GPCRs.

PSD-95 competes for β-arrestin recruitment to CRFR1. We previously demonstrated
that CRFR1 internalization was β-arrestin-dependent (Holmes et al., 2006), and it was
previously shown that GRK5-mediated phosphorylation of the β1 AR prevented PSD-95
binding to the receptor (Hu et al., 2002).

Therefore, we hypothesized that PSD-95

interactions with CRFR1 might antagonize β -arrestin interactions with the CRFR1. When
tested, we found that overexpression of myc-PSD-95 attenuated CRF-stimulated
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Figure 4.4: PSD-95 has no effect on CRFR1- or CRFR1-ΔTAV-medi ated ERK1/2 phosphorylati on .
(A) Representative immunoblot showing ERK1/2 phosphorylation in response to 500 nM CRF treatment for
0, 2, 5, and 10 min in HEK 293 cells transfected with HA-CRFR1 and either scrambled shRNA, GFP-PSD95, or PSD95 shRNA. Also shown is the total expression of ERK1/2, HA -CRFR1, GFP-PSD-95 and
endogenous PSD-95. Densitometric analysis of ERK1/2 phosphorylation represents the mean ± SEM of four
independent experiments. (B) Representative immunoblot showing ERK1/2 phosphorylation in response to
500 nM CRF treatment for 0, 2, 5, and 10 min in HEK 293 cells transfected with HA -CRFR1-ΔTA V and
either scrambled shRNA, GFP-PSD-95, or PSD95 shRNA. Also shown is the total expression of ERK1/ 2,
HA-CRFR1, GFP-PSD-95 and endogenous PSD-95. Densitometric analysis of ERK1/2 phosphorylation
represents the mean ± SEM of four independent experiments.
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Figure 4.5: Role of PSD-95 on CRFR1 internalization. Agonist-stimulated internalization of HA-CRFR1
or HA-CRFR1ΔTA V in cells co-transfected with either control plasmid, GFP-PSD-95, or PSD-95 shRNA.
The internalization of HA-tagged receptors labelled with Alexa Fluor 647-conjugated mouse anti-HA
antibody was measured in cells treated with 500 nM CRF for 30 minutes and compared with vehicle treated
control cells. The data represents the mean ± SD of 6 independent experiments. * p< 0.05 versus control.
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β-arrestin2 recruitment to HA-CRFR1 (Fig. 4.6A), and that shRNA knockdown increased
β-arrestin2 recruitment to HA-CRFR1 (Fig. 4.6B).

Thus, it appeared that PSD-95

antagonized CRFR1 internalization by preventing β -arrestin interactions required for the
endocytosis of the receptor.

PSD-95 is not independently involved in CRFR1-mediated sensitization of 5-HT2AR
signaling. Previously, we demonstrated that CRFR1 preactivation sensitized 5-HT2ARstimulated IP formation via a mechanism that required intact CRFR1 and 5-HT2AR PDZ
binding motifs (Magalhaes et al., 2010). Therefore, we tested the effect of PSD-95 shRNAmediated knockdown on CRFR1-stimulated enhancement of 5-HT2AR signaling. In HEK
293 cells transfected with CRFR1, 5-HT2AR and scrambled shRNA, pretreatment with 500
nM CRF for 30 min resulted in an increase in the maximum efficacy for 5-HT-stimula ted
IP formation, when compared to cells that were not CRF pretreated (Fig. 4.7). However,
PSD-95 shRNA down-regulation

of PSD-95 expression did not block the CRF

pretreatment- induced increase in the maximum efficacy for 5-HT-stimulated IP formatio n
in CRFR1 and 5-HT2AR expressing cells (Fig. 7). Taken together, these results indicated
that PSD-95 does not independently contribute to the heterologous sensitization of 5HT2AR signaling.
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Figure 4.6: PSD-95 antagonizes β-arrestin2 recruitment to CRFR1.

(A) Bioluminescent Resonance

Energy Transfer (BRET) was employed to quantify the recruitment of β -arrestin2 to CRFR1 with control
vector or myc-PSD95. An initial BRET ratio was calculated followed by 500nM CRF stimulation for the
time shown in Figure. BRET ratios were repeatedly calculated following CRF stimulation and plotted over
time. BRET ratios are expressed as values above the prestimulated basal reading. The data are representative
of the mean ± SD of 4 independent experiments, respectively. (B) BRET readings corresponding to the
recruitment of β-arrestin2 to CRFR1 with control shRNA or PSD-95 shRNA. An initial BRET ratio was
calculated followed by 500nM CRF stimulation.

BRET ratios are expressed as values above the

prestimulated basal reading. The data are representative of the mean ± SD of 4 independent experiments.
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Figure 4.7: PSD-95 shRNA knockdown is insufficient to prevent CRFR1-medi ated enhancement of 5HT2A R-mediated signaling. 5-HT stimulated dose response curves for inositol phosphate (IP) formation in
HEK 293 cells that are transfected with 1 μg of plasmid cDNA encoding HA -CRFR1 and 1 μg of plasmid
cDNA encoding FL-5-HT2A R along with 3 μg of plasmid cDNA encoding either scrambled shRNA (SCR)
or PSD-95 shRNA. Transfected HEK 293 cells were treated either with or without 500 nM CRF for 30 min
prior to being treated with increasing concentrations of 5-HT for 30 min. The data represent the mean ± SEM
of 4 independent experiments.
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4.4 Discussion
We find here that PSD-95, like SAP97 is a MAGUK family PDZ protein that
interacts with CRFR1 in the brain and regulates CRFR1 trafficking, but not CRFR1mediated ERK1/2 signalling (Dunn et al., 2013). Thus, PSD-95 is a second documented
CRFR1-interacting PDZ protein that contributes to the regulation of CRFR1 activity (Dunn
et al., 2013). Our interest in the interaction of PDZ proteins with CRFR1 stems from our
previous observation that intact PDZ binding motifs are required for CRFR1-mediated
heterologous sensitization of 5-HT2AR signaling in response to CRF pretreatment
(Magalhaes et al., 2010). Although PSD-95 on its own does not appear to be the PDZ
protein that is required for CRFR1-mediated sensitization of 5-HT2AR signaling, it does
contribute to the regulation of CRFR1 endocytosis.

The mechanism by which PSD-95

attenuates CRFR1 endocytosis appears to involve its competition with β-arrestin proteins
for receptor binding.
Although the regulatory activity of PSD-95 appears to differ depending upon the
GPCRs examined, PSD-95 appears to regulate CRFR1 and β1 AR activity in a simila r
manner (Hu et al., 2000; Xu et al., 2001; Xia et al., 2003; Gavarini et al., 2006; Zhang et
al., 2007; Sun et al., 2009). In the case of both receptors, PSD-95 antagonizes receptor
internalization, but does not alter Gαs-mediated cAMP signaling (Hu et al., 2000). The
antagonism of endocytosis appears to be a common feature of PSD-95 activity as it also
regulates the internalization of the 5-HT2AR (Hu et al, 2000; Xia et al., 2003; He et al,
2004). Here, we provide evidence that the PSD-95 functions to antagonize the recruitme nt
of β-arrestin2 to CRFR1. This provides a mechanism by which PSD-95 overexpressio n
antagonizes

CRFR1

internalization

and

PSD-95 knockdown

increases

CRFR1
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internalization in response to agonist treatment. In agreement with this hypothesis, it has
been reported that the recruitment of β-arrestin2 to 5-HT2AR in mouse frontal cortex
corresponds with the concomitant decrease in PSD-95 association with 5-HT2AR (Schmid
et al., 2010). Interestingly, the fact that GRK5 phosphorylation, which often precedes βarrestin recuirtment, disrupts PSD-95 interactions with the β1 AR is also consistent with a
PSD-95/β-arrestin competition model (Hu et al., 2002). Taken together, it is plausible that
PSD-95 may antagonize the internalization of any GPCR that encodes a class I PDZbinding motif at the end of its C-tail by inhibiting β-arrestin2 recruitment.
We previously showed that SAP97, a MAGUK family PDZ protein, plays an
essential role in regulating both CRFR1- and 5-HT2AR ERK1/2 signaling, but that this
occurs via a mechanism that was independent of receptor PDZ motif interactions (Dunn
et al., 2013; Dunn et al., 2014). Because both SAP97 and PSD-95 share extensive sequence
homology and are both substrates for ERK1/2 phosphorylation, we expected that PSD-95
would also contribute to the regulation of ERK1/2 activity (Sabio et al., 2004; Sabio et al.,
2005; Cai et al., 2006). However, we found shRNA knockdown of PSD-95 in HEK 293
cells did not alter CRFR1-stimulated activation of ERK1/2 phosphorylation, suggesting
that the regulation of ERK1/2 signaling was unique to SAP97. Although PSD-95 and
SAP97 share sequence homology, SAP97 differed from PSD-95 in that it encodes an amino
terminal L27 domain. Thus, it was possible that this L27 domain may have coupled SAP97
to a MAPK signaling complex that was integral for ERK1/2 phosphorylation, whereas
PSD-95 would not associate with this complex. Future structure-function studies will be
required in order to investigate the potential contribution of the SAP97 L27 domain to
GPCR-mediated activation of ERK1/2 signaling.
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In a previous study, we demonstrated a heterologous sensitization mechanis m
whereby CRFR1 is capable of enhancing 5-HT2AR-mediated IP formation via a mechanis m
that requires receptor endocytosis and recycling as well as intact receptor PDZ-binding
motifs (Magalhaes et al., 2010). This prompted us to screen a PDZ protein array for
potential PDZ proteins that interact with both the CRFR1 and 5-HT2AR C-tails and PSD95 and SAP97 were identified as potential interacting proteins (Dunn et al., 2013). We
have demonstrated that both PSD-95 and SAP97 interact with endogenous CRFR1 in brain
homogenates and with overexpressed receptor in HEK 293 cells, but were unable to show
that they are required for the heterologous sensitization of 5-HT2AR signaling (Dunn et al.,
2014). This is despite the fact that SAP97 appears to enhance Gαq-mediated signaling by
the 5-HT2AR (Dunn et al., 2014).

A previous study has also demonstrated that the

association of PSD95 with 5-HT2AR enhanced 5-HT2AR signal transduction (Xia et al.,
2003). Thus, both SAP97 and PSD-95 facilitate 5-HT2AR Gαq-mediated signaling by an
unknown mechanism, but do not appear to be exclusively involved in the CRFR1-mediated
sensitization of 5-HT2AR-mediated signaling.

Thus alternative CRFR1- and 5-HT2AR-

interacting proteins will have to be investigated.
Developing new strategies to manipulate CRFR1 function is of increasing
importance as CRFR1 has been identified as a potential pharmacological target for the
treatment of mood disorders and psychiatric disease (Overstreet & Griebel, 2004; Chaki et
al., 2004). Interestingly, PSD-95 has previously been linked the psychiatric disorder
schizophrenia (Ohnuma et al., 2000; Kristiansen et al., 2006), and the efficacy of atypical
antipsychotics has demonstrated a dependence on the endogenous presence of PSD-95
(Abbas et al., 2009). Thus, PSD-95 is directly implicated as an important molecule
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involved in mood regulation. In the current study, we have identified PSD-95 as a novel
interacting partner of CRFR1 in the cerebral cortex that is capable of inhibiting CRFR1
internalization by antagonizing β-arrestin2 recruitment. Thus, it is possible that targeting
of PSD-95 interactions with GPCRs may function to alter β-arrestin-mediated signaling
downstream of GPCRs that encode PDZ binding motif and/or enhance their resensitizatio n
by increasing their rate of endocytosis.
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Chapter 5: Discussion
5.1 Summary
In the previous three chapters, the role of PDZ domain-containing proteins SAP97
and PSD95 in regulating GPCRs such as CRFR1 or 5-HT2AR has been thoroughly
documented.

Because PSD-95 was already demonstrated to regulate 5-HT2AR functio n

(Xia et al., 2003), our objectives were as follows:
1.

Evaluate whether SAP97 regulates CRFR1 signalling and trafficking

2.

Evaluate whether SAP97 regulates 5-HT2AR signalling and trafficking
•

Determine whether SAP97 is responsible for CRFR1-mediated
sensitization of 5-HT2AR signalling

3.

Evaluate whether PSD-95 regulates CRFR1 signalling and trafficking
•

Determine whether PSD-95 is responsible for CRFR1-mediated
sensitization of 5-HT2AR signalling

In Chapter 2, SAP97 was identified as a novel interacting partner of CRFR1 in the
brain capable of maintaining receptor surface expression following agonist activation by
inhibiting receptor endocytosis (Dunn et al., 2013). Both the interaction and functio na l
consequence of suppressing internalization were found to be dependent on the CRFR1
PDZ-binding motif on the distal tip of the carboxyl terminal tail (Dunn et al., 2013).
Although this interaction had no effect on CRF-induced cAMP accumulation, the
endogenous expression of SAP97 was integral for CRF-mediated ERK1/2 phosphorylatio n
in HEK293 cells and pituitary adenoma AtT20 cells (Dunn et al., 2013). Interestingly, this
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effect occurred independently of SAP97 interactions with receptor, as SAP97 knockdown
reduced the phosphorylation of ERK1/2 by both a truncated CRFR1ΔTAV and CRFR2
which lack type I PDZ-binding motifs (Dunn et al., 2013).
In Chapter 3, SAP97 was further demonstrated as an interacting partner of 5-HT2AR
in the brain and this interaction – via the CRFR1 PDZ-binding motif – was similar ly
capable of suppressing receptor endocytosis (Dunn et al., 2014).
expression

The endogenous

of SAP97 in HEK293 cells was integral for 5HT-induced

ERK1/2

phosphorylation via either 5-HT2AR or the truncated 5-HT2ARΔSCV, which lacks the PDZbinding motif on the distal tail of the receptor (Dunn et al., 2014). Interestingly, SAP97
did not appear to have a significant effect on CRF-induced cAMP accumulation; however,
endogenous SAP97 expression and an intact 5-HT2AR PDZ-binding motif were essentia l
for maximal 5-HT-induced IP3 signalling (Dunn et al., 2013; Dunn et al., 2014). Finally,
knockdown of endogenous SAP97 was insufficient to abolish the previously described
mechanism whereby CRF-pretreatment provides an enhancement of 5-HT2AR-mediated
IP3 signalling (Magalhaes et al., 2010; Dunn et al., 2014). This suggested that SAP97 is
either not involved, or not exclusively involved in the crosstalk between these two
receptors.
In Chapter 4, the structurally similar PSD-95 was identified as a novel interacting
partner of CRFR1 in the brain (Dunn et al., submitted).

This interaction was further

demonstrated by colocalization of CRFR1 with PSD95 in dendritic puncta in cultured rat
neurons, and both the biochemical interaction and this colocalization was found to be
dependent on an intact PDZ-binding motif (Dunn et al., submitted). Like SAP97, PSD-95
was demonstrated to play an inhibitory role in CRFR1 endocytosis and had no effect on
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the truncated CRFR1ΔTAV mutant that lacks the PDZ-binding motif interaction site (Dunn
et al., 2013; Dunn et al., submitted).

Interestingly, PSD-95 did not seem to play a

significant role in either CRF-medited cAMP signalling or ERK1/2 phosphorylatio n;
however, PSD-95 appears to compete with β-arrestin2 binding to CRFR1, thereby
providing a potential mechanism for PSD-95’s ability to suppress receptor internalizatio n.

5.2 PSD-95 and SAP97 in the Regulation of GPCR
Trafficking
In the aforementioned chapters, SAP97 was demonstrated to suppress CRFR1 and
5-HT2AR internalization (Dunn et al,. 2013; Dunn et al., 2014). Similarly, the homologue
PSD-95 was demonstrated to suppress CRFR1 internalization, and a previous study by
another group has demonstrated that PSD-95 can also inhibit 5-HT2AR internalizatio n
(Dunn et al., submitted; Xia et al., 2003). In this previous study, HEK293 cells transiently
transfected with 5-HT2AR and either empty plasmid or PSD-95 were treated with vehic le
or 5-HT and examined using immunofluorescent confocal microscopy (Xia et al., 2003).
Cells were then analyzed qualitatively to determine whether 5-HT2AR internalizatio n
occurred, as characterized by the appearance of 5-HT2AR-positive cytosolic vesicles
following stimulation (Xia et al., 2003). In our studies, we attempted a more quantitative
approach using surface immunofluorescent labeling of receptors for flow cytometry and
arrived at a complimentary conclusion:

overexpression of PSD-95 led to decreased

CRFR1-endocytosis, and overexpression of SAP97 led to decreased CRFR1- and 5HT2AR-endocytosis (Dunn et al., 2013; Dunn et al., 2014; Dunn et al., submitted ).
Furthermore, we were able to knockdown endogenous SAP97 or PSD-95 in HEK293 cells
and, in every case, receptor internalization was enhanced (Dunn et al., 2013; Dunn et al.,
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2014; Dunn et al., submitted). Taken together, it is clear that SAP97 and PSD-95 work to
maintain CRFR1 and 5-HT2AR on the cell surface by inhibiting receptor internalization.
It is noteworthy that amongst the three independent studies presented in this thesis,
truncation of the CRFR1 or 5-HT2AR PDZ-binding motif led to dysfunctional receptor
internalization. This is not the first time the PDZ-binding motif has been implicated as an
essential motif for GPCR trafficking, as it was first identified as being essential for β2 AR
recycling (Cao et al., 1999). Since this study, many GPCRs have been identified to be
regulated by PDZ domain-containing proteins via the receptor PDZ-binding motif
(Magalhaes et al., 2012). In regards to PSD-95’s regulation of GPCRs, the majority of
studies have demonstrated PSD-95 to influence some aspect of GPCR trafficking via its
interaction with the PDZ-binding motif (Magalhaes et al., 2012). PSD-95 appears to
suppress the agonist-induced internalization of 5-HT2AR, β1 AR, and most recently CRFR1
(Xia et al., 2003; Hu et al., 2000; Dunn et al., submitted).

Conversely, PSD-95 may

promote constitutive internalization of 5-HT2CR and D1 R (Gavarini et al., 2006; Zhang et
al., 2007). A more recent study has now demonstrated that PSD-95 promotes the recycling
of D1 R to the membrane (Sun et al., 2009). Prior to the current studies, SAP97 had
similarly been identified to promote β1 AR recycling (Gardner et al., 2007). Now it has
been suggested that SAP97 can inhibit the internalization of CRFR1 and 5-HT2AR (Dunn
et al., 2013; Dunn et al., 2014). Although there are some discrepancies, the majority of the
work on PSD-95 and SAP97 conclude that these proteins promote the membrane
localization of GPCRs by either inhibiting receptor endocytosis or promoting receptor
recycling.

However, it remains plausible that the effects of these proteins on GPCR
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trafficking may be specific to the GPCR in question, and the complimentary traffick ing
machinery available to a specific cell type.

5.2.1

PSD-95 Regulation of β-arrestin Recruitment
A potential mechanism whereby PSD-95, and foreseeably SAP97, may regulate

GPCR endocytosis may involve modulating the recruitment β-arrestins. In Chapter 4, we
demonstrated that overexpression of PSD-95 overexpression in HEK293 cells led to
decreased β-arrestin2 recruitment to CRFR1 and decreased receptor internalizatio n,
whereas PSD-95 shRNA knockdown led to enhanced β-arrestin2 recruitment and increased
CRFR1 internalization (Dunn et al, submitted). It is plausible that PSD-95 may prevent
the recruitment of β-arrestins to a subset of GPCRs, thereby inhibiting β-arrestin-dependent
receptor endocytosis. This hypothesis is supported by a previous study investigating the
recruitment of β-arrestin2 to 5-HT2AR (Schmid and Bohn, 2010). In this study, stimulatio n
of 5-HT2AR by an agonist led to the recruitment of β-arrestin2 and the dissociation of PSD95 away from the receptor; however, PSD-95 did not dissociate in β-arrestin2 knockout
mice (Schmid and Bohn, 2010). Together with the current study on CRFR1, it is plausib le
that PSD-95 and β-arrestins could compete for binding to certain GPCRs to influence the
trafficking fate of the receptor, whereby PSD-95 would promote membrane localizatio n
and stabilization of the receptor, and β-arrestins would initiate the endocytotic process.
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5.3 PSD-95 and SAP97 in the Regulation of GPCRMediated Signalling
In the current studies, we were unable to find a role for PSD-95 or SAP97 in the
CRFR1-mediated activation of Gαs, as measured by the accumulation of secondary
messenger cAMP (Dunn et al., 2013; Dunn et al., submitted). In comparison, the β 1 AR
shares a similar class I PDZ-binding motif to CRFR1 and neither PSD-95 nor other PDZdomain-containing proteins MAGI-2 or GIPC demonstrated any significant role in β 1 ARmediated cAMP signalling (Hu et al., 2000; Xu et al., 2001; Hu et al., 2003). Although
PSD-95 was previously reported to inhibit D1 R-mediated cAMP signaling, a more recent
study has suggested that PSD-95 has no significant effect in D1 R-mediated Gαs activatio n
or cAMP accumulation (Zhang et al., 2007; Sun et al., 2009). Apart from these studies,
there have been some documentations of other PDZ-domain containing proteins having a
regulatory role over GPCR-mediated signaling via Gαs. However, few consistencies have
been found between different receptors, and conflicting studies exist (Magalhaes et al.,
2012). One piece of evidence suggesting minimal effect of PDZ interactions on cAMP
signalling comes from Chapters 2 and 4 (Dunn et al., 2013; Dunn et al., submitted). When
examining CRF-mediated cAMP accumulation, there was no significant difference s
observed between wild-type CRFR1 and the truncated CRFR1ΔTAV mutant which lacks
the PDZ-binding motif required for prototypical interactions with PDZ domain-containing
proteins (Dunn et al., 2013; Dunn et al., submitted). If PDZ domain-containing proteins
were important for CRF-mediated cAMP signalling, one might expect that simply
truncating the PDZ-binding motif, thereby abolishing the ability of most PDZ domaincontaining proteins to interact with the receptor, would have some effect on the
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accumulation of cAMP. With all of the evidence considered, we conclude that neither
PSD-95 nor SAP97 appear to play a significant, generalized role in GPCR-mediated cAMP
signaling, and this may be consistent amongst other members of the PDZ domaincontaining protein family.
Interestingly, we did observe a significant role for SAP97 in regulating 5-HT2ARmediated Gαq activation, as measured by the accumulation of the secondary messenger IP 3
(Dunn et al., 2014). This is supported by a previous study which demonstrated that
overexpression of PSD-95 led to enhanced maximum efficacy of 5-HT2AR-mediated IP3
signalling (Xia et al., 2003). Although overexpression of SAP97 resulted in a negligib le
shift to the left in our dose-response curve, the knockdown of endogenous SAP97 led to a
significant decrease in the maximum efficacy for IP 3 accumulation (Dunn et al., 2014).
Furthermore, the truncated 5-HT2ARΔSCV mutant which lacks the PDZ-binding motif
showed a similar decrease in the maximum efficacy for IP 3 accumulation when compared
to the wild-type 5-HT2AR (Dunn et al., 2014). This result reinforces the importance of
PSD-95, SAP97, and perhaps other PDZ domain-containing proteins in the promotion of
5-HT2AR-mediated signalling via Gαq. Other PDZ domain-containing proteins that have
been implicated in regulating Gαq signalling include NHERF1, which was demonstrated
to increase coupling and activation of Gαq with parathyroid 1 receptor (PTH1R), and
NHERF2 which increased secondary messenger IP 3 accumulation via LPA2R (Wang et
al., 2010; Oh et al., 2004). Additionally, NHERF2 was shown to increase coupling of Gαq
to PTH1R, while decreasing PTH1R coupling with Gαs (Wang et al., 2010). In regards to
PSD-95 and SAP97, it appears that these proteins are important for Gαq-coupled signalling
via 5-HT2AR, but not Gαs-coupled signalling via CRFR1 (Xia et al., 2003; Dunn et al.,
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2014; Dunn et al., 2013; Dunn et al., submitted). It is possible that PSD-95 and SAP97
may act similarly to NHERF2 in biasing GPCRs towards Gαq-coupling while, in this case,
providing minimal influence over Gαs-coupling.

5.3.1
SAP97 in the Regulation of GPCR-Mediated ERK1/2
Signalling
A consistent and novel finding amongst the enclosed studies was the observation
that SAP97 appears to be an integral protein for ERK1/2 phosphorylation (Dunn et al.,
2013; Dunn et al., 2014). When using SAP97 shRNA in HEK293 cells, both CRFR1- and
5-HT2AR-mediated ERK1/2 phosphorylation was significantly reduced when compared to
control with scrambled shRNA (Dunn et al., 2013; Dunn et al., 2014). Additionally, using
SAP97 siRNA in AtT20 cells, which endogenously express CRFR1, also led to a
significant decrease in CRF-mediated ERK1/2 phosphorylation (Dunn et al., 2013).
Surprisingly, SAP97 shRNA knockdown in HEK293 cells also led to significant inhibitio n
of ERK1/2 phosphorylation via CRFR2, and via truncated mutants CRFR1ΔTAV and 5HT2ARΔSCV: all of which lack the class I PDZ-binding motif which is fundamental for
SAP97’s interaction (Dunn et al., 2013; Dunn et al., 2014). This unexpected find ing
suggests that SAP97’s role in CRF- and 5-HT2AR-mediated ERK1/2 phosphorylation goes
beyond its interaction with the receptor and may indicate that SAP97 is an integral protein
in MAPK signalling as a whole. Albeit beyond the scope of the current studies, SAP97’s
potential role in regulating general ERK1/2 phosphorylation is an exciting finding as
MAPK signalling is fundamental in modulating cellular growth, proliferation, and
apoptosis and understanding its regulation is relevant for the development of new cancer
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treatments (Roberts and Der, 2007). If this hypothesis holds true, it may provide some
reasoning behind why insertional mutations of the SAP97-encoding gene in transgenic
mice exhibit growth retardation in utero and perinatal lethality (Caruana and Bernstein,
2001).
Although this is the first indication of SAP97 as an integral protein for GPCRmediated ERK1/2 phosphorylation, previous studies have demonstrated proteins of the
MAPK signalling pathway, like ERK2, to be capable of phosphorylating SAP97 (Sabio et
al., 2005). As a consequence of this phosphorylation, SAP97 becomes disconnected from
GKAP protein which indirectly links SAP97 to the cytoskeleton (Sabio et al., 2005). Taken
together with the current studies, it is foreseeable that SAP97 could maintain CRFR1, 5HT2AR, and perhaps other GPCRs at the cell membrane to allow for agonist activation and
the propagation of MAPK signalling, but also provide an unknown role in ERK1/2
phosphorylation independent of receptor interactions.

One potential function could be

scaffolding MAPK family members in close proximity similarly to what has been shown
for β-arrestins (Tohgo et al., 2002). Upon ERK1/2 phosphorylation and activatio n,
ERK1/2 or another MAPK family kinase could phosphorylate SAP97, thereby interrupting
its interaction with the cytoskeleton and encouraging the trafficking or sorting of SAP97
and its bound receptor(s). This could hypothetically lead to receptor internalization and
the preclusion of further agonist activation and MAPK signalling, consequently acting as
a negative feedback mechanism for MAPK signalling. Future studies could examine what
role SAP97 plays in regulating MAPK signalling and the potential interplay between
ERK1/2 and SAP97.
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Despite extensive structural homology between SAP97 and PSD-95, PSD-95
shRNA knockdown in HEK293 cells had no significant effect on CRFR1-mediated
ERK1/2 phosphorylation in our study (Dunn et al., submitted). This could have multip le
explanations.

Firstly, it could be that SAP97 is exclusively involved in ERK1/2

phosphorylation when compared to PSD-95. The most obvious structural difference of
SAP97 when compared to PSD-95 is the inclusion of an L27 protein-protein interactio n
domain on the distal amino terminal. It is possible that this L27 domain is essential for
targeting SAP97 to the MAPK signalling pathway and perhaps providing a means for
scaffolding these kinases in close proximity. Secondly, it is possible that the endogenous
expression of SAP97 was capable of compensating for the loss of PSD-95, therefore no
significant decrease in ERK1/2 phosphorylation was observed. This is supported by the
observation

that some PDZ domain-containing

proteins

can exhibit

functio na l

compensation as a consequence of downregulating PDZ domain-containing proteins of
similar background (Misawa et al., 2001). Thirdly, the function of these PDZ domaincontaining proteins may be cell-type-specific and dependent upon the compliment of
MAPK signalling proteins available. As we have only tested PSD-95’s role on MAPK
signalling in HEK293, other cell types may be considered.

5.4 Crosstalk between CRFR1 and 5-HT2AR
The initial reasoning for investigating the potential for PDZ domain-containing
proteins in the regulation of CRFR1 and 5-HT2AR originated following the observation
that preactivation of CRFR1 was capable of enhancing 5-HT2AR-mediated IP3 signalling,

157

and that this result occurs dependently upon both receptors containing intact PDZ-binding
motifs (Magalhaes et al., 2010). This unidirectional relationship between CRFR1 and 5HT2AR has been proposed to be a potential molecular mechanism underlying stresssensitive mood disorders such as anxiety disorders and depression (Magalhaes et al., 2010).
We went on to perform a PDZ-binding array using the PDZ-binding motifs of CRFR1 and
5-HT2AR with a subset of peptides containing known PDZ domains in search of a potential
protein, or proteins, which may facilitate this crosstalk (Dunn et al., 2013). In doing so,
we identified SAP97, PSD-95, MAGI1, MAGI2, MAGI3, CAL, PDZK1, MUPP1 and
PTPN13 as possible candidates for regulating the crosstalk between CRFR1 and 5-HT2AR,
as well as each receptor’s independent function (Dunn et al., 2013). The current studies
focused on SAP97 and PSD-95.
Despite the shRNA knockdown of either SAP97 or PSD-95 in HEK293 cells, the
CRFR1-mediated enhancement of 5-HT2AR-mediated IP3 signalling was still observed
(Dunn et al., 2014; Dunn et al., submitted). This result has a few possible explanatio ns.
Firstly, it is possible that neither SAP97 nor PSD-95 participate in the CRFR1-mediated
enhancement of 5-HT2AR-mediated IP3 signalling.

In this case, we still have MAGI1,

MAGI2, MAGI3, CAL, PDZK1, MUPP1 and PTPN13 to consider for future studies (Dunn
et al., 2013). Secondly, it could be that the shRNA-mediated knockdown of PSD-95 and/or
SAP97 via transient transfection wasn’t sufficiently complete to abolish the receptor
crosstalk. In this case, targeted knockout-animals may need to be explored. Thirdly, it
could be that SAP97 and/or PSD-95 participate in the CRFR1-mediated enhancement of
5-HT2AR signalling, but they are not exclusively involved. In this case, knocking down
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one of these proteins could allow for another PDZ domain-containing protein to
compensate for its loss.
Such a compensation mechanism amongst PDZ domain-containing proteins has
been previously described in double-knockout mice for synaptic proteins MALS1 and
MALS2 (Misawa et al., 2001). Interestingly, synaptic transmission appears unaltered in
these transgenic mice despite targeted double-knockout of MALS1 and MALS2 (Misawa
et al., 2001). However, this double-knockout resulted in a significant upregulation of
MALS3 protein, suggesting MALS3 could compensate for the loss of MALS1 and MALS2
to maintain synaptic function (Misawa et al., 2001). It is possible that PSD-95, SAP97
and/or other PDZ domain-containing proteins could exhibit a similar degree of functio na l
redundancy in regards to the CRFR1-mediated enhancement of 5-HT2AR signaling.
Therefore, a future strategy could include utilizing multiple different shRNA constructs
against combinations of PDZ domain-containing proteins to examine if any combinatio n
of knocked-down PDZ domain-containing proteins could abolish the CRFR1-mediated
enhancement of 5-HT2AR-mediated IP3 signalling.

5.5 Implications to Mental Health
The CRFR1-mediated enhancement of 5-HT2AR-mediated IP3 signalling has been
a proposed molecular mechanism for stress-induced anxiety and depressive disorders
(Magalhaes et al., 2010). Although neither SAP97 nor PSD-95 shRNA knockdown were
successful in abolishing the CRFR1-mediated enhancement of 5-HT2AR signaling, the
maximum efficacy following CRF-pretreatment was still significantly lower during SAP97
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shRNA knockdown when compared to scrambled shRNA, and trended to be lower during
PSD-95 shRNA knockdown (Dunn et al., 2014; Dunn et al., submitted).

These

observations are likely due to effects primarily on 5-HT2AR. However, they still have
significance to the field of mental health research. 5-HT2AR has been demonstrated to be
upregulated in the postmortem brain tissue of schizophrenic individuals, and the efficac y
of atypical anti-psychotics has been demonstrated to be dependent upon the ability to
downregulate 5-HT2AR-mediated signalling and upregulate mGluR2 signalling (Catapano
and Manji, 2007; Fribourg et al., 2011). Furthermore, the action of atypical anti-psychotic s
and mood-altering hallucinogens via 5-HT2AR appear dependent upon the endogenous
expression of PSD-95 (Abbas et al., 2009). Therefore, it is foreseeable that SAP97 may be
of similar importance to PSD-95 in the regulation of mood through their regulation of 5HT2AR, as well as CRFR1 (Dunn et al., 2014; Dunn et al., 2013; Xia et al., 2003; Dunn et
al., submitted).
Like 5-HT2AR, CRFR1 has been recognized as a molecular target for the treatment
of mental illness and inhibitors of CRFR1 function have been demonstrated to have
anxiolytic and antidepressant-like qualities (Mansbach et al., 1997; Catapano and Manji,
2007). Additionally, the HPA axis stress response is initiated by the hypothalamic release
of CRF into the anterior pituitary by acting on CRFR1 and CRFR2 receptors (Tsigos and
Choursos, 2002; Janssen and Kozicz, 2013). The ability of SAP97 and PSD-95 to regulate
CRFR1 and 5-HT2AR function may provide some explanation to their associations to
psychiatric disease (Toyooka et al., 2002; Clinton et al., 2003; Clinton & MeadorWoodruff, 2004; Toro and Deakin, 2005; Clinton et al., 2006; Kristiansen, 2006; Tsai et
al., 2007; Sato et al., 2008; Funk et al., 2009). Pharmacologically targeting the interactio ns
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between receptors 5-HT2AR or CRFR1 with SAP97, PSD-95, or other candidate PDZ
domain-containing proteins could lead to specific regulation strategies for these receptors
and the psychiatric disorders they underlay.

Rather than modulating neurotransmitte r

availability, as is the case with selective serotonin-reuptake inhibitors, or SSRIs, we can
begin to not only target specific receptors activated by these neurotransmitters, but
modulate specific signalling pathways or receptor trafficking processes that underlie a
spectrum of mental illnesses.

5.6 Contribution to the Molecular Physiology of GPCRs and
PDZ Domain-Containing Proteins
These studies mark the first documentations of specific PDZ domain-containing
proteins regulating CRFR1 function, and the identification of a second PDZ domaincontaining protein capable of regulating 5-HT2AR (Dunn et al., 2013; Dunn et al.,
submitted; Dunn et al., 2014). Additionally, these are only the second and third GPCRs
shown to have their trafficking and/or signalling properties regulated by SAP97, and the
fifth by PSD-95 (Magalhaes et al., 2012). Considering it is estimated that 20% of GPCRs
have PDZ-binding motifs, and over 800 GPCRs have been identified in the human genome,
it is safe to assume that this field is still in its infancy (Lee and Zheng, 2010; Fredriksson
et al., 2003). Notably, this is also the first indication that SAP97 could play an integral role
in ERK1/2 phosphorylation, and this appears to go beyond its interaction with GPCRs
(Dunn et al., 2013; Dunn et al., 2014). Although this result was unexpected and outside
the scope of the designed studies, it is one of the most curious due to its implications on
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general MAPK signalling and as a consequence cellular growth, proliferation, and
apoptosis.
GPCRs are influential in the regulation of every aspect of human physiolo gy;
therefore, any advancement in the understanding of how they can be regulated could
contribute to the design and development of new pharmacological treatment and preventio n
strategies for a multitude of human pathologies (Bockaert et al., 2010; Heng et al., 2013).
Dozens of studies have been published on the role of specific PDZ domain-containing
proteins in regulating GPCRs; however, it is unclear whether each PDZ domain-containing
protein has specific functional consequences on GPCRs, or whether this regulatory role is
dependent upon the receptor in question or the cell-type in which the interaction takes
place. In regards to PSD-95 and SAP97, it now appears these proteins act generally on a
subset of GPCRs to promote their membrane localization by antagonizing receptor
internalization and/or promoting receptor recycling.

Their ability to suppress receptor

internalization may be a consequence of competitive binding to the receptor with βarrestins.

PSD-95 and SAP97 do not appear to have a general role in Gαs-mediated

signalling; however, they may provide a bias towards Gαq-coupling and activation. Future
studies will look to elucidate the specific roles of PSD-95, SAP97, and other PDZ domaincontaining proteins in regulating the diversity of GPCR-mediated signalling pathways and
trafficking mechanisms in hopes of developing new treatment strategies for human disease.
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